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Summary 
Human T-Lymphotropic virus type 1 (HTLV-1) maintains persistent infection in the host by 
driving expansion of HTLV-1-infected T cells.  However, the wide variation observed in 
clonal abundance in vivo remains unexplained.  We hypothesize that the site of proviral 
integration in the host cell genome determines the rate of expression of HTLV-1 genes such 
as the viral transactivator Tax, which in turn determine the level of clonal expansion in vivo. 
Utilising Molecular biology techniques, High-throughput sequencing and computing tools, 
we have developed a high-throughput method for the amplification, mapping and 
quantification of proviral integration sites. We have used this technique, in combination with 
bioinformatics analysis, to identify factors associated with clonal expansion.  Using PBMCs 
sorted for CD4
+
 and CD8
+
 T cell subsets, we observed differences in the form of the clonal 
distribution between the cell types.  In addition, using flow-cytometric sorting of Tax 
expressing CD4
+
 cells, we identified genomic patterns associated with the presence or 
absence of spontaneous Tax expression.  We have also identified a correlation between the 
expression of Tax and the size of the infected clones. Finally, we identified genomic factors 
associated with HTLV-1 integration in vitro, suggesting a possible role of these factors in 
targeting of the pre-integration complex to particular sites in the host genome.    
The thesis will detail and discuss the findings from these analyses, as well as their impact on 
the current knowledge. These results would play a role in improving our understanding of 
HTLV-1 persistence in the face of a strong immune response, and may provide excellent 
basis from a population level to test mechanisms of proviral latency in natural infection.   
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1.1. Human T-Lymphotropic virus 
Human T-Lymphotropic virus Type 1 (HTLV-1) was the first identified human retrovirus. 
Originally identified from a cell line developed from the cells of a patient with cutaneous T 
cell leukemia (Poiesz et al., 1980), it is currently estimated to infect more than 10 million 
individuals worldwide, and while it is often carried as an asymptomatic persistent infection, it 
is associated with a number of diseases, in particular inflammatory disease and T cell 
malignancies, for which there is currently no cure or preventive vaccine.  
Seven subtypes of HTLV-1 are currently known, distinguished by nucleotide substitutions in 
the Env and long terminal repeats (LTR) regions (Gessain and Cassar, 2012; Slattery et al., 
1999). The different subtypes are often associated with particular geographic regions, while 
subtype A (termed the cosmopolitan strain) is found in multiple infection hotspots (Gessain 
and Cassar, 2012). 
HTLV-1 is a member of a large group of deltaretroviruses, Primate T-Lymphotropic viruses 
(PTLVs, Figure ‎1.1). So far within this group 4 genotypes of human retroviruses have been 
identified (Kalyanaraman et al., 1982; Calattini et al., 2005; Wolfe et al., 2005) and 4 
genotypes infecting exclusively non-human primates (Simian T-Lymphotropic viruses – 
STLVs; Slattery et al., 1999). The low sequence diversity between STLV-1 and HTLV-1, 
indicates a relatively recent common ancestor. Compared to HTLV-1, HTLV-2 has not been 
associated with a specific disease outcome and is usually carried at a lower viral burden than 
HTLV-1 (Murphy et al., 2004). The more recently identified HTLV-3 and HTLV-4 are 
distantly related to either HTLV-1 and HTLV-2, and have so far only been found in a small 
number of individuals in Central Africa (Mahieux and Gessain, 2011). 
The viral burden of HTLV-1 is measured by the proviral load (PVL) which is quantified by 
the number of proviral copies per 100 peripheral blood mononuclear cells (PBMCs). It has 
20 
 
recently been demonstrated by limited dilution cloning of naturally infected cells that, at least 
for non-malignant infected cells, there is a single proviral copy per cell (Cook et al., 2012), 
implying that the PVL measurement is equivalent to the percentage of infected PBMCs in 
each patient. The PVL is remarkably stable over time in a given patient, but can vary by 
several orders of magnitude between patients (Demontis et al., 2013; Matsuzaki et al., 2001).  
The two main questions in HTLV-1 research are:  
1) How does the virus maintain lifelong persistent infection in the face of a strong, 
constitutive immune response?  
2) What determines the risk of HTLV-1 associated disease? 
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Figure ‎1.1: HTLV-1 and related viruses. 
Phylogenetic tree of HTLV-1 and related viruses, based on nucleotide sequences of viral genes. 
Primate T-lymphotropic viruses (PTLVs) include both different subtypes of the human T-
lymphotropic viruses   (HTLVs) and the closely related simian T-lymphotropic viruses (STLVs). The 
most widespread variant of HTLV-1 is the cosmopolitan strain subtype A (arrow). The distribution of 
HTLVs and the close sequence homology within each PTLV group suggests multiple zoonotic events. 
Figure adapted from Mahieux and Gessain (2011).  
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1.2. HTLV-1 Epidemiology 
HTLV-1 prevalence varies greatly world-wide, and appears to be mostly focused in particular 
endemic hotspots. These include Japan, Africa, the Caribbean islands and South America 
(Figure ‎1.2; Proietti et al., 2005). In some endemic regions, such as Kyushu in Japan, 
seroprevalence can be as high as 8% of blood donors (Maeda et al., 1984).  
Transmission of HTLV-1 requires cell-cell contact (Yamamoto et al., 1982b) and cell-free 
blood products are non-infectious (Jason et al., 1985). HTLV-1 can be transmitted through 
blood transfusions (Okochi and Sato, 1984) or by sexual contact (Murphy et al., 1989a; 
Moriuchi and Moriuchi, 2004). Transmission through breast-feeding from mother to child is 
frequent (Hino et al., 1997), with an increased risk of transmission with increased duration of 
breast-feeding (Ureta-Vidal et al., 1999). Due to the known methods of virus transmission, in 
many areas seroprevalence data comes from routine screening of pregnant women and blood 
donations (Brant et al., 2011; Gessain and Cassar, 2012). 
The worldwide seroprevalence rates of HTLV-1 infection are difficult to estimate. Most 
recent estimate predicts up to 10 million individuals infected in known HTLV-endemic areas. 
These, however, are thought to be underestimated in some highly populated areas such as 
China, India and East Africa (Gessain and Cassar, 2012). 
Seroprevalence in England and Wales is estimated at about 79 cases per million blood 
donations (HPA - Health protection agency. See - 
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HTLV/Epidemiology/) and 
470 cases per million pregnant women (Taylor et al., 2005). The majority of HTLV-1 
infected individuals in the UK originate from HTLV-1-endemic countries (HPA; Tosswill et 
al., 2000). 
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Figure ‎1.2: HTLV-1 world-wide prevalence.  
Map shows countries with endemic HTLV-1, or with a low prevalence of HTLV-1.  
Figure from Watanabe, 2011. 
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1.3. Cellular and Molecular biology of HTLV-1 
While HTLV-1 has been shown in vitro to infect multiple cell types (see below), the infection 
in vivo appears to be restricted to the CD4
+
 T-cells (the main reservoir of HTLV-1) and CD8
+
 
cells (Richardson et al., 1990; Nagai et al., 2001a). 
 
1.3.1. HTLV-1 receptor 
While HTLV-1 predominantly infects CD4
+
 T cells in vivo it does not use the CD4 molecule 
as an attachment receptor. HTLV-1 is able to attach in vitro to a variety of cell types 
(Yamamoto et al., 1984). HTLV-1 or HTLV-1-pseudotyped virus has been shown to infect 
many different cell types, including T cells, B cells, monocytes (Koyanagi et al., 1993) 
dendritic cells (Jones et al., 2008), epithelial cells (Setoyama et al., 1998) and astrocytes 
(Lehky et al., 1995), suggesting that the receptor is present on various cell types. Over the last 
few years three molecules have been identified as playing an important role in HTLV-1 entry: 
Glucose transporter 1(GLUT-1; Manel et al., 2003; Jin et al., 2006), Heparan Sulfate 
Proteoglycans (HSPGs; Pinon et al., 2003; Jones et al., 2005) and Neuropilin-1 (NRP-1; 
Ghez et al., 2006; Jin et al., 2010).  
The interplay between the three molecules involved in HTLV-1 cell entry is not yet fully 
understood, however current models suggest sequential binding of HSPGs, NRP1 and 
GLUT-1 leading to the necessary conformation change of Env and viral entry (reviewed in 
Ghez et al., 2010).  
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1.3.2.  Molecular events leading to proviral integration 
Like other viruses, a retrovirus must identify and enter its host cell, be transported to its target 
intracellular compartment (the nucleus in the case of retroviruses), initiate the expression of 
its own genes and replication of its genome, followed by the assembly of nascent virions and 
release from the infected cell. The retrovirus replication cycle also contains certain steps that 
are characteristic of retroviruses – reverse transcription of its single-stranded RNA genome to 
double-stranded DNA, and integration of the double-stranded DNA molecule into the 
genome of the host cell. The retroviral replication cycle is a complex process that involves 
several viral proteins and recruitment of host factors (reviewed in Goff, 2007).  
Viral entry and uncoating 
The specific mechanisms identified that HTLV-1 uses in order to infect CD4
+
 T-cells are 
detailed in section  1.5.2.  HTLV-1 virions are effectively 100% cell-associated and are 
transmitted through cell-to-cell contact via the virological synapse (Igakura et al., 2003) 
The entry of retroviruses to a target cell requires the viral attachment and fusion protein Env, 
as well as a host cell receptor. Env is processed prior to budding from an infected cell to 
generate a trimeric complex of two domains, an extracellular surface domain (SU) largely 
responsible for the binding to the receptor and a transmembrane domain (TM) (Moulard and 
Decroly, 2000; DeLarco and Todaro, 1976; Einfeld, 1996).  HTLV-1 Env is a 62 kDa protein 
(Pique et al., 1992, reviewed in Jones et al., 2011). The host cell receptor varies between 
different retroviruses and is one of the chief factors that determine host-cell tropism.  The 
best described retroviral receptors are those for HIV-1: attachment to the primary receptor 
CD4 is required to enable the subsequent conformational changes and binding to a co-
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receptor, which is either the chemokine receptor CCR5 or CXCR4 (Dalgleish et al., 1984; 
Permanyer et al., 2010).   
Viral entry to a host cell requires the fusion of the retroviral and cell membranes following 
the binding of the retroviral SU protein to the receptor molecules. Two modes of entry have 
been observed in retroviruses:  while most retroviruses are able to mediate entry by direct 
fusion of the viral and host cell membranes in a pH-independent manner, certain retroviruses 
require a low pH for efficient entry and release into the host cell cytoplasm, via endocytosis 
and subsequent release of the viral core from the acidified endosome (McClure et al., 1990; 
Yamada and Ohnishi, 1986; Barnard et al., 2004).  
Trafficking within the cell and reverse transcription 
Retroviruses such as HTLV-1 are approximately 2 orders of magnitude smaller than their 
target lymphocytes. In order to complete their replication cycle they must be transported 
within the cell to reach the nucleus. HIV has been shown to travel towards the nucleus using 
both the actin and microtubule components of the host cell cytoskeleton (Arhel et al., 2006; 
McDonald et al., 2002; Naghavi et al., 2007). HTLV-1 also takes advantage of host 
cytoskeleton: HTLV-1 infection via the virological synapse requires polarization of the 
microtubule organizing center (MTOC, see section  1.5.2) towards the site of cell-cell contact 
(Igakura et al., 2003); this polarization is triggered by HTLV-1 Tax protein (Nejmeddine et 
al., 2005). The formation of the virological synapse has since been observed also in HIV-1 
between CD4
+
 T cells and between dendritic cells and T cells (Jolly et al., 2004; McDonald et 
al., 2003). 
27 
 
Reverse transcription, a hallmark of retroviral infection, is the multistep process in which the 
virus transcribes its single-stranded RNA genome to a linear, double-stranded DNA molecule 
(Gilboa et al., 1979). This process is mediated by the retroviral RT protein, a product of the 
pol gene (Hill et al., 2005), and contains several distinct steps. DNA synthesis during reverse 
transcription is primed by a tRNA primer binding to a unique primer binding site in the 
retroviral genome; HTLV-1 utilizes tRNA
pro 
as the primer for its reverse transcription. The 
RNA present in the RNA:DNA duplexes formed during this process is degraded by RNase H 
activity of the RT protein. Two strand-transfer or translocation (‘jump’) steps during this 
process result in duplication of the U3, R and U5 domains, generating two direct repeats – the 
long terminal repeats (LTR). The double-stranded DNA proviruses produced by this process 
remain associated with viral and host proteins, and this protein DNA complex is termed the 
pre-integration complex (PIC). 
Nuclear entry 
Productive infection by retroviruses usually requires the target host cell to undergo mitosis, 
because the PIC can enter the nucleus only after disassembly of the nuclear membrane. A 
notable exception to this are the lentiviruses (e.g. HIV-1), which interact with the nuclear 
pore complex (NPC). Interactions between Integrase protein and TPNO3 / importin α have 
been shown to play a role in HIV-1 nuclear import (Levin et al., 2010). The HIV-1 capsid 
protein (CA), which is associated with the PIC, must also play a role, as a single point 
mutation in this protein (N74D) can alter the interaction between the PIC and the NPC (Lee 
et al., 2010). In addition, nuclear localization signal domains (NLS) are found on other 
components of the lentiviral PIC including Integrase and matrix proteins (Bouyac-Bertoia et 
al., 2001; von Schwedler et al., 1994). 
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Integration 
Integration into an infected cell genome is one of the defining features of retroviral infection, 
although integration by different mechanisms can also take place in certain other viral 
infections, such as infection with human papilloma virus (HPV) and hepatitis B virus (HBV). 
Whereas integration in HBV and HPV is non-essential for expression of viral proteins 
(Neuveut et al., 2010; Hafner et al., 2008), it is essential for the efficient expression and 
replication of retroviruses. Integration requires the activity of the retroviral protein Integrase 
(produced from the pol gene), and other host factors. Integration can take place at any site in 
host genome, but each retrovirus has a specific bias to certain types of integration site (Derse 
et al., 2007; Wu et al., 2003; Mitchell et al., 2004); this bias is partly attributable to host 
factors that bind the PIC.  The best-described integration-targeting factor is lens epithelium-
derived growth factor/p75 (LEDGF/p75), which binds directly to HIV-1 integrase 
(Cherepanov et al., 2003). LEDGF may play a role in entry to the host nucleus (Llano et al., 
2004) and it appears to be used by the virus as a chromatin-tethering factor, increasing 
integration efficiency and biasing integration towards active transcription units (Maertens et 
al., 2003; Ciuffi et al., 2005; Shun et al., 2007; De Rijck et al., 2010). The viral protein CA 
may also play a role in integration site selection, as a point mutation in this protein can alter 
the integration site bias in the genome (Schaller et al., 2011); the mechanism of this is not 
clear. The process of integration is further detailed in chapter  4.1. 
 
29 
 
 
 
Figure ‎1.3: Molecular mechanisms leading to retroviral provirus integration 
The replication cycle of retroviruses include multiple steps leading up to the integration of the 
retroviral provirus into the host cell genome. Following entry of the uncoated viral core into the host 
cell, the single-stranded RNA molecule is reverse transcribed to double-stranded DNA. The protein 
coated proviral DNA (PIC – pre-integration complex) is then required to enter the host cell nucleus 
and undergo integration into the host cell DNA. See text for further details. Figure adapted from Goff, 
2007.  
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1.3.3. HTLV-1 gene expression 
HTLV-1 carries two RNA copies of its genome in the virion, which are reverse transcribed 
inside the host cell. This is followed by integration of the double stranded DNA provirus into 
the host genome, flanked by the LTR on both sides. The HTLV-1 proviral genome is nearly 9 
kb long, it encodes the retroviral genes gag, pro, pol and env, as well as the pX region at its 3’ 
end (Figure ‎1.4; Shuh and Beilke, 2005), which contains non-structural genes (viral accessory 
and regulatory genes), differentially expressed by alternative splicing. These plus strand 
transcripts may be unspliced, singly spliced or doubly spliced.  
The first gene to be expressed is tax. This encodes the viral transactivator Tax, required for 
expression of other proviral genes (Bex and Gaynor, 1998; Kashanchi and Brady, 2005), as 
well as a large number of host factors through interaction with transcription factors and 
chromatin remodellers (Boxus et al., 2008). See Chapter 5.1 for further details, Tax 
transactivates proviral genes by recruiting host transcription machinery to 3’ Tax-responsive 
elements (TRE) located at the promoter region in the LTR (Brady et al., 1987). Tax is 
required for activation of other proviral genes and is implicated with many aspects of   
HTLV-1 mediated host gene deregulation (Ng et al., 2001; Matsuoka and Jeang, 2007). 
The regulatory protein Rex, regulates proviral gene expression on a post-transcriptional level. 
Rex is essential for establishing in vivo infection in the rabbit model (Ye et al., 2003a), and 
regulates the nuclear export of doubly spliced versus unspliced transcripts (Hidaka et al., 
1988). The Rex responsive element is a short sequence present in the U3-R region of the LTR 
recruiting Rex to the transcript via a stem-loop structure (Seiki et al., 1988; Grone et al., 
1994). The resulting Rex-mRNA complex recruits additional host factors which enables it to 
translocate out of the nucleus (Kashanchi and Brady, 2005). Due to the role of Rex in 
regulating export of unspliced and singly spliced transcripts, it has been implicated in 
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determining bi-phasic kinetics of viral gene regulation, where by initially Tax/Rex are 
expressed, and all other transcripts follow as the levels of Tax and Rex are decreased (Rende 
et al., 2011; Rende et al., 2012).  
The accessory protein p12 is expressed from open reading frame I (ORF I) of the pX. It 
localizes in the endoplasmic reticulum of the host cell (Ding et al., 2001) and has various 
functions, including decreased surface expression of MHC-1 (Johnson et al., 2001) and 
activation of various mitogenic pathways such as activation of STAT-5 (Nicot et al., 2001) 
which results in reduced dependency on interleukin 2 (IL-2) for cell proliferation.  
p13, and p30 accessory proteins are expressed from ORF II of the pX. Though they share part 
of their sequence, their localization and function differ (Koralnik et al., 1993). Selectively 
localizing to the inner membrane of the mitochondria (Ciminale et al., 1999), p13 appears to 
be involved in modulating apoptosis in the infected cell and to sensitize cells to reactive 
oxygen species (Hiraragi et al., 2005). p30 regulates gene expression by sequestering 
Tax/Rex mRNA in the nucleus (Nicot et al., 2004) and by binding to the Rex responsive 
element (Sinha-Datta et al., 2007). In the rabbit model of HTLV-1 infection, translation of 
p13 and p30 were shown to be required for establishing infection with a high PVL (Bartoe et 
al., 2000; Silverman et al., 2004), and it has been shown in the nonhuman primate (NHP) 
model that p12 and p30 are essential in establishing the infection due to their role in 
sustaining the infection of dendritic cells (DCs; Valeri et al., 2010).  
Only one gene is encoded on the reverse strand of the HTLV-1 genome. The recently 
identified HTLV-1 b-zip factor  (HBZ; Larocca et al., 1989; Gaudray et al., 2002), is 
transcribed from the 3’ end of the provirus. HBZ appears to have a role in regulation of Tax 
mediated transactivation (Gaudray et al., 2002; Basbous et al., 2003) through recruitment of 
host cofactors including CREB-2, JunB and c-Jun. 
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HBZ protein is difficult to detect in HTLV-1 infected cells using existing techniques, even in 
cells expressing a high level of HBZ mRNA (Suemori et al., 2009), although HBZ protein 
can be readily detected by western blot of lysates from cells transfected with HBZ expression 
vectors (Suemori et al., 2009). This has raised the question whether HBZ protein is actually 
translated in vivo. At least one study has demonstrated by altering the HBZ ATG start codon 
that the effect of HBZ on Tax is exerted at the mRNA level (Satou et al., 2006). In cells 
infected with an HTLV-1 molecular clone, a large proportion of HBZ mRNA is retained in 
the nucleus in a Rex-independent manner (Rende et al., 2011). The strongest evidence for the 
existence of HBZ protein in vivo is the anti-HBZ immune response: approximately 10% of 
patients carry anti-HBZ antibody responses (Enose-Akahata et al., 2013) and HBZ-specific 
cytotoxic T lymphocytes (CTLs) are detected in over 30% of infected individuals (Hilburn et 
al., 2011). Tax-specific CTLs, conversely, are found in all patients (Jacobson et al., 1990; 
Goon et al., 2004a; Hilburn et al., 2011). Thus, the difficulty in detecting HBZ protein in 
PBMCs suggests that either protein levels are under the limit of detection of our current 
methods, or that the export or translation of HBZ is regulated by the virus 
.  
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Figure ‎1.4: Gene expression map of HTLV-1 genome. 
HTLV-1 genes are transcribed to either unspliced /spliced mRNAs. Black lines denote mRNA, orange 
boxes denote protein coding sequence. HTLV-1 sense strand encodes the essential retroviral genes: 
gag, pro, pol and env, as well as additional genes from the pX region. Expression of these genes is 
initiated from a promoter located on the 5’LTR. The antisense gene HBZ is expressed from a 
promoter at the 3’LTR on the reverse strand. Figure from Lairmore et al., 2012 
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1.4. HTLV-1 associated clinical outcomes 
While over 90% of infected individuals remain life-long asymptomatic carriers (AC), HTLV-
1 has been associated with several distinct clinical manifestations, including T cell 
malignancies, inflammatory diseases, and particular co-infections with other pathogens.  
 
1.4.1. Malignancy 
Adult T-cell Leukemia/Lymphoma (ATLL) is a severe malignancy associated with HTLV-1 
infection (Gallo et al., 1983). Almost exclusively a CD4
+
 T cell malignancy, ATLL carries a 
poor prognosis even on existing treatment (Ratner et al., 2009). ATLL is estimated to affect 
up to 5% of infected individuals, often in their sixties or older, several decades after infection 
(Yamaguchi and Watanabe, 2002; Murphy et al., 1989b).  
ATLL is classified (Shimoyama, 1991) into four main disease subtypes: Smouldering, 
chronic, acute and lymphoma type. Diagnosis of ATLL is based on histological evidence of T 
cell malignancy, the presence of morphologically abnormal cells in the blood (“flower cells”) 
and confirmation of HTLV-1 infection by serology or polymerase chain reaction (PCR). The 
different subtypes are distinguished by the involvement of different tissues, in particular skin 
(cutaneous ATLL), lymphocyte count and percentage and different blood markers such as 
calcium levels.  
Acute and lymphoma types carry the most severe prognosis, and median survival stands at 13 
months from diagnosis (Ratner et al., 2009). The chronic and smouldering subtypes carry a 
better prognosis, however both can develop into acute ATLL (Nicot, 2005). 
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1.4.2. Inflammatory disease 
HTLV-1 has been associated with a number of inflammatory diseases. These include uveitis, 
an inflammation of the eyes (Mochizuki et al., 1992); polymyositis, an inflammatory 
myopathy (Morgan et al., 1989); infectious dermatitis, an inflammation manifested as skin 
lesions which usually affects children in HTLV-1-endemic countries (LaGrenade et al., 
1990), and arthritis (Nishioka et al., 1989). HTLV-1 has been associated with some 
neurological manifestations of disease such as polyneuropathy, motor neuron disease and 
cognitive deficiencies, associated with lymphocyte infiltration of the central nervous system 
(CNS; Araujo and Silva, 2006). Infected individuals can develop more than one manifestation 
of HTLV-1 related disease (Nakagawa et al., 1995). 
The most common and best studied HTLV-1-associated inflammatory disease is HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP). This is an inflammation of 
the CNS affecting up to 5% of infected individuals (Gessain et al., 1985). It can affect 
HTLV-1-infected individuals decades after infection or rapidly (Nakagawa et al., 1995). It is 
characterized by a T-lymphocyte infiltration through the blood-brain-barrier to the spinal 
cord, and extensive damage of the axons and myelin, in particular in the lower lumbar region 
(Yoshioka et al., 1993). Diagnostic criteria for HAM/TSP were determined by the World 
Health Organization (WHO, 1989). Sixty percent of patients report weakness of the legs as 
the primary symptom (Araujo et al., 1998), although initial symptoms also include bladder 
dysfunction or weakness, back pain or sensory symptoms of the legs (Araujo and Silva, 
2006). Confirmation of the disease is made by the presence of anti-HTLV-1 antibodies or 
HTLV-1 antigens in the cerebrospinal fluid (CSF) by ELISA. Abnormal lymphocytes, high 
white blood cell (WBC) counts or high protein levels may also be found in the CSF.  
36 
 
HAM/TSP is a chronic illness which can progress slowly or acutely and there is no 
prognostic marker to indicate which individuals will require wheelchair. The severity of 
disease is measured based on motor disability such as the Kurtzke disability status scale 
(Kurtzke, 1955) 
HAM/TSP currently has no effective cure. Current therapies focus on managing the related 
symptoms such as spasticity and pain. Recently, attempts have been made to reduce the 
proviral load (using antiretroviral therapy or by modulating viral expression by histone 
deacetylase (HDAC) inhibitors) or to modulate lymphocyte proliferation or cytokine 
production (by the use of interferon or ciclosporin) (Araujo et al., 2008).  
 
1.4.3. Coinfection 
HTLV-1 is also associated with an exacerbated form of certain co-infections. The more 
severe, disseminated form of the helminth Strongyloides stercoralis (St) is associated with 
HTLV-1 infection (Marcos et al., 2008) and there is evidence that the co-infection 
predisposes to the development of ATLL (Nakada et al., 1987). HTLV-1 carriage is also 
associated with Mycobacterium tuberculosis infection (de Lourdes Bastos et al., 2009) and 
with more severe disease (Pedral-Sampaio et al., 1997). Co-infection with HTLV-1 and the 
human immunodeficiency virus type 1(HIV-1) is often associated with a relatively high CD4
+
 
T cell count and symptoms resembling HAM/TSP (Beilke et al., 2005).  
 
1.4.4.  Mechanisms of HTLV-1-mediated pathogenesis 
It is still not clear what is the mechanism of pathogenesis in HTLV-1-associated disease. 
37 
 
Imaging of the spine of HAM/TSP patients, as well as Investigations of the cell infiltrates in 
the CSF during various stages of the disease have led to the following three models of 
pathogenesis (Hollsberg, 1997; Araujo and Silva, 2006): 
1) The direct toxicity of T cells – HTLV-1-specific CTL killing of infected glial cells 
(Lehky et al., 1995). 
2) The autoimmunity (mimicry) model – suggests cross reactivity between viral and 
neuronal antigens. HTLV-1-specific antibodies or CTLs are activated by exposure to 
viral antigens, travel to the CNS where they cross-react to a “self” antigen presented 
on glial cells (Nagai et al., 1996), such as the neuronal heterogenous nuclear 
ribonucleic protein-A1 (Levin et al., 2002) 
3) Bystander model – suggests that the immune response within the CNS against 
infected cells triggers the release of inflammatory cytokines such as TNFα leading to 
damage of nearby cells (Ijichi et al., 1993; Daenke and Bangham, 1994). 
It is poorly understood what are the mechanisms enabling or driving an infected clone to 
transform into a malignant one, however it is likely to be a combination of both viral and host 
factors. While Tax protein has been implicated in cell transformation both in vitro 
(Grassmann et al., 1989) and in vivo (Hasegawa et al., 2006), it is not thought to be necessary 
for maintenance of the malignant clone: proviruses from the majority of ATLL patients lose 
Tax expression, either through large deletions of the provirus (Tamiya et al., 1996) - some of 
which appear to have occurred prior to integration (Miyazaki et al., 2007), through point 
mutations (both missense or nonsense) in the tax gene (Furukawa et al., 2001) or through 
DNA methylation at the 5’ LTR preventing Tax-response element-mediated expression of 
viral genes (Taniguchi et al., 2005). While Tax mRNA is often absent in ATLL cases, HBZ is 
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consistently found in ATLL (as well as other infected individuals) (Satou et al., 2006), 
suggesting that HBZ is necessary for maintenance of the infected clone. 
 
1.4.5. Animal models of HTLV-1 infection and HTLV-1-associated 
disease  
Owing to the rare and insidious nature of HTLV-1 infection, it is necessary to use animal 
models in order to study the early steps in infection. One of the most common models for the 
study of early infection and virus dissemination is the rabbit, which can be efficiently 
infected to a high PVL (Miyoshi et al., 1985, Haynes et al., 2010). However, a recent study 
comparing the rabbit and NHP models of infection showed that when examining the role of 
particular proviral genes in establishing infection, the different models do not provide the 
same results (Valeri et al., 2010). HTLV-1-infected rabbits do not develop HTLV-1 
associated disease (Dodon et al., 2012).  
Transgenic mouse models are often used to study tumour formation driven by HTLV-1 genes 
(Hasegawa et al., 2006; Satou et al., 2011). A more recently developed mouse model is the 
humanized mice, where the human hematopoietic stem cells are used to reconstitute a variety 
of hematopoietic cells in an immune deficient mouse (Van Duyne et al., 2009), providing a 
more physiological context for establishment of virus infection in vivo. Two approaches for 
this have been used – the hematopoietic cells were either infected in vitro prior to 
engraftment (Banerjee et al., 2010) or a humanized mouse was infected by intraperitoneal 
inoculation with irradiated HTLV-1-producing cells (Villaudy et al., 2011). The humanized 
mouse model allows for the study of the early events in infection, as well as development of 
tumours in the context of human T cells. However, an important drawback with currently 
used models is the lack of a functional immune response which is predicted to play a major 
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role in shaping the virus dissemination in human HTLV-1 infection. A recently developed 
HLA-A2-expressing mouse strain was developed that is able to present antigens to the CTL 
response. This model is currently being tested for use in HTLV-1 infection research (Dodon 
et al., 2012). 
 
HTLV-1-related viruses in their natural hosts can also be used as models of HTLV-1 biology 
in the human. Bovine Leukemia Virus (BLV; Miller et al., 1969) is a B-lymphotropic 
deltaretrovirus. Natural infection of its bovine host can either remain asymptomatic or cause 
enzootic bovine leukemia, a B-cell malignant disease manifested as lymphoid tumours. 
Transmission of the virus appears similar to HTLV-1, through BLV-infected cells present in 
body fluids such as blood and milk. BLV infection of cattle is used as a model for 
tumorigenesis, and for the testing of potential therapeutic or vaccine approaches in the 
context of an effective immune response (Rodriguez et al., 2011). In a similar manner, old-
world primates such as baboons, naturally infected with STLV-1, can be used to test potential 
therapeutics (Afonso et al., 2010).  
While these animal models are potentially useful for the study of HTLV-1 molecular biology 
and proviral load, there is no good model for HTLV-1-induced HAM/TSP, and existing 
animal models either require using a different, related virus, or they fail to replicate the 
delicate balance between virus-driven replication and immune selection of infected T-cell 
clones.  
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1.4.6. Host and viral determinants of disease 
So far the main predictor of inflammatory and malignant disease is the proviral load. The 
median PVL of asymptomatic carriers is at about 0.3%. The median PVL exceeds 5% for 
HAM/TSP patients and can exceed 100% in ATLL cases (Nagai et al., 1998). The prevalence 
of HAM/TSP rises exponentially with the PVL, in loads above 1%, and in a 10 year followup 
study of 64 HAM/TSP patients (Matsuzaki et al., 2001) a higher proviral load was associated 
with a faster disease progression, suggesting a role for proviral load in pathogenesis. A high 
proviral load is also considered to be a prognostic factor in ATLL (Iwanaga et al., 2010), as 
well as blood markers such as high lactic dehydrogenase and hypercalcemia (Tsukasaki et al., 
2009).  
Since the proviral load is such an important predictor of pathogenesis and disease 
progression, efforts have focused on improving our understanding of what determines the 
proviral load, and in seeking therapeutic approaches for reducing the proviral load.  
Expression of Tax in CD4
+
 T-cells may play a role in disease:  at a given proviral load, 
HAM/TSP patients have a higher proportion of Tax
+
CD4
+
 T cells than asymptomatic HTLV-
1 carriers (Asquith et al., 2005b). 
HTLV-1-specific CTLs can kill Tax-expressing cells in vitro (Asquith et al., 2005a; Hanon et 
al., 2000a). The viral suppression assay (Asquith et al., 2005a) is a flow-cytometry based 
assay which quantifies the efficiency (Tax cells killed per day per CD8
+
 cell) of the CTL 
response to Tax. Fresh unstimulated PBMCs are incubated overnight in the presence of 
different numbers of autologous CD8
+
 T cells, and surviving Tax-expressing cells are 
quantified by flow cytometry. The strength of this assay is that naturally-processed viral 
antigens are presented to autologous CD8
+
 T-cells, with minimal in vitro manipulation. The 
viral suppression efficiency has been found to be inversely correlated with the proviral load 
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and with proportion of Tax-expressing cells (Kattan et al., 2009); however, at a given viral 
suppression efficiency, the proviral load was still higher in HAM/TSP patients than in ACs 
(Asquith et al., 2005a). Tax expression, therefore, varies between individuals, but also within 
individuals. This variable level of Tax expression may have a direct impact on HTLV-1 
dynamics, since cells that express Tax after overnight ex vivo culture turn over faster in vivo 
(Asquith et al., 2007) and CD4
+
 T cells that express a greater amount of Tax are killed more 
efficiently in vitro by autologous CTLs (Kattan et al., 2009). 
It is not known what determines the rate, amount and timing of Tax expression by an 
individual cell.  
 
The role of host genetics  
The risk of developing HTLV-1-related disease varies between different endemic countries. 
HAM/TSP is more frequent in Africa and the Caribbean than in Japan (Maloney et al., 1998; 
Kaplan et al., 1990). The incidence of disease cannot be explained by viral sequence (Daenke 
et al., 1990; Niewiesk et al., 1994). This suggests that the genetic background could play a 
role in determining disease risk. In a genetic association study carried out on an ethnically 
homogenous group in the Kagoshima prefecture of Kyushu, Japan, more than 40 candidate 
genes were examined. HLA-A*02 and HLA-Cw*08 were found to be protective (associated 
with a lower load in ACs and with remaining asymptomatic) and HLA-B*54 was found to be 
associated with increased risk of HAM/TSP (Jeffery et al., 1999; Jeffery et al., 2000; Vine et 
al., 2002). In particular, HLA-I alleles which are predicted to strongly bind HBZ are 
associated with a better outcome of HTLV-1 infection (Macnamara et al., 2010). More 
recently, further analysis of the same cohort has demonstrated that the protective effect of 
HLA-Cw*08 and the detrimental effect of HLA-B*54 was limited to those individuals which 
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also carry a particular killer cell immunoglobulin-like receptor (KIR) allele, KIR2DL2 (Seich 
Al Basatena et al., 2011). Class II alelles HLA-DRB1*0101 has been found to be associated 
with increased risk of HAM/TSP (Kitze et al., 1998). The 191C allele of IL-15 has been 
found to be associated with reduced proviral load (Vine et al., 2002). This is of particular 
interest because IL-15, which is upregulated by Tax, is thought to increase survival of CD8
+
 
T cells in HTLV-1 infection (Azimi et al., 2001).  
While the genetic polymorphisms give insight into mechanisms of HTLV-1 infection (such as 
the role of MHC genes in controlling the proviral load), these factors only explain less than 
10% of the observed variation in proviral load. (Vine et al., 2002; Bangham, 2008) 
 
Gender appears to play a part in infection and disease. HTLV-1 is transmitted from male to 
female with higher frequency than female to male (Murphy et al., 1989a), and it is suspected 
that girls are at higher risk of infection through breast-feeding compared with boys (Ureta-
Vidal et al., 1999). As a result, more women than men are infected with HTLV-1. Infected 
men have an increased lifetime risk of ATLL (incidence in Japan – 3-5% in males compared 
to 1-2% of females; Yamaguchi and Watanabe, 2002), while women have a higher risk of 
HAM/TSP (Maloney et al., 1998). Deterioration of HAM/TSP symptoms appears to be more 
rapid in women with disease onset pre-menopause, which suggests a role for hormones in 
disease progression (Lima et al., 2005).  
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1.5. Dynamics of HTLV-1 infection 
HTLV-1 causes a persistent life-long infection in infected individuals. This persistent 
infection remains at a constant level despite a strong specific constitutively active immune 
response, and can lead to severe or fatal disease. It is still not clear how the virus regulates its 
expression and replication in order to escape this immune control and maintain a constant 
viral burden. The proviral load, in turn, is our best prognostic marker for HTLV-1 associated 
disease. This suggests that in order to better understand and monitor HTLV-1 dynamics and 
pathogenesis, we must take a closer look at the proviral load itself (Figure ‎1.6), and what 
determines the proviral load.  
 
1.5.1. The immune response to HTLV-1  
Innate immunity 
The interferon pathway appears to play a role in infection and pathogenesis. In vitro infection 
of pDCs appears to induce an interferon-α (IFNα) response, mediated by the Toll-like 
receptor (TLR) 7 (Colisson et al., 2010), which is known to respond to single stranded RNA 
(Kawai and Akira, 2011). HTLV-1, in response, appears to impair the IFN response in 
infected pDC as these show decreased IFN production ex vivo (Hishizawa et al., 2004). It is 
not clear, however, whether the IFN response is beneficial in HTLV-1 infection. Tattermusch 
and colleagues have recently shown that interferon-stimulated genes (including genes that are 
inducible by type 1 or type 2 IFNs) are upregulated in HAM/TSP compared with high-load 
ACs (Tattermusch et al., 2012) and this upregulation was found to be correlated with disease 
severity. Furthermore this study has shown that neither Tax nor HBZ mRNA were 
downregulated by IFNα treatment of infected cells. While IFNα treatment has shown some 
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promise in ATLL when used in conjunction with AZT (azidothymidine; Hodson et al., 2011; 
Kchour et al., 2007), it is not been shown to be very effective in the treatment of HAM/TSP 
(Arimura et al., 2007).  
 
Adaptive immunity 
HTLV-1 infection elicits a strong antibody response. In the serum of HTLV-1infected 
individuals antibodies against Gag, Env, Tax, Rex and HBZ can be found (Lal et al., 1994; 
Burbelo et al., 2008; Enose-Akahata et al., 2013). While in the sera of the majority of patients 
antibodies against Tax were found (de Souza et al., 2011), anti-HBZ antibodies are only 
found in about 10% of cases (Enose-Akahata et al., 2013). 
There is typically a higher titre of anti-Env and anti-Tax antibodies in HAM/TSP patients 
than in ACs, but a positive correlation between the proviral load and antibody titre is not 
always found (Kira et al., 1992; de Souza et al., 2011; Burbelo et al., 2008). Anti-HTLV-1 
antibody titres vary between patients but appear to be stable in a patient over time (Burbelo et 
al., 2008).  
It is not clear what role, if any, anti-HTLV-1 antibodies may have in controlling the infection: 
because of the highly cell-associated nature of the virus, it is thought that antibodies have 
limited impact on the infection. 
The arm of the immune system that has the most significant impact on HTLV-1 infection is 
the HTLV-1-specific CTL response. The association of particular MHC-I alleles with 
protection from HTLV-1-associated disease and low proviral load (Bangham, 2008), as well 
as the existence of escape mutations in known CTL epitopes (Niewiesk et al., 1995) suggest a 
significant role of the CTL response in exerting selection upon HTLV-1. CTLs recognize 
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short linear peptides processed through the endogenous pathway and presented on MHC-1 
molecules. There is a high frequency of activated anti-HTLV-1 CTLs in the blood of HTLV-
1 infected individuals, both patients with HAM/TSP (Jacobson et al., 1990) and 
asymptomatic carriers (Parker et al., 1992). The immunodominant viral protein is Tax, 
followed by Gag and Pol (Goon et al., 2004a). In the context of the common HLA-A*0201 
allelle, one epitope, Tax11-19, has been shown to elicit a particularly strong CTL response 
(Elovaara et al., 1993; Nagai et al., 2001b; Kozako et al., 2011). In recent years, more 
attention has been given to the “quality” of the CTL response (Bangham, 2009), rather than 
focusing on CTL frequency. There is now strong evidence that the CTL frequency in 
response to a given antigen concentration is not a useful measure of the effectiveness of the 
immune response. A better index of CTL efficiency is the functional avidity, defined as the 
reciprocal value of the peptide concentration at which 50% of specific CTLs respond to 
antigen (Kattan et al., 2009).  
The HBZ protein is not immunodominant (Suemori et al., 2009), however recent evidence 
has emerged which suggests that the anti-HBZ CTL response has significant clinical 
importance. MacNamara et al used predictions of binding strength of HTLV-1-derived 
peptides to the MHC I allelles present in a large HTLV-1 infected individual cohort from 
Kagoshima, Japan (Jeffery et al., 1999). They found that possession of HLA alleles that are 
predicted to bind strongly to HBZ peptides is protective in HTLV-1 infection, and the 
number of strong binding HBZ peptide-binding HLA alleles correlated negatively with 
HTLV-1 proviral load (Macnamara et al., 2010). Further work has demonstrated that patients 
with IL-2-secreting HBZ-specific CTLs were more frequent in ACs and individuals with a 
low PVL (Hilburn et al., 2011).  
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The CTL response mounted against HTLV-1 may be repressed by Tregs: There is an inverse 
correlation between CTL lysis efficiency (measured using the viral suppression assay 
described above) and the percentage of CD4
+
FoxP3
+
Tax
–
 cells (Toulza et al., 2008).  The 
high frequency of FoxP3
+
 cells could be explained (Toulza et al., 2010) by Tax-driven 
upregulation of CCL22, which is a ligand for the CCR4 molecule expressed on FoxP3
+
 cells.  
 
1.5.2.  HTLV-1 proliferation 
Proliferation of a retrovirus can take place by one of two mechanisms. Mitotic spread is the 
passive replication of the provirus that accompanies mitosis of infected cells. This will result 
in expansion of existing clones, in each of which all daughter cells share the same proviral 
integration site. Infectious spread is the de novo infection of a new cell, generating a new 
infected clone with a different integration site. Mitotic and infectious spread can also be 
distinguished by the replication mechanism involved – while mitotic spread utilizes the host 
cell machinery and DNA polymerase to replicate the DNA, infectious spread uses the error 
prone viral reverse transcriptase in order to complete the viral replication cycle. 
 
Mechanism of cell-cell transmission for de-novo infection 
HTLV-1 is extremely highly cell-associated, and cell-cell contact is required for transmission 
of the virus (Yamamoto et al., 1982b). The virological synapse (Error! Reference source 
not found.A) is a virus-induced area of cell-cell contact (Igakura et al., 2003) which allows 
transmission of the virus between infected and target cell, by polarization of the cytoskeleton 
towards the uninfected cell. This polarization is triggered by the viral gene Tax as well as by 
stimulation of the intercellular adhesion molecule-1(ICAM-1; Nejmeddine et al., 2005; 
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Nejmeddine et al., 2009). Tax has been shown to increase the efficiency of HTLV-1 
transmission by over 10 fold (Mazurov et al., 2010). The virological synapse is similar to the 
immunological synapse, however while in the virological synapse the microtubule organizing 
center (MTOC) is polarized in the HTLV-1 infected cell towards the cell-cell junction 
(Igakura et al., 2003), triggered by adhesion molecules, the MTOC in the case of the 
immunological synapse is polarized in the responding T cell towards the antigen presenting 
cell, triggered by the T cell receptor (Grakoui et al., 1999). The use of electron tomography to 
visualize the virological synapse demonstrated that the virus particles are present in multiple 
clefts within the synapse, surrounded by tightly bound plasma membranes forming confined 
intracellular sites (Majorovits et al., 2008). This is consistent with the observation that cell 
free virus particles are not found in plasma, and suggests a mechanism of escape from 
immune surveillance by HTLV-1-specific antibodies and complement (reviewed in 
Nejmeddine and Bangham, 2010).  
While not produced by primary infected lymphocytes, cell free HTLV-1 virions can be 
recovered from some chronically infected cell lines such as MT2, and these can inefficiently 
infect other cells in vitro (Fan et al., 1992; Mazurov et al., 2010). Cell free infection of 
dendritic cells (DCs) has been described (Macatonia et al., 1992; Jones et al., 2008), and 
these infected DCs were able, in turn, to productively infect primary T cells ex vivo by cell-
to-cell contact. It is not clear what role this mechanism may play in vivo (Error! Reference 
source not found.B), however the fact that HTLV-1-specific CD4
+
 cells are more likely to 
be infected with HTLV-1 themselves (Goon et al., 2004b), may be explained by presentation 
of HTLV-1 peptides on infected DCs in the context of MHC-II, allowing preferential 
infection of HTLV-1 specific Th cells.  
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Another observation recently reported was the visualization by electron microscopy of 
extracellular viral clusters on the surface of infected cells in vitro(Error! Reference source 
not found.C), reported to form bio-film like carbohydrate rich assemblies (Pais-Correia et al., 
2010) . These are suggested to allow a protective environment for transmission of virus 
particle to target cells on the surface of both infected and target cell. 
It is difficult to quantify the role played by each mechanism in vivo.  
 
 
 
 
 
Figure ‎1.5: Mechanisms of HTLV-1 cell-cell transmission 
Three proposed mechanisms of viral transmission to susceptible cell. (A) Viral transmission via the 
virological synapse, an isolated area of cell-cell contact which allows for the transmission of HTLV-1 
particles to a target cell avoiding exposure to the humoral immune response. (B) Cell free infection of 
dendritic cells leads to cell-cell transmission to susceptible T cells. (C) Virus accumulation at cell 
surface in biofilm like structures. Figure adapted from Nejmeddine and Bangham, 2010 
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Mitotic expansion of infected cell clones 
It is not clear what determines infected cell proliferation in HTLV-1 infection. HTLV-1 
infection has been shown to drive through cell cycle checkpoints  (Matsuoka and Jeang, 
2005) and regulate apoptosis of infected cells, both could result in a higher proliferation of 
infected cells. (Kasai and Jeang, 2004). HTLV-1-infected cells turn over faster in vivo 
(Asquith et al., 2007). Two viral genes have been implicated. As discussed above, Tax has 
been shown both in vitro (Grassmann et al., 1989) and in vivo (Hasegawa et al., 2006) to be 
sufficient for efficient cell transformation.  More recently HBZ has been shown to be able to 
promote cell proliferation and to drive cell transformation in a mouse model (Satou et al., 
2011).  
 
The ratio of infectious to mitotic spread 
Two lines of evidence led to the conclusion that mitotic spread plays a significant role in 
maintenance of the proviral load: First, integration site analysis, demonstrated the existence 
of long-lived expanded clones in vivo (Furukawa et al., 1992; Cavrois et al., 1996; Wattel et 
al., 1995; Etoh et al., 1997; Gillet et al., 2011). Second, the low observed frequency of 
sequence diversity between HTLV-1 isolates compared with that of other retroviruses (Ina 
and Gojobori, 1990; Overbaugh and Bangham, 2001) is consistent with the idea that the 
majority of proviral replication takes place using the proofreading host cell DNA polymerase 
rather than the error-prone reverse transcriptase.  
The ratio of mitotic to infectious spread of HTLV-1 is not currently known. Moreover, there 
is little known about the role that expression of proviral genes play in determining this ratio. 
Both HBZ and Tax have been shown to be able to drive cell proliferation, therefore both may 
50 
 
have a role in driving mitotic spread in vivo. Tax protein has also been shown to play a role 
in driving cell-to-cell transmission of HTLV-1, and indeed it is possible that a central 
function of Tax is to drive infectious spread (Nejmeddine et al., 2005; Mazurov et al., 2010). 
At the same time, Tax is a major immunogen, exposing an infected cell clone to the immune 
response.  
The proviral load, therefore, is composed of the sum of all infected cell clones. We postulate 
two main selection forces determining the clone size: the first is the ability of a cell clone to 
proliferate, and the second, is its susceptibility to be killed. If these selection forces acted 
equally across cell clones we would expect to see an equal survival advantage in all clones, 
and each clone would reach the same abundance in the steady state.  
 
This work focused on developing experimental and bioinformatics methods for the 
investigation of the clonal distribution of the load, in order to test specific hypotheses 
regarding the role of the genomic environment and proviral expression in in vivo clonal 
expansion.  
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Figure ‎1.6: The clonal distribution of the proviral load. 
Infected cell clones can be distinguished by their unique integration site (UIS). Virus proliferation can 
take place either by mitotic spread (expansion of infected clones, all daughter cells sharing the same 
integration site) or by infectious spread (generating a new infected clone with a novel integration site). 
This takes place on a background of mostly uninfected cells. The proviral load is the sum of all 
infected T cell clones (% infected PBMCs). 
 
 
  
52 
 
1.6. Aims 
The work aims to develop a high-throughput sequencing based method to amplify, map and 
quantify HTLV-1 proviral integration sites from HTLV-1 infected cells, and then use the 
method to test the following hypotheses:  
1) The genomic environment flanking the proviral integration site is associated with 
targeting of the provirus to the genome, and with the long-term clonal expansion of 
infected cells. 
2) The genomic environment flanking the integration site is associated with proviral 
gene expression from the 5’LTR, which in turn has an effect on clonal expansion of 
infected cells.  
3) The infected CD8+ cells shape the infected cell clonal distribution in vivo.  
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Chapter 2 -  Materials and Methods 
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2.1. Primary cells and cell lines 
2.1.1. Patient samples 
Blood samples were donated by HTLV-1-infected individuals attending the HTLV-1 clinic at 
the National Centre for Human Retrovirology (Imperial College Healthcare NHS trust) at St 
Mary’s Hospital, London UK, with fully informed written consent. This study was approved 
by the UK National Research Ethics Service (NRES reference 09/H0606/106). Diagnosis of 
HAM/TSP was done according to WHO criteria (WHO, 1989). 
PBMCs were isolated from blood using Histopaque-1077 (Sigma-Aldrich) and cryo-
preserved in fetal bovine serum (FBS; Gibco – Life Technologies) containing 10% dimethyl-
sulfoxide (DMSO; Sigma-Aldrich).  
2.1.2. Cell lines used 
HTLV-1 negative Jurkat cells (Schneider et al., 1977) were used as negative control and for 
in vitro infection (see below). Tarl2 (Tateno et al., 1984) is an HTLV-1-infected rat leukocyte 
cell line containing one copy of the HTLV-1 provirus per cell. MT2 (Miyoshi et al., 1980) is 
an HTLV-1-producing cell line. All cell lines were cultured at containment level 2 (Jurkat) or 
3 (MT2 and Tarl2) lab in complete medium: RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 1% l-Glutamine, 1% penicillin/streptomycin and 10% heat-inactivated 
FBS. Cells were maintained at a concentration of 10
5
-10
6
 cells/ml.  
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2.1.3. In vitro infection of Jurkat cells 
Two independent assays of in vitro infection were carried out (one by Dr. Nicolas Gillet, see 
Table ‎3.1). Jurkat cells were co-cultured for 3h with γ-irradiated (137 Cs, 40,000 cGy) MT2 
cells pre-labelled with anti-CD4 MicroBeads (Miltenyi). MT2 cells were then depleted from 
the co-culture using magnetic separation (Miltenyi), and infected Jurkat cells were 
maintained in culture for 14 days in complete medium at 37⁰C with 5% CO2. Genomic DNA 
was extracted and the proviral integration sites analysed as described below. Integration sites 
from MT2 were also analysed to exclude possible contamination of the Jurkat integration 
sites. No contaminating MT2 integration sites were found after 14 days. 
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2.2. Cell sorting  
2.2.1. Tax sorting 
See also Figure ‎2.1. PBMCs from 10 patients with HAM/TSP with a high proviral load 
(range 12.2-50.6 copies per 100 PBMCs) were depleted of CD8
+
 cells using anti-CD8 
antibody-coated magnetic beads (Miltenyi) and incubated in complete medium for 18 hours 
at 37⁰C with 5% CO2. After 18h culture, the cells were fixed and permeabilized 
(eBioscience), and then stained for intracellular expression of Tax (anti-Tax mAb LT4, 
Tanaka et al 1991), as well as surface expression of CD4 (clone RPA-T4, eBioScience), and 
CD8 (clone SK1, eBioScience). Live/Dead cell marker (Invitrogen) was used to exclude 
possible autofluorescence by dead cells. Cells were sorted by Fluorescence-activated cell 
sorting (FACS; FACSAria IIIU, BD Biosciences) to isolate two populations of live CD4
+
 
cells based on Tax expression. 
The flow gating strategy (FACSDiva, BD Biosciences; Figure ‎2.2A) was as follows: first 
dead cells and doublets were excluded. The gate was then set on CD4
+
CD8
–
 cells (the vast 
majority of CD8
+
 cells had been depleted) and then on Tax-expressing or non-expressing 
cells. Gates were set to ensure a clear demarcation between the Tax
+
 and Tax
–
 populations.  
DNA was extracted from whole unsorted PBMCs from each patient and analysed separately 
to identify the patient of origin of each clone; 46% of the clones were attributed in this way.  
Recovered cells from all 10 patients were combined in two pools, respectively CD4
+
Tax
+
 
cells and CD4
+
Tax
–
 cells. The DNA from each pool was extracted, and integration sites 
content analysed (see ‎2.4 below).  
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Figure ‎2.1: Protocol for flow-sorting of Tax-expressing cells. 
(A) CD8
+
 depleted PBMCs from 10 HAM/TSP patients were studied. The cells were incubated 
overnight, and then sorted for Tax expressing or non-expressing cells by FACS (Figure ‎2.2).  
(B) Recovered cells from all 10 patients were combined into two cell pools of CD4
+
Tax
+
 cells and 
CD4
+
Tax
–
 cells. (C) Genomic DNA was extracted from each cell pool separately, and integration site 
analysis was carried out.  
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Figure ‎2.2: Flow cytometry sorting by Tax expression.  
(A) Representative FACS plots of the gating procedure used for sorting CD4
+
Tax
+
 (‘TAX pos’) and 
CD4
+
Tax
–
 (‘TAX neg’) cells. Gate setting was used to unequivocally distinguish between negative 
and positive populations. (B) Purity testing of Tax-sorted cells, Tax
+
 cells not detected. (C) Purity 
testing of Tax
+
 sorted cells, 0.2% were Tax
–
.  
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2.2.2. CD4+ and CD8+ T-cell sorting 
See also Figure ‎2.3. Uncultured, cryopreserved PBMCs from 12 HTLV-1 infected individuals 
(6 patients with HAM/TSP and 6 asymptomatic carriers) were sorted for CD4
+
 and CD8
+
 
expression, using positive selection magnetic sorting (Miltenyi). In order to maximize purity 
and recovery, cells were sorted 4 times (repeating each selection), first positively selecting 
CD4
+
 cells, and then positively selecting CD8
+
 cells from the CD4
–
 fraction.  
Unsorted PBMCs, as well as each sorted fraction was stained for CD3 (clone UCHT1, 
eBioscience, CD4 (clone RPA-T4, eBioscience) and CD8 expression (clone SFCI21Thy2D3, 
Beckman Coulter). FACS (CyAn™, Beckman Coulter) was used to analyse the purity of the 
resulting populations and to quantify the cell populations in the unsorted samples.  
 
 
 
 
Figure ‎2.3: Cell sorting approach for the purification of CD8
+
 and CD4
+
 cell populations. 
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2.3. Molecular biology methods 
2.3.1. DNA extraction 
DNA was extracted from primary cells and cell lines using the DNeasy Blood & Tissue kit 
(Qiagen) according to manufacturer’s instructions and eluted and stored in EB buffer 
(Qiagen). 
DNA concentration was quantified using Nanodrop 1000 (Thermo Scientific).  
2.3.2. Proviral load measurements 
All primers described in this section are detailed in Appendix I. The proviral load was 
measured by quantitative PCR (QPCR) method using Light cycler
®
2.0 (Roche). PCR was 
carried out using the LightCycler
®
 FastStart DNA Master^PLUS reagent (Roche) according 
to manufacturer’s instructions. Proviral copies were quantified using Tax specific primers 
(SK43, SK44, Kwok et al., 1988) and normalized to number of cells using β-Actin specific 
primers (Actin-fw, Actin-rev). Tax amplification was done over 45 cycles of 10 seconds at 
95⁰C, 5 seconds at 58⁰C, 8 seconds at 72⁰C and 10 seconds at 87⁰C. Amplification of actin 
was done over 45 cycles of 10 seconds at 95⁰C, 5 seconds at 60⁰C, 12 seconds at 72⁰C and 2 
seconds at 85⁰C.  
Standard curves were generated from Tarl2 DNA at 6 different concentrations (5 to 0.02 
ng/μl) and DNA samples were tested at 3 different concentrations (5 to 0.56 ng/μl). The 
proviral load was determined as the mean number of Tax copies per 100 cells. 
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2.3.3. LTR sequencing 
Because the HTLV-1 LTR varies in sequence among isolates, the LTR was sequenced using 
Sanger sequencing (MRC Clinical Sciences Centre Genomics Laboratory) before 
amplification of the integration site using patient-specific primers. PCR conditions were: 3 
minutes at 98⁰C; 35/45 cycles of 10 seconds at 98⁰C, 20 seconds at 64⁰C, 20 seconds at 72⁰C 
followed by 10 min at 72⁰C, using primers flanking the 5’LTR-Gag junction. We assumed 
that the sequence of the primer binding sites in the 5’LTR and 3’LTR were identical.  
 
 
 
 
 
 
 
Figure ‎2.4: Location of the primers used to amplify the LTR region.  
The forward primer (5LTRFW) and the sequencing primer (LTRseq) are upstream of the LM-PCR 
primers binding sites (Bio3, Bio5, see Figure ‎3.2B); reverse primer (5LTRRV) is downstream of the 
LTR-Gag junction in order to enable the complete amplification of the desired region.  
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2.4. Analysis and quantification of proviral integration sites 
2.4.1. Preparation of integration site libraries for sequencing 
Analysis of HTLV-1 proviral integration sites is detailed in Chapter 3. See also figure 3.1.  
Up to 10 μg of DNA is sheared using focused-ultrasonicator (Covaris S2) using the following 
conditions: Initial quick burst step - 20% duty cycle, level 5 intensity, 200 cycles per burst, 5 
seconds followed by 5% duty cycle, level 3 intensity, 200 cycles per burst, 90 seconds.  
This is followed by enzymatic end repair to blunt the using 15U T4 DNA polymerase (New 
England Biolabs – NEB), 50U T4 Polynucleotide Kinase (NEB) and 5U DNA Polymerase I, 
Large (Klenow) Fragment (NEB) for 30 minutes at 20⁰C. This is followed by adding a base 
on 3’ ends using 30U Klenow Fragment (3'-5' exo-) for 30 minutes at 37⁰C.  
The DNA fragments are ligated to partially double stranded linkers (figure 3.2) containing a 
sample-identifying 6 base barcode using NEB Quick Ligation Kit.  
Two-step PCR is used to selectively amplify the HTLV-human genome junction at the 
3’LTR. The first PCR is carried out between the two primers Bio3 (at the LTR) and Bio4 (at 
the linker) and the second (nested) PCR between Bio5 (at the LTR) and P7 (at the linker). 
The second PCR step is also used to prepare the required ends for high-throughput 
sequencing by adding P5 to the Bio5 primer. PCR conditions for both PCR steps are 30 
seconds at 96⁰C; 7 cycles of 5 seconds at 94⁰C, 60 seconds at 72⁰C; 23 cycles of 5 seconds at 
94⁰C, 60 seconds at 68⁰C; and 9 minutes at 68⁰C. 
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2.4.2. Library quantification prior to sequencing.  
Prepared libraries of PCR-amplified products were combined based on DNA concentration. 
Libraries were then quantified using QPCR which more specifically quantifies DNA 
amplicons which contain the correct structure for high-throughput sequencing. A standard 
curve was based on previously quantified and sequenced libraries.  
2.4.3. Flow cell design 
HTLV-1 integration site DNA libraries were sequenced in the Illumina sequencing platform. 
These sequencing systems use flow cells devided into 8 lanes, one of which is always used as 
control and contains only DNA libraries containing bacteriophage phiX DNA. The samples 
on each flow cell were sorted according to the following criteria:  
1) Samples were randomly mixed between the lanes.  
2) Where more than one sample from a particular patient was sequenced, the samples 
were represented only once on each lane, to enable the barcode sorting analysis.  
3) Where more than one sample from a particular patient was sequenced, the same 
barcode was not used more than once with samples from the same patient to avoid 
bias due to the use of a particular barcode.  
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2.4.4. High-throughput sequencing using the Illumina pipeline 
Prepared libraries were sequenced by Dr. Laurence Game and Adam Giess at the MRC 
Clinical Sciences Centre Genomics lab at the Hammersmith Hospital, London on an Illumina 
GAIIx or HiSeq 2000 sequencer. Sequencing was paired-end (50 bp each read) with a 6 bp 
barcode. PhiX DNA was used on one of the lanes as a control. The Illumina analysis pipeline 
was used for image processing, base-calling and alignments, with default filter and quality 
settings. Alignment of the reads was done using the Eland Paired algorithm of CASAVA 
against the UCSC human genome build 18 (excluding haplotypes, unplaced contigs and 
mitochondrial sequences) and HTLV-1 sequences. The last cycle of each read was excluded 
from the alignment, for increased accuracy.  
Three sequencing reads were performed (figure 3.3): Read 1 uses the HTLVseq sequencing 
primer, generating a sequence at the integration site; Read 2 uses the SBS8 sequencing 
primer, generating a sequence at the shear site and Read 3 uses the SBS8rev sequencing 
primer, defining the sample-identifying 6-base barcode.  
65 
 
2.5. Bioinformatics 
2.5.1. Random sites 
As a matched control for the experimentally derived HTLV-1 integration sites, a random list 
of integration sites generated in silico was produced. A list of 192,171 genomic coordinates 
was generated in silico by Nirav Malani (Group of FD Bushman, U Penn, USA) based on 
genomic coordinates in hg18 chromosomes (excluding gaps).  
In order to eliminate any in silico sites that originate from genomic regions where true 
integration sites would not be identified (gaps, repeated regions), 50 bp DNA sequences at 
the genomic sites (as well as “paired end” matches within 200 bp) were generated using the 
Galaxy tool (Blankenberg et al., 2010) and back-aligned to the human genome reference 
through the Illumina pipeline in an identical manner to the “true” integration sites. Resulting 
export files were extracted using the same filters (see chapter 3 for details) as “true” 
integration sites resulting in a total of 176,514 sites.  
A “single read” sample (not including the “paired” sites within 200 bp, total of 170,433 sites) 
was also generated but was found not to differ significantly from the paired list with respect 
to the genomic environment.  
66 
 
2.5.2. Annotation of genomic environment 
Genomic environment flanking Integration sites were compared with specific annotations to 
the human genome. See Table ‎4.3 for detailed information and references for each dataset 
used.  
Transcription unit and CpG islands data were retrieved from publicly available datasets on 
the NCBI ftp site (ftp.ncbi.nih.gov/gene/) and UCSC tables (Karolchik et al., 2004), 
respectively. Transcription factor and chromatin remodeler chromatin immunoprecipitation -
sequencing (ChIP-seq) datasets were retrieved from published datasets (see Table ‎4.3). 
Where possible, data from primary CD4
+
 cells were used; otherwise, data from human CD4
+
 
cell lines or other available cell line. Where raw ChIP-seq data were available we used the 
SISSRs algorithm (Jothi et al., 2008) to identify the position of a putative transcription factor 
binding site. Comparisons of genomic coordinates of integration sites and genomic 
annotations were carried out using the R package hiAnnotator 
(http://malnirav.github.com/hiAnnotator), kindly provided by Nirav Malani and Frederic 
Bushman (University of Pennsylvania, USA)  
 
2.5.3. Quantification of Tax expressing/non-expressing clones 
To calculate the fraction of Tax
+
 cells in a given clone, the frequency of Tax
+
 and Tax
–
 cells 
were normalized to the mass of genomic DNA per cell from each respective cell population, 
to correct for experimental variation in efficiency of genomic DNA isolation (Table ‎5.1).  As 
proviral load data was not available for Tax-sorted samples, clonal abundance was quantified 
by the number of sisters per clone.   
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2.5.4. Calculation of CD8+ T-cell contribution to the proviral load 
The contribution of infected CD8
+
 cells to the proviral load of each infected patient was 
calculated by using two approaches:  
1) Calculation based on proviral load in either CD4+ or CD8+ population. If (
       
    
) is 
the proviral load within CD8
+
 cells, and 
    
    
 is the proportion of PBMCs which are 
CD8
+
, the contribution of infected CD8
+
 cells to the proviral load is calculated in the 
following manner:  
Equation ‎2.1 
% of load in CD8
+
 cells = 
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2) The proportion of cells identified within the unsorted PBMC integration site data as 
belonging to CD8
+
 clones.   
 
2.5.5. Statistics 
Statistical analysis was carried out using R version 2.13.0 (http://www.R-project.org/). See 
text for details of particular statistical tests. Where appropriate, non-parametric tests were 
used. Results were considered statistically significant when p < 0.05.  
Two separate logistic regression analyses were carried out, respectively, to identify 
independent predictors of HTLV-1 integration targeting (Chapter 4) and independent 
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predictors of Tax positivity (Chapter 5). Input variables used were published ChIP-seq 
datasets (see ‎2.5.2 above, Table ‎4.3). For integration targeting (Chapter 4), the binary 
outcome measure was a “true” integration site (from 4521 identified in vitro integration sites) 
or a “false” integration site (45210 random genomic locations). For spontaneous Tax 
expression (Chapter 5), the binary outcome was either Tax positivity (20813 Tax
+
 cells) or 
Tax negativity (10326 Tax
–
 cells). For each outcome variable, two separate analyses were 
carried out, respectively at two distances from the integration site - 100 bases and 1kb. Each 
transcription factor binding site (TFBS) was tested (presence or absence of the TFBS within a 
given distance of the integration site) as an independent predictor in each analysis.  
The multivariate analysis approach is detailed in Figure ‎2.5. First, for each TFBS and at each 
distance, we tested whether the relative position (upstream/downstream) of the integration 
site and the TFBS determined the outcome by using a likelihood ratio test to compare two 
competing models: 1) presence or absence of TFBS upstream or (separately) downstream; 2) 
presence or absence of TFBS, regardless of relative position. Next, we carried out univariate 
analysis of each individual TFBS, based on the model chosen by the likelihood ratio test. 
Only TFBS that were significant (p-value < 0.05) after correction for multiple comparisons 
(Benjamini-Hochberg) were used in the multivariate analysis. Multivariate analysis was 
carried out using a step-down logistic regression method. 
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Figure ‎2.5: Analytical approach for multivariate analysis. 
Multivariate analysis was used in order to find independent correlates of proviral integration and 
proviral expression. For integration targeting, the binary outcome measure was a “true” integration 
site (from 4521 identified in vitro integration sites) or a “false” integration site (45210 random 
genomic locations). For spontaneous Tax expression, the binary outcome was Tax positivity (20813 
Tax
+
 cells) or Tax negativity (10326 Tax
–
 cells). Analytical steps for building multivariate logistic 
model are detailed here (see also section ‎2.5.5).   
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Chapter 3 -  High-throughput method for 
mapping, identification and quantification 
of retroviral integration sites 
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3.1 Introduction 
3.1.1 Previous methods used for analysis of integration sites 
The importance of studying the clonal distribution and proviral integration sites in HTLV-1 
infection was realized shortly after the identification of the virus. Yoshida et al. (1984) 
demonstrated that HTLV-1 infection preceded the clonal expansion of a putative malignant 
clone in ATLL patients utilizing a southern blot assay which reveals a strong band when a 
large (i.e. abundant) clone is present. Owing to the low sensitivity of this assay, newer 
methods were developed based on inverse-PCR (IPCR; Takemoto et al., 1994) and linker-
mediated PCR (LMPCR; Wattel et al., 1995).  The LMPCR technique has also been used to 
identify genomic integration sites of other retroviruses (e.g. analysis of MLV integration in 
Wu et al., 2003 or of HIV integration in Schroder et al., 2002) and by this group (Meekings et 
al., 2008) and others (Derse et al., 2007) to identify a small number of clones from HTLV-1-
infected cells.  Though effective, the LMPCR method was affected by 3 major limitations: 
First, the use of restriction enzymes limited the ability to identify integration sites which were 
not within a specific proximity range from the nearest restriction site (Wang et al., 2008).  
Second, the techniques were limited with respect to the number of integration sites 
reasonably identified in a single experiment from each patient, leading to a severe under-
estimation of the true number of infected clones in a patient. Third, those techniques were not 
quantifiable, and any estimation of the proportion of infected cells in a given clones would 
have required further laborious and inefficient quantitative techniques.  
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3.1.2 The use of high-throughput sequencing in retroviral 
integration research 
The Illumina (previously Solexa) high-throughput sequencing technology (Bentley et al., 
2008) is based on sequencing-by-synthesis mechanism. This technology employs bridge 
amplification of flow cell-tethered templates followed by sequencing using fluorescently 
labelled reversible chain terminators, to deliver a large number of short reads (as of 2012, up 
to 3 billion reads per flow cell on the HiSeq 1000/2000, Liu et al., 2012).  
The development of high-throughput sequencing techniques (Holt and Jones, 2008) has 
opened the door to developing methods for deeper analysis of integration site of retroviruses, 
retroviral vectors and other retroelements (Wang et al., 2008; Gabriel et al., 2009; Williams-
Carrier et al., 2010). However the challenge to improve the recovery and accurately quantify 
the relative frequency of the integration sites remained. Approaches to tackle these problems 
included the use of a combination of restriction enzymes (Wang et al., 2010), use of phage 
Mu retrotransposition (Brady et al., 2011) and non-restrictive linear amplification–mediated 
PCR (nrLAM-PCR; Gabriel et al., 2009). However, even a combination of restriction 
enzymes, and to a lesser extent the use of transposons, still require recognition motifs that 
could limit recovery and may skew quantification (Brady et al., 2011).  
3.1.3 Aim  
We aimed to develop a new approach, based on the Illumina high-throughput sequencing 
platform, which would be able to address the limitations of the previous methods and 
simultaneously map and quantify an unprecedented (in HTLV-1) number of distinct 
integration sites from infected PBMCs.  This chapter will detail the main steps in this 
approach, as well as its strength and limitations.  
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Figure ‎3.1: Process of LMPCR – amplification of HTLV-1 integration sites 
(A) The region of interest is the junction between the 3’LTR and the human genome. (B) DNA is 
randomly sheared by sonication. (C)-(D) DNA ends are blunt ended and A base is added at 3’ ends to 
allow ligation to linker (Figure ‎3.2). (E) PCR step between primers Bio3 (LTR specific, patient 
specific primers are used) and Bio4 (linker specific). (F) Nested PCR step between primers Bio5 
(LTR specific) and P7 (linker specific). P7 and P5 oligonucleotides are required for attachment to 
Illumina flow cell. P5 oligonucleotide is added by including it in the PCR primer (P5-Bio5). P7 is 
designed into the linker.  
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3.2 Method description 
3.2.1 Preparation of libraries for sequencing 
Based on the classical LMPCR, our method was modified to address the limitations of the 
previous techniques and is illustrated in Figure ‎3.1.  The target site of interest (Figure ‎3.1A) 
is the junction between the 3’LTR of HTLV-1 and the human genome.   First, the use of 
restriction enzymes to digest the genomic DNA is replaced by random shearing of the DNA 
using sonication (Figure ‎3.1B). This eliminates the possibility of a systematic loss of 
integration sites that lie far from the nearest restriction site, and also allows us to quantify the 
frequency of the integration sites (see below).  The sheared DNA is blunt-ended (Figure 
‎3.1C) and ligated to a partially double-stranded adaptor (Figure ‎3.1D, Figure ‎3.2), which is 
then followed by a nested PCR (Figure ‎3.1E/F). This nested PCR strategy enhances the 
specificity and sensitivity of the assay. The use of a partially double-stranded linker used 
(similar to splinkerette, see Devon et al., 1995) improves specificity of the assay by allowing 
the selective amplification (during first PCR) of amplicons containing HTLV-1 LTR only.  
The linkers used also contain a 6-base barcode sequence, unique to each sample. This 
barcode enables the multiplexing of multiple samples per lane (usually up to 40 on the 
HiSeq).  
Lastly, the resulting DNA libraries are sequenced on the Illumina platform, generating a 
remarkable number of reads originating from a high number of individual clones.  
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Figure ‎3.2: linker structure. 
(A) Structure of the partially double stranded linker used for analysis of proviral integration sites. The 
nested PCR primers (P7, Bio4), as well as the paired sequencing primer sequences are highlighted. 
The linker does not contain a complementary sequence for the Bio4 primer, thus increasing PCR 
specificity (DNA containing proviral sequences only will be amplified). P7 is also used as grafting 
primer for attachment of resulting DNA amplicon to the flow cell. 6 base sample-specific barcode 
(here denoted by NNNNNN) is located between the sequencing primer binding site and P7 binding 
site. (B) Basic structure of ligated DNA. The Bio5, Bio3 primer binding sites (Wattel et al., 1995) are 
HTLV-1-specific, used for nested PCR of HTLV-1 integration sites.  
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3.2.2 High-throughput sequencing 
The specificity of the technique is further improved by using a sequencing primer which 
binds a site, 5 bases short of the LTR terminus (Figure ‎3.3). This ensures that reads from all 
true HTLV-1 integration sites will begin with the sequence ACACA, and enables us to 
programmatically eliminate any reads arising from mispriming of the sequencing primer and 
focus only on true integration sites.   
Sequencing of integration sites containing amplicons (Figure ‎3.3) is done on the Illumina 
platform. Each amplicon is sequenced 3 times:  
1) Using a sequencing primer complementary to the HTLV-1 LTR – sequence (50 bases) 
maps to the integration site 
2) Using a sequencing primer complementary to the linker, reading into the genomic 
sequence – sequence (50 bases) maps to the shear site. 
3) Using a sequencing primer complementary to the linker, reading into the 6-base 
sample-specific barcode.  
Figure ‎3.3: Amplicon basic structure for high-throughput sequencing 
The LMPCR process to prepare the integration site libraries for sequencing is detailed in Figure ‎3.1. 
P5, P7 are required oligonucleotides for attachment to Illumina flow cell. Each amplicon is sequenced 
three times (detailed above). As the 3’LTR and 5’ LTR terminus are identical, we would expect 50% 
of amplicons to contain HTLV-1 specific sequences instead of human genomic sequence. These are 
identified by alignment and removed bioinformatically (see below). 
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3.3 Data extraction –DEISA  
3.3.1 Main steps in pipeline 
In order to extract the data generated by the Illumina sequencing, I developed a bespoke 
application on the platform of the Microsoft ACCESS system – DEISA (Data Extraction for 
Integration Site Analysis). The application (Figure ‎3.4) provides a user-friendly interface 
controlling a large number of SQL tables and queries, ensuring consistency between 
experiments in the manner by which data is extracted, and allows other users to extract data 
for their experiments without any previous knowledge or expertise in using SQL or ACCESS.   
The input file to DEISA is the Illumina export file, which contains all sequenced reads, their 
mapping (as performed using the efficient large-scale alignment of nucleotide databases 
(ELAND) algorithm in the Illumina GERALD/CASAVA pipeline) and several quality 
details.  DEISA is able to auto-import the files, and then process them in turn.  The process is 
composed of the following steps:  
1) Data filtering – the sequencing reads are screened for specificity (must begin with 
ACACA), the quality of sequencing and the quality of mapping. 
2) Lane data extraction (Figure ‎3.5) – identification of the integration sites by distinct 
read 1 genomic coordinates, calculating the number of shear sites by the number of 
distinct read 2 genomic coordinates for each integration site. Sorting of integration 
sites to the different barcodes on a multiplexed lane. 
3) Data refinement – removal of artifact UIS (UIS which were mapped to a particular 
genomic locations but are in fact a PCR duplicate of another UIS with a small 
PCR/sequencing error causing a mismapping), calibration of the number of shear-sites 
(see below) and generation of the final list of integration sites.  
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3.3.2 Criteria used  
Three main criteria are used for initial assessment of each read:  
1) Quality of sequence cluster – remove reads which come from clusters overlapping on 
the flow cell, which do not produce reliable sequences. 
2) Specificity – Read1 sequence (Figure ‎3.3) must start with ACACA (for HTLV-1 
integration sites). 
3) Quality of mapping to the human genome. The Sequence must be uniquely mapped to 
the human genome reference in both reads, with a mapping score >10 (based on the 
Illumina Gerald pipeline and is required to be of reasonable length (measured by the 
genomic coordinates difference between the integration site and the shear site).  
Sequences mapped uniquely to the upstream LTR are also quantified separately.   
 
3.3.3 Quantification 
PCR bias is a known complexity when using a variable template (Polz and Cavanaugh, 
1998), in particular because of preferential amplification of short fragments in each 
successive round of PCR (Figure ‎3.9).  This PCR bias eliminates the ability to rely solely on 
the number of reads for determining the frequency of each integration site (the clonal 
abundance).  The random shearing of the DNA prior to ligation to the adaptor allows an 
alternative form of quantification (Figure ‎3.6) – as the shearing site of the DNA will occur in 
a different position for DNA originating from each infected cell, by counting the number of 
different shear sites we are able to count the number of cells in each clone. We define an 
infected clone as all the cells which share an integration site.  We define the different cells 
sharing an integration site as sisters (thus, the clone abundance is the total number of sisters 
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in a given clone,  ). We define a clone which was only identified once as a singleton (i.e. 
clones for which    ).  
We define three main measures of abundance of a given clone:  
                                                
The clone abundance -                                          
          
The relative abundance – the share of the load taken up by each clone: 
Equation  3.1                       
  
∑   
 
   
 
The Absolute abundance – the number of sisters of each clone per 10000 PBMC: 
Equation  3.2                           
  
∑   
 
   
 
 
3.3.4 Barcode errors 
We assume that the probability that HTLV-1 integrates at the same genomic location in two 
infected individuals is negligibly small, because previous studies (Meekings et al., 2008; 
Derse et al., 2007) showed no evidence of hot-spots of HTLV-1 integration. Therefore any 
UIS identified in more than one sample on the same sequencing lane is assumed to be a 
barcode read error and resolved by assigning the integration site to the sample where more 
unique shear sites were identified for that clone (or in the case of two singletons, to the 
sample with the greater number of PCR duplicates for that clone).  If both samples have the 
same number of PCR duplicates for the clone (normally if both = 1) the integration site 
cannot be reliably assigned, and is discarded.   
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3.3.5 Data purification 
Prior to generating the final integration site list for each sample, a step of data purification is 
carried out:  
1) Integration sites mapped to chromosome ‘Y’ in a sample coming from a female 
subject are removed. 
2) Removal of “twins” – on certain occasions, a change of one or a few bases (due to 
misincorporation during PCR or ambiguity in sequencing) could result in a 
mismapping of some duplicates of an integration site, suggesting a new integration 
site. We eliminate those by disregarding smaller ‘clones’ where the integration site 
lies within 2 bases of the site in a larger (more abundant) clone in the same sample, 
and by sequence similarity as quantified by the ClustalW algorithm 
( ) 
 
Figure ‎3.4: DEISA start page 
81 
 
Figure ‎3.5: Example of data extraction of a complete flow cell 
Illustration of the process of filtering high-throughput sequences for analysis of HTLV-1 integration 
sites. Figure from a lane on a typical sequencing run, using Ilumina Genome Analyser II. 
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Figure ‎3.6: Quantification of proviral integration sites.  
Two clones are shown for illustration. The clones are identified based on shared integration site 
(pink). The clonal abundance of each given clone is based upon the number of unique shear sites 
(green) for that clone. Identical shear sites (PCR duplicates) are excluded.  
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3.3.6 Oligoclonality index 
The ability to quantify the integration sites has provided an unprecedented view of the clonal 
distribution in HTLV-1 infection (Figure ‎3.11A). This has allowed us to define the 
oligoclonality index (OCI, Figure ‎3.7), a parameter which describes the clonal distribution. 
The OCI varies between the two extremes of 0 (polyclonal, all clones share an equal share of 
the proviral load) and 1 (monoclonal, all infected cells belong to a single clone), and is 
calculated in a similar manner to the Gini index (Gini, 1912). The OCI removes the need for 
arbitrary categories of mono/oligo/polyclonality and is an objective, rigorous parameter for 
comparison of clonality within and between infected individuals and cell populations.  
 
 
Figure ‎3.7: Oligoclonality index (OCI) - a parameter of clonal distribution 
The oligoclonality index is a measure of clonal distribution inequality. Ranking the clones in 
descending order of clonal abundance (X axis) and calculating the relative proportion of the load (Y 
axis), its value can be described as the ratio between the dark shaded area between the cumulative 
abundance curve and the line of equality, and the lightly shaded area above the line of equality.  
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3.3.7 Correction for multiple hits at same sites in large clones.  
We assume, for the purpose of quantification of clonal abundance, that due to the random 
shearing, DNA coming from each cell will be sheared at different sites. The likelihood that 
two cells belonging to the same clone have the same shear site by chance increases with the 
number of cells in that clone. In order to quantify this likelihood, Nicolas Gillet carried out an 
experiment where patient DNA was used in successively lower concentrations.  “True” sister 
count for each clone was estimated by multiplying the dilution factor by the observed number 
of shear sites in the lowest concentration for the same clone.  
A spline function (Equation  3.3), fitted by Dr. Charles Berry to this curve, can be used to 
estimate the clonal abundance of highly abundant clones with a large number of shear sites.  
Equation  3.3         (
   (   (    ))          (     ( )     (  )) 
           (     ( )       (  ))
 ) 
 
 
 
Figure ‎3.8: Calibration curve for correction of clonal abundance.  
Experiments performed by Nicolas Gillet. Calibration curve was fitted by Charles Berry.  See text 
above for details.  
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3.3.8 Calculation of  sensitivity 
Loss of proviral integrations can take place during each successive step of the process, by 
loss of DNA during purifications, by incomplete enzymatic processes or during sequencing 
and analysis steps. This requires careful monitoring of ratio of proviral copies recovered to 
the expected number of copies calculated from the independent measure of the proviral load 
and the amount of DNA available.  This ratio is a useful measure of sensitivity, and an 
indicator of the success of each sample on a particular flow cell.   
The calculation of sensitivity is carried out in the following manner:  
                                                
                                         
          
Equation  3.4                                       ∑  
 
   
 
  
Equation  3.5 
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Equation  3.6   
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3.4 Results 
3.4.1 Yield 
The number of proviral integrations (sisters) recovered varies between infected individuals, 
and largely depends on the input (DNA + proviral load of the sample).  See Table ‎3.1 for 
details of the datasets used in the experiments described in this work.  
 
 
Table ‎3.1: Integration site datasets used 
Dataset Cell type total UIS 
total infected 
individuals 
reference Chapter 
in vitro (1) Jurkat 4521 N/A Gillet et al., 2011 4 
in vitro (2) Jurkat 1805 N/A This work 4 
In vivo (1) a PBMC 78563 63 Gillet et al., 2011 4 
In vivo (2) PBMC 20202 10 This work 5 
Tax Negative CD4
+
 6700 10 (pooled) This work 5 
Tax Positive CD4
+
 13054 10 (pooled) This work 5 
In vivo (3) PBMC 22510 12 This work 6 
CD4
+
 cells CD4
+
 33073 12 This work 6 
CD8
+
 cells CD8
+
 2399 12 This work 6 
Random UIS N/A 176505 N/A This work control 
                                                 
a
 Where multiple time points were available for any single patient, samples from only the most recent 
time point were used for this work. In addition, only patients with a single clinical diagnosis were 
included (e.g, patients with both ATLL and HAM/TSP were excluded).  
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3.4.2 Confirmation of PCR bias 
The distribution of the mean number of PCR duplicates by amplicon length in a 
representative sample is shown in Figure ‎3.9.  The results confirm the previously reported 
bias towards short fragments: shorter fragments are more often found, and have a higher 
number of PCR duplicates than longer fragments. This observation therefore confirms the 
need for a PCR duplicate-independent method of quantification.    
Amplicon length varies typically mostly between ~100 and ~500 bases, because of  the 
preferential amplification of short fragments and the more efficient generation of clusters 
with amplicons under 500 bases (Quail et al., 2008). 
 
Figure ‎3.9: Shorter fragments are amplified more efficiently by PCR.  
The mean of number of PCR duplicates is inversely correlated with the amplicon length, confirming a 
bias towards a more efficient amplification of short fragments by PCR. Figure from a typical 
sequencing run, using Illumina Genome Analyser II.  
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3.4.3 Recovery of proviral integrations  
The recovery plot of the data described in chapter 6 is shown in Figure ‎3.10, using data from 
the Illumina HiSeq platform.  The majority of the samples were of relatively high input 
(owing to the high proviral load) and the median recovery was 4.2%. There was a weak (non-
statistically significant) negative correlation between the input proviral copies and the 
recovery, which may reflect the limited ability of PCR to amplify a high number of different 
amplicons simultaneously. 
 
 
 
Figure ‎3.10: Recovery versus input proviral copies.  
The median recovery is 4.2% of input sisters (proviral copies). There is a weak inverse correlation 
between proportion of recovery and number of input copies. Data from experiment conducted on the 
HiSeq 2000.  
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3.4.4 OligoClonality index 
Representative clonal frequency distributions from two asymptomatic patients identified by 
this method are shown in Figure ‎3.11.  The experimental protocol enables us to rank the 
integration sites by the clonal abundance in vivo (Figure ‎3.11A) and interrogate the genomic 
environment flanking the integration site.   We are then able to quantify the shape of the 
clonal distribution   (Figure ‎3.11B) and use that to compare the distribution between different 
infected individuals, between cell populations, before and after treatment and over time.  
 
In 2011, Nicolas Gillet and colleagues reported that as predicted, in the malignant state the 
OCI is higher, reflecting selective proliferation of the putative malignant clone. There was no 
difference between the OCI of HAM/TSP patients and that of ACs (Figure ‎3.12).  
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Figure ‎3.11: Example of the clonal distribution of two typical asymptomatic patients.  
(A) Two alternative depictions of the clonal distribution in order of clone size from the largest to the 
smallest. The histogram shows for each clone the number of sisters identified (note difference in scale 
between patients). The inset pie chart shows the relative proportion of the load occupied by each 
clone. Patient 1 is more oligoclonal than patient 2, with the largest clone representing approximately 
9% of the proviral load. Patient 2 has a more uniform clone frequency distribution, in which no clone 
represents more than 2% of the load. (B) Cumulative proportion of the clone across all clones in 
decreasing order of size allows the calculation of the OCI (see Figure ‎3.7) 
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Figure ‎3.12: Oligoclonality and estimated total number of clones.  
Figure adapted from Gillet et al., 2011.  (A) OCI is significantly higher for ATLL patients than non-
malignant cases. There is no significant difference between asymptomatic carriers and HAM/TSP 
patients. (B) The high PVL of HAM/TSP appears to be explained by a higher clone count. 
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3.1 Discussion 
In order to more profoundly understand and monitor the proviral load of HTLV-1-infected 
individuals, it is necessary to monitor and understand the different clones that make up the 
proviral load. We have developed a method that is able to simultaneously amplify, map and 
quantify the proviral integration sites.  This method has two main advantages over other 
techniques. The first is its high sensitivity. The random shearing prevents the loss of 
integration sites (including potentially major clones) that lie far from the nearest restriction 
site, and the high-throughput sequencing allows the identification of an unprecedented (in 
HTLV-1) number of clones from each patient. The second main advantage is the ability to 
quantify each integration site. The random shearing results in a unique shear site for each 
infected cell, and the simultaneous sequencing of both the integration site and the shear site 
allows the relative quantification of recovered clones.  
Not all proviruses in the sample are sequenced. The stochastic nature of the detection of a 
given integration site by LMPCR has been described by Cavrois et al. (1995) and high-
throughput sequencing is also subject to sampling error. Calculation of the predicted number 
of proviruses input allows us to calculate the percentage of expected proviruses that are 
observed. However, it should be noted that any sample represents a small proportion of all 
infected cells in the blood. We assume equal mixing of the infected cells in the circulation 
(this assumption may be unjustified in solid lymphoid tissues such as the lymph node), and 
therefore that there should be no particular bias towards certain infected T-cell clones in the 
blood sample used. Similarly, the random shearing of DNA using this method for 
identification of integration site effectively eliminates restriction site dependent bias in 
recovery of any particular provirus. While we do not anticipate any systematic loss of 
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particular clones, the probability of re-recovery of any one particular clone may depend on its 
abundance. 
This method can be used for two parallel avenues of research. The mapping of the genomic 
integration site allows us to study the genomic environment of the integrated provirus in great 
detail, using the available annotations to the human genome. This allows us to interrogate the 
genomic environment in order to test for whether the genomic environment determines the 
proviral integration targeting, clonal expansion or expression of proviral genes (Gillet et al., 
2011, Chapter 4, Chapter 5 of this work).   At the same time, this method provides a marker 
for each HTLV-1 infected clone. This can be used to track an infected clone over time, in 
response to therapy, to quantify the appearance of new mutations and to test hypotheses on 
the possible role of that clone in pathogenesis. This can be done on a population level, in the 
context of all other clones, without the need for limited dilution cloning of T cells, which 
requires a lengthy period of cell culture, which may be further from the physiological state of 
the cell or may select for particular subtypes of clones that are able to grow in culture.   
There are two main limitations to this method, which are shared with any other method based 
on high-throughput sequencing. The sequencing of samples using the Illumina method may 
not be as efficient in extremely high GC content sites (Aird et al., 2011). The second 
limitation is its dependency on the available human genome reference. The human genome 
reference still contains some minor gaps (Kidd et al., 2010), as well as repeats and highly 
polymorphic sites which are not possible to map sequence data to with confidence.  This 
should be considered in particular when comparing sequencing data to random expectation, 
and to make sure that the random expectation is drawn from a more “realistic” human 
reference (see section ‎2.5.1).  When comparing two datasets of integration sites to each other, 
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there is no a priori reason to assume that one will be systematically less efficiently mapped 
than the other.   
Lastly, similar to most studies of HTLV-1 infection, there is a sensitivity limit, dependent on 
the proviral load, determined by the number of input copies of the provirus in the protocol. 
While the proviral load can vary greatly between different individuals (Nagai et al., 1998 
Demontis et al., 2013), a very low copy number would result in a small number of sisters 
(integrations) detected, significantly reducing the power of this technique. We do not expect 
basic mechanisms of selection on infected clones to differ between high- and low-load 
patients. 
Our method of analysis and quantification of retroviral integration sites is flexible. With 
minor adjustments, both the experimental and the analytical aspects of the method can be 
used for other retroviruses, retroelements or gene therapy vectors. It can be used for 
monitoring response to anti-retroviral treatment, for the analysis of mechanisms contributing 
to HIV latency, for tracking positive selection of gene therapy clones in treated patients and 
for identification of novel insertions due to reactivation of endogenous retroviruses in humans 
and animals.   
For HTLV-1 research, this method has opened the door to multiple lines of research. It has 
recently been used to demonstrate there is a single provirus copy per cell in non-malignant 
infected CD4
+
 cells (Cook et al., 2012), and there is a currently on-going project using high-
throughput sequencing data of HTLV-1 integration site aimed at estimating the total number 
of infected clones in the blood, and to use that in order to model the ratio of infectious to 
mitotic spread in HTLV-1.  Deep integration site analysis can be used as a guide in defining 
pre-malignant clones and the molecular biology mechanisms that may be involved in clonal 
transformation, as well as investigating the role of infected T-cell clones in the HTLV-1-
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associated inflammatory diseases. Finally, this method will also be an indispensable tool to 
investigate the determinants of the rate of proviral gene expression and the balance of 
selection of infected clones during chronic infection, using a genome-wide approach which 
could lead to suggested mechanisms to be tested using molecular biology techniques.   
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Chapter 4 -  The role of the genomic 
environment in determining proviral 
integration targeting and clonal 
expansion 
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4.1 introduction 
4.1.1 Retroviral integration 
Viral DNA integration is the process by which a double-stranded viral DNA molecule is 
inserted into the host genome, allowing expression of viral genes from the host chromosome. 
While certain DNA viruses can integrate into host DNA, in the case of retroviral infection, 
the integration into the host genome is a necessary step in the virus replication cycle, required 
for expression (Sakai et al., 1993) and persistence of the retroviral genome in the infected 
cell. The proviral integration is mediated by the integrase (IN) protein, processed from the 
gag-pro-pol open reading frame (Nam et al., 1988) and carried to the infected cell within the 
virion.  
The reverse transcription step in the retroviral replication cycle results in the formation of a 
double-stranded linear DNA molecule, a direct copy of the RNA genome carried in the virion 
flanked by two repeated regions (long terminal repeats, LTR). The DNA is coated by host 
and viral proteins, composing the PIC (Bowerman et al., 1989). Whether the PIC requires a 
cell to be dividing in order to enter the nucleus depends on the virus: while lentiviruses can 
infect both dividing and non-dividing cells, most retroviruses, such as murine leukemia virus 
(MLV), require cell division for efficient infection (Roe et al., 1993; Lewis and Emerman, 
1994; Naldini et al., 1996).  
The integration process is composed of three main steps: processing, joining and repair. The 
3’ end processing step, results in the removal of two nucleotides from either 3’end of the 
double stranded molecule by IN, resulting in a 5’ overhang in both sides. This is followed by 
a strand transfer step, where the IN forms a new phosphodiester bond between the viral 3’OH 
end and host cell DNA. This creates a gap at both ends of the integrated molecule which is 
thought to be completed by host DNA repair enzymes. The result is the duplication of a 
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number of bases at the integration site at either end of the integrated provirus. The integrated 
HTLV-1 provirus is flanked by a 6-base repeat of duplicated human genome (Seiki et al., 
1983). 
Different host genes have been found to play a role in integration. The barrier-to-
autointegration factor gene was identified in Moloney murine leukemia virus as a component 
of the PIC, increasing the efficiency of integration by preventing auto-integration (integration 
of the LTR ends to sites within the viral DNA) (Lee and Craigie, 1998). The host proteins 
Hmga1, INI1 and LEDGF/p75 have also been identified to interact with the HIV PIC (Van 
Maele et al., 2006). Lens epithelium-derived growth factor (LEDGF/p75) has been well 
characterized as an integrase co-factor (Cherepanov et al., 2003), targeting the PIC, 
increasing integration efficiency and determining integration site distribution (Maertens et al., 
2003; Ciuffi et al., 2005; Shun et al., 2007).  
 
4.1.2 Integration site selection bias. 
The site of retroviral integration can be important for both virus replication and for 
pathogenesis, because it may affect both viral and host gene expression. The genomic 
environment at the site of integration may affect the level of expression of proviral genes 
(Shan et al., 2011) leading to a latent infection (Siliciano and Greene, 2011).  
Retroviral integration has the ability to alter host gene expression in cis through various 
mechanisms jointly referred to as insertional mutagenesis. Integration of the provirus can 
either induce aberrant expression through the introduction of the viral promoter or enhancer, 
or inactivate a gene through disruption of induction, expression or correct splicing (Uren et 
al., 2005). It is also likely that higher-order mechanisms could be affected, whereby the 
integration alters the 3 dimensional folding of the genome, causing long-range effects, for 
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example by integration in proximity to binding sites of host factors such as CCCTC-binding 
factor (CTCF), known to play a role in DNA looping (Hou et al., 2008)  
The pattern of integration sites from in vitro and in vivo samples provides insight into the 
effect of proviral integration site on the survival of the infected clones: deleterious integration 
(for example through haploinsufficiency) would be subject to negative selection. In contrast, 
insertions which enable or promote cell proliferation in vivo may be found in expanded 
clones.  
A startling example of the importance of testing for integration site bias was shown in the 
case of gene therapy vectors (Hacein-Bey-Abina et al., 2008), where the selective expansion 
of certain clones can result in adverse outcomes (Fehse and Roeder, 2008).  
Integration sites can be found across the host cell genome, but they are not random. There is a 
weak nucleotide consensus target site favoured by retroviruses (Wu et al., 2005). On a 
broader scale, integration is often favoured within transcriptionally active regions. Retroviral 
integration site selection has been found to be associated with transcription units (Schroder et 
al., 2002; Wu et al., 2003), the transcriptional level of the genomic environment (Maxfield et 
al., 2005) and nucleosomal positioning (Roth et al., 2011). 
Integration site selection differs between different retroviruses, thus the integration site 
choice cannot be simply explained by accessibility of chromatin to the integration machinery. 
Derse et al have shown that integrases closely related in peptide sequence also share similar 
integration site bias (Derse et al., 2007). This is consistent with the idea that closely related 
integrases would utilize similar host factors in order to direct the PIC to the chromatin and 
facilitate DNA integration. The host protein LEDGF/p75 has been identified as an HIV-1 
integrase cofactor (Maertens et al., 2003) which has a significant impact on integration site 
targeting (Ciuffi et al., 2005; Shun et al., 2007). More recently, a second host factor, HRP-2, 
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was identified in LEDGF knock-out cells, and found to have an effect on directing integration 
site selection in those cells (Schrijvers et al., 2012; Wang et al., 2012). More recently, several 
bromodomain and extraterminal domain (BET) proteins, Brd2, Brd3 and Brd4, have been 
shown to directly bind MLV IN and knock-down of all three significantly reduced MLV 
integration at transcription start sites (Sharma et al., 2013). There are no known integrase 
cofactors in HTLV-1 infection.  
 
4.1.3 HTLV-1 integration sites selection 
HTLV-1 was first shown to have a non-specific integration (without a particular preferred 
site) by Seiki and colleagues (Seiki et al., 1984). With improvements in both the techniques 
used to identify HTLV-1 integration sites, and the understanding of the human genome, a 
more refined picture of integration site specificity emerges. The nucleotide sequence in the 
immediate vicinity of the integration site is not random but is biased towards a loose 
consensus sequence (Chou et al., 1996; Derse et al., 2007; Meekings et al., 2008). Using 
hybridization methods and LMPCR, it was shown that integration is biased towards regions 
of the target host genome with a high GC content (Zoubak et al., 1994; Derse et al., 2007), 
Work mostly done on integration sites from ATLL cases/cell lines showed a bias towards 
integration in or near genes (Ozawa et al., 2004; Hanai et al., 2004; Doi et al., 2005). Since 
these studies lacked the ability to quantify the clonal abundance of observed integration sites, 
it is difficult to assess how many of the bias differences observed between malignant and 
non-malignant cases were in fact differences between clones of low and high abundance. In 
more recent years, it was shown that in integration sites found in patients without 
malignancy, there is also a bias towards integration near transcription start sites and CpG 
islands, and that this bias is greater for integration sites found in infected patients (after years 
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of selection) than in cell lines infected in vitro (Derse et al., 2007; Meekings et al., 2008). The 
refined understanding of factors determining the bias in targeting of the integration site to the 
human genome is important; however, in order to understand the effect of long-term selection 
in the host it is necessary to address the association between the genomic environment and 
the survival and expansion of the infected clone to identify the factors that determine the 
success or failure of each clone.  
The integration site can be used to identify each infected clone, because each mitotic 
replication results in two sister cells that share an identical integration site. The association 
between clonal distribution and disease has been studied in ATLL (Yoshida et al., 1984), 
HAM/TSP (Furukawa et al., 1992) and co-infected patients with Strongyloides or infectious 
dermatitis (Gabet et al., 2003; Gabet et al., 2000). Clonality was initially visualized by 
southern blot (Yoshida et al., 1984), by counting bands on gel electrophoresis following 
IPCR (Takemoto et al., 1994) which was able to distinguish crudely between patients with a 
“monoclonal” or “oligoclonal” pattern of integration, in whom one or several bands were 
visible on the gel, and “polyclonal patients” in whom no discrete band was detected. The use 
of classical sequencing following LMPCR (Wattel et al., 1995) allowed the isolation of a 
larger number of integration sites, but the quantification of integration site frequency was 
probably biased by preferential PCR amplification of short products (see section ‎3.3.3).  
The development of high-throughput sequencing method discussed in this work by Dr. 
Nicolas Gillet and myself has opened the door to a deeper, more refined understanding of the 
role of the genomic environment in determining integration site and long term clonal 
abundance, in malignant and non-malignant cases; in disease versus healthy carriers; and by 
suggesting further mechanistic avenues of research into the role of the proviral expression, 
integration site and the immune selection in determining clone size and proviral load.   
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4.1.4 Aim 
In order to understand any association between the genomic environment flanking the 
integrated provirus and the proviral expression, it is imperative to refine our understanding of 
the attributes that are associated with de novo proviral integration, as well as the factors 
which promote or inhibit long-term clonal expansion. In this work I used previously 
published as well as unpublished integration site data with the aim to test the hypothesis that 
the HTLV-1 provirus integration site is favoured near particular genomic elements, and 
whether the effect of the genomic environment on the clonal expansion is symmetrical with 
respect to the integrated provirus.  
 
 
 
 
 
 
Figure ‎4.1: Genomic environment flanking the integrated provirus 
Blue blocks denote a genomic feature (e.g. transcription start site). ‘Upstream’, ‘Downstream’ and 
relative orientation are defined relative to the sense strand of the HTLV-1 provirus.  The distance to 
the nearest genomic feature is calculated separately for upstream (closer to the 5’ LTR) and 
downstream features, and unless otherwise stated, calculated as the distance between the integration 
site and the nearest end of the genomic feature.   
103 
 
4.2  Results 
4.2.1 The genomic environment flanking the proviral integration site 
A schematic description of the genomic environment flanking the integration site is shown in  
Figure ‎4.1. We defined ‘upstream’ and ‘downstream’ with respect to the integrated provirus: 
‘upstream’ denotes elements nearer to the 5’LTR end of the provirus; ‘downstream’ denotes 
elements in closer proximity to the 3’ end of the provirus. Therefore – ‘upstream’, 
‘downstream’, ‘same’ and ‘opposite’ sense are all defined with respect to the plus strand 
proviral open reading frames (which include the proviral transactivator Tax). For each 
genomic feature (e.g. transcription start site) we defined the minimal distance to the 
integration site as the difference between the genomic coordinates of the nearest respective 
feature (either upstream or downstream) and the integration site.  
 
4.2.2 In vitro infection as a model of initial integration targeting 
preferences.  
Details of datasets used are summarized in Table ‎3.1. In order to examine the initial 
integration site preference we infected Jurkat T-cells by a short co-culture with lethally 
irradiated MT2 cells (HTLV-1-producing cell line). After 2 weeks (to allow elimination of 
residual MT2 cells) the integration sites were analysed using our high-throughput method for 
identification and quantification of retroviral integration sites (Chapter 3). Two independent 
experiments were carried out, using the same protocol. No significant differences were found 
between the two datasets (Figure ‎4.10), and they were therefore pooled to form one combined 
in vitro dataset.  
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In order to examine the genomic integration bias during chronic infection (after decades of 
infection and clone selection) we used recently published integration site data (Gillet et al., 
2011) – that were obtained using the identical high-throughput protocol described here: these 
data included integration sites analysed from PBMC samples from 63 subjects with 3 clinical 
manifestations of HTLV-1 infection: ACs, HAM/TSP and ATLL (Table ‎4.1). Where more 
than one timepoint was available per patient, the most recent timepoint was used. Patients 
with more than one clinical manifestation (i.e. diagnosed both with ATLL and HAM/TSP) 
were excluded. The abundance of each clone was quantified as the number of copies of that 
clone per 10000 PBMCs, and the clones were divided into bins according to their abundance 
using logarithmic scale delimiters (Table ‎4.2) 
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Table ‎4.1: In vivo integration sites – sample data by patient (Gillet et al., 2011) 
Clinical 
Statusa 
Patient 
code 
Gender PVLb 
Sequencing results 
# sequencing reads # proviruses # clones 
AC HAY F 3.6 88587 8034 2070 
AC HBE F 3.6 7860 1400 888 
AC HBF F 7.6 264490 3536 1615 
AC HBK F 8.9 232565 4284 980 
AC HBT F 0.5 12183 295 126 
AC HBX F 2.7 42889 1607 642 
AC HBY M 1.6 10377 540 422 
AC HCM F 0.6 134303 216 55 
AC HCS M 5.4 35281 257 76 
AC HDA F 0.3 10290 133 89 
AC HDG M 2.7 90212 2776 1042 
AC HDR F 2.7 44265 1252 471 
AC HDS F 2.5 18010 1775 952 
AC HES F 17.7 31271 3574 1981 
AC HEZ F 3.4 44252 3753 1935 
AC HFE F 6.5 12767 1298 702 
AC HFG F 1.6 44436 940 412 
AC LFP F 0.6 59035 343 242 
ATLL AN M 24.3 28545 2324 45 
ATLL C3 F 64 15560 2969 5 
ATLL C4 F 20.4 64408 10315 30 
ATLL 
HCG-
LEY 
M 8 71393 3312 2039 
ATLL 
HDM-
LFK 
F 6.3 38787 2513 637 
ATLL JH F 31.2 76432 14639 107 
ATLL KD5 F 21.2 39703 2065 10 
ATLL LEP M 21.2 78233 10063 276 
ATLL LER M 52.3 7017 1053 7 
ATLL LEU F 45.5 19440 6656 6 
ATLL LEZ M 26.7 86061 2843 243 
ATLL LFA F 10.6 30600 4293 1025 
ATLL LFC F 12.3 29217 5661 2426 
                                                 
a AC: Asymptomatic Carriers; ATLL: Adult T-cell Leukemia/Lymphoma; HAM/TSP: HTLV-1-Associated 
Myelopathy / Tropical Spastic Paraparesis. 
b PVL : proviral load – number of copies per 100 cells 
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Clinical 
Statusa 
Patient 
code 
Gender PVLb 
Sequencing results 
# sequencing reads # proviruses # clones 
ATLL LFE F 7.4 28028 3768 1258 
ATLL P7 F 18.3 39283 12980 3182 
ATLL S1 F 18.1 27415 9138 829 
ATLL S2 F 10.8 7531 1338 234 
ATLL S4 M 16.7 14621 1982 629 
ATLL S5 F 3.6 24410 4391 53 
ATLL S6 M 15 24823 5880 282 
HAM-TSP TAA F 2.2 70585 5995 1805 
HAM-TSP TAL F 8.7 106366 12839 3024 
HAM-TSP TAN F 4 21024 2083 1388 
HAM-TSP TAS F 3 13485 1478 901 
HAM-TSP TAT F 9.6 10525 2204 1281 
HAM-TSP TAW F 1.4 94529 3528 1006 
HAM-TSP TAY F 1.4 66941 3582 1069 
HAM-TSP TAZ M 12.5 13636 3545 1965 
HAM-TSP TBA F 9.6 27784 2679 1215 
HAM-TSP TBC F 20 84806 26108 7460 
HAM-TSP TBG F 14.6 76744 16617 3609 
HAM-TSP TBJ F 15.8 16907 2791 1442 
HAM-TSP TBO F 7 13519 1904 1066 
HAM-TSP TBP M 3.5 36279 5855 3604 
HAM-TSP TBR F 4.7 47148 2949 1461 
HAM-TSP TBS F 10.4 21127 5216 2396 
HAM-TSP TBU F 1.1 70258 1846 749 
HAM-TSP TBW M 7.3 124980 13240 3136 
HAM-TSP TCG F 3.6 28031 1678 766 
HAM-TSP TCO F 1.8 17903 789 497 
HAM-TSP TCQ M 5 44629 3830 2155 
HAM-TSP TCR M 5.9 38437 3606 2048 
HAM-TSP TCT F 5.5 26719 3407 1943 
HAM-TSP TDA M 6.2 7125 1165 805 
HAM-TSP TW F 8.9 112958 16420 3749 
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Table ‎4.2: In vivo integration sites (Gillet et al., 2011) – sample data by clone abundance 
 
Clone numbers by absolute abundance bin
a
  
Clinical 
Status
b
 
No. Patients <0.1 0.1-1 1-10 >10 Total 
AC 18 3201 10275 1192 32 14700 
ATLL 20 42 11627 1587 67 13323 
HAM/TSP 25 14234 33521 2748 37 50540 
Grand Total 63 17477 55423 5527 136 78563 
 
 
 
4.2.3 Integration sites are favoured within genes at the same 
orientation as the host gene. 
As previously reported (Gillet et al., 2011) 47% of integration sites are found within genes. 
This indicated that HTLV-1 integration is somewhat favoured within genes (compared to 
43% of random sites, p<10
-11, Χ2 test). As expected by chance, ~50% of proviruses integrated 
within host genes lay in the same transcriptional orientation as the host gene (Figure ‎4.2).  
While at the level of primary infection (in vitro) both integration in the same and the opposite 
orientation are favoured, integration sites found in infected subjects (in vivo) contained fewer 
integration events in the opposite orientation to the host gene than would be expected by 
chance and the bias towards integration in the same orientation increased with clone 
abundance.  
 
                                                 
a Absolute abundance – number of proviruses per 10000 PBMC 
b AC: Asymptomatic Carriers; ATLL: Adult T-cell Leukaemia/Lymphoma; HAM/TSP: HTLV-1-Associated 
Myelopathy / Tropical Spastic Paraparesis 
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Figure ‎4.2: HTLV-1 integration within transcription units.  
Clonal abundance was quantified by absolute abundance – number of copies per 10000 PBMCs. The 
proportion of HTLV-1 integration sites within transcription units was compared to random 
expectation. Integration within genes was favoured for initial infection (in vitro) but during chronic 
infection was disfavoured for integration in the opposite orientation (in vivo). The increased 
frequency of integration was higher with increasing clonal abundance. The relative orientation is with 
respect to the sense strand of HTLV-1. 
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4.2.4 Bias towards integration in proximity to transcription start site 
(TSS) is asymmetric 
Gillet et al reported (2011) an association between clonal abundance and integration within 
10kb of a TSS. In the present work I examined the genomic features in the immediate vicinity 
of the integration site, either upstream or downstream of the integration site. I found (Figure 
‎4.3) that the strongest bias was at a distance of 1kb between the integration site and the 
nearest TSS (highest odds ratio compared to random sites). We refined our analysis to test 
whether the effect observed was directional. The results showed (Figure ‎4.3) that same-sense 
transcriptional orientation (both upstream and downstream) was favoured to a similar extent 
in both in vitro and in vivo integration sites. However in the opposite orientation, this bias 
was weaker (closer to random expectation) in the in vivo sites compared to the in vitro sites. 
At the distance in which the integration bias was the highest – 1kb from the integration site – 
the positive trend towards integration in proximity to TSS with increasing clonal abundance 
(previously reported) was only maintained for the integrations at the same orientation (i.e., 
for those proviruses integrated in the same transcriptional orientation as the nearest host 
TSS); in particular this was true for those integrated with a nearby downstream TSS rather 
than upstream (Figure ‎4.4).  
While the proportion of integration sites in proximity to TSS was similar between in vitro and 
in vivo sites in the same orientation, it was reduced in vivo for the opposite orientation.   
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Figure ‎4.3: HTLV-1 proviral integration in proximity to transcription start sites (TSS). 
Mountain plot –the X axis denotes the distance from the integration site to the nearest TSS (on a log 
scale, positive values represents downstream from the integration site, negative values represent 
upstream from the integration site). Windows are non-cumulative. Y axis denotes the odds ratio 
(compared to random sites) of having a TSS within this distance of an integration site. Whiskers 
denote the standard error. Peak preference (highest odds ratio) both for same and opposite orientation 
was at 1kb of the integration site.  ‘Upstream’, ‘Downstream’ and the relative orientation are with 
respect to the sense strand of HTLV-1. 
111 
 
 
Figure ‎4.4: Proviral integration within 1kb of a transcription start site (TSS). 
Absolute clonal abundance was quantified by absolute abundance – number of copies per 10000 
PBMCs. The proportion of proviral integration sites within 1kb of a TSS was compared between 
integration sites (in vitro and in vivo) and with random expectation. When the nearest TSS was in the 
same orientation as the integrated provirus, the odds ratio was similar between in vitro and in vivo 
sites, and increased with clone size. ‘Upstream’, ‘Downstream’ and the relative orientation are with 
respect to the sense strand of HTLV-1. 
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4.2.5 Integration sites are favoured in proximity to CpG islands in an 
asymmetric fashion 
It was previously reported that integration is favoured within 10 kb of a CpG island 
(Meekings et al., 2008) and that this bias is greater with increasing clonal abundance (Gillet 
et al., 2011). Here I extended this analysis and found that the strongest bias (highest odds 
ratio) both in vivo and in vitro was at a distance of 1kb from the nearest CpG island (Figure 
‎4.5). At this distance, the trend towards stronger bias in larger clones was observed mostly for 
integration with a CpG island downstream (Figure ‎4.6).  
 
 
 
 
Figure ‎4.5: HTLV-1 integration in proximity to CpG island.  
Integration was favoured in proximity to CpG islands. Peak bias (highest odds ratio) was at within 
1kb from integration site, and then decline back to random expectation. ‘Upstream’, ‘Downstream’ 
are with respect to the sense strand of HTLV-1. 
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Figure ‎4.6: Integration within 1kb of a CpG island 
Integration with a CpG island downstream was favoured in vivo, with an increase in bias with 
increased clone size. Clonal abundance was measured by copies per 10000 PBMCs. ‘Upstream’, 
‘Downstream’ are with respect to the sense strand of HTLV-1.  
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4.2.6 Integration sites are symmetrically favoured in proximity to 
TFBS  
Since proviral integration is biased towards transcriptionally active regions of the genome, 
we wished to test the hypothesis that proviral integration in proximity to transcription factor 
binding sites (TFBS) is associated with integration targeting, proviral expression or clonal 
abundance. The TFBS data used was publicly available datasets of genome binding positions 
of transcription factors, chromatin regulators and histone modifiers isolated in ChIP-seq 
experiments. Where available we used data from primary CD4
+
 cells; otherwise, we used 
data from Jurkat or other human cell lines. Where primary data was available, we used the 
SISSRs Perl script (Jothi et al., 2008) which is designed to predict the site of transcription 
factor binding; otherwise, reported peak data was used. See Table ‎4.3 for complete listing of 
the datasets used.  
Both in vitro and in vivo integration sites showed a bias towards integration in proximity to 
TFBS in general: 28% of in vitro and 25% of in vivo sites (compared with 20% of random 
sites) lay within 1kb of at least one of the TFBS tested (Figure ‎4.7). However, when 
examining the TFBS separately, both in vitro and in vivo there was a remarkably strong bias 
(high OR) towards integration in proximity to specific TFBS, in particular certain histone 
acetylases (HATs) , HDACs, STAT-1 and p53 ChIP-seq sites.  
Two interesting patterns emerged in this analysis. First, the bias towards integration in 
proximity to most TFBS (e.g. p300, Figure ‎4.8B) was largely symmetrical, there was a 
similar odds ratio upstream and downstream of the integration site. In contrast, the bias 
towards integration near certain TFBS (e.g. STAT-1, Figure ‎4.8D) was asymmetrical, 
showing a higher bias towards one direction (often downstream). Second, for some of the 
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Figure ‎4.7: HTLV-1 integration in proximity to any TFBS tested.  
Integration in proximity to at least one of the TFBS tested (see Table ‎4.3) was favoured. Higher odds 
ratio was observed for in vitro sites than in vivo. ‘Upstream’, ‘Downstream’ are with respect to the 
sense strand of HTLV-1. 
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transcription factors, we observed a sharp decrease at 10 bases from the integration site (e.g. 
STAT-1, Figure ‎4.8D). This pattern was consistently observed in multiple in vitro and in vivo 
datasets (Figure ‎4.10 and Figure ‎4.11, respectively), suggesting that this is a real effect rather 
than simply caused by the smaller number of integration sites immediately adjacent to the 
TFBS. 
TFBS have been observed to co-localize in the human genome (Dunham et al., 2012), 
therefore we wished to test which TFBS of those studied were associated with integration 
independently from the other TFBS. A multivariate analysis approach was utilized (Figure 
‎4.9). First, a likelihood ratio test was used to compare between two alternative analyses for 
each TFBS in order to test whether the integration was selectively associated with either 
upstream or downstream integration: a univariate test for both upstream and downstream and 
a bivariate test comparing upstream vs downstream, and subsequently tested each individual 
annotation separately as an explanatory variable using a univariate model. All factors that 
were significant in this univariate analysis (p. value < 0.05 after correction for multiple 
comparisons) were combined in a multivariate model, using a step-down approach, until only 
independent significant factors (p < 0.05) remained. Two separate multivariate models were 
made, respectively, to identify TFBS within 100 bases and within 1000 bases of the 
integration site (Figure ‎4.9). Most factors that were independently associated with integration 
targeting were symmetrically associated around the integration site. The factors which had 
the highest odds ratio were the transcription factor p53 and Histone deacetylase 6. 
When comparing clones of different clonal abundance, it was observed that TFBS that were 
associated with integration targeting were often associated with small (low-abundance) 
clones (Figure ‎4.12).  
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Figure ‎4.8: HTLV-1 integration in proximity to transcription factor binding sites.  
Integration site targeting was associated with close proximity to certain transcription factor binding 
sites. Notable selected TFBS are shown here, see Table ‎4.3 for a list of the maximum odds ratio for 
each TFBS tested. Differences in preference between in vitro and in vivo remained the same even 
when randomly sampling the same number of in vivo sites as are in vitro sites (not shown), therefore 
we exclude the possibility that the difference is due to differences in clone numbers. ‘Upstream’, 
‘Downstream’ are with respect to the sense strand of HTLV-1. 
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Figure ‎4.9: HTLV-1 integration in proximity to TFBS - multivariate analysis  
TFBS (ChIP-seq identified binding sites for transcription factors, histone modifiers and chromatin 
regulators) independently associated with integration of HTLV-1 was identified using multivariate 
analysis. OR – odds ratio.  Outcome measure was ‘True’ integration site. TFBS shown above the line 
were associated with an excess frequency of integration compared with random (OR>1); TFBS below 
the line were significantly less likely to lie near the provirus (OR <1). Model 1 and Model 2 (carried 
out independently) test for TFBS within 1kb and 100bp of integration site, respectively. Arrow 
denotes orientation of integrated provirus. Dotted line – TFBS were associated with integration either 
upstream or downstream.  
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Figure ‎4.10: Bias towards integration in proximity to TFBS is consistent across datasets. 
Pattern of integration preference in proximity to transcription factor binding sites was consistent 
between different datasets resulting from independent experiments. ‘Upstream’, ‘Downstream’ are 
with respect to the sense strand of HTLV-1. 
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Figure ‎4.11: Bias towards integration in proximity to TFBS similar between clinical outcomes 
Pattern of integration in proximity to transcription factor binding sites was similar between clones 
identified from patients of different clinical subtypes. ‘Upstream’, ‘Downstream’ are with respect to 
the sense strand of HTLV-1. 
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Figure ‎4.12: Integration in proximity to TFBS is most associated with smallest clones.  
Bias towards integration in proximity to TFBS was higher for less expanded clones. ‘Upstream’, 
‘Downstream’ are with respect to the sense strand of HTLV-1. 
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Table ‎4.3 Human genome annotations used in this work 
Annotation 
Functional 
category 
Cell type Reference (see below)  
peak 
calling 
algorithm 
Max. 
OR 
RefSeq 
genes 
 N/A Fujita et al., 2011 N/A 
 
CpG 
islands 
 
NRSF 
(REST) 
Transcription 
factor / 
silencer 
Jurkat Jothi et al., 2008; 
Johnson et al., 2007 SISSRs 167.57 
CTCF 
Insulator / 
regulation of 
chromatin 
architecture 
pr CD4 Jothi et al., 2008; Barski 
et al., 2007 SISSRs 12.89 
BRG1 
Chromatin 
regulators HeLa Euskirchen et al., 2011 Peak-Seq 
2.31 
INI1 2.75 
BAF155 2.62 
BAF170 1.81 
cJun 
Transcription 
factors 
K562 Raha et al., 2010 Peak-Seq 2.33 
cFos 
GM12878 Rozowsky et al., 2011 SISSRs 
39.15 
cMyc 8.25 
JunD 30.49 
E2f4 GM06990 Lee et al., 2011 See ref 2.99 
E2f6 K562 Trojer et al., 2011 SISSRs 7.45 
Foxp3 
Act. CD4 
Birzele et al., 2011 MACS 
5.21 
Treg 6.98 
GATA1 
K562 Fujiwara et al., 2009 SISSRs 
19.21 
GATA2 17.79 
NFkB GM12878 Kasowski et al., 2010 Peak-Seq 2.62 
STAT1 Act. CD4 
Liao et al., 2011 SISSRs 
335.45 
STAT1IFN 
IFNγ 
Stim. CD4 8.18 
Yy1 K562 
Myers lab for the 
ENCODE project. GEO 
Accession code:  
GSM803470 
MACS 2.28 
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Annotation 
Functional 
category 
Cell type Reference (see below)  
peak 
calling 
algorithm 
Max. 
OR 
Znf263 K562 Frietze et al., 2010 Sole-
Search 3.66 
CBP 
Histone 
modification 
enzymes 
 
pr CD4 Wang et al., 2009 SISSRs 
11.43 
p300 48.88 
MOF 31.93 
Tip60 33.45 
PCAF 34.90 
HDAC1 14.30 
HDAC2 93.15 
HDAC3 223.49 
HDAC6 91.80 
p53 
Transcription 
factor IMR90 Botcheva et al., 2011 SISSRs 343.70 
Rad21 
Cohesin 
component GM12878 
Myers lab for the 
ENCODE project.  
GEO accession code:  
GSM803416 
MACS 1.64 
SUZ12 
(PRC2) 
Chromatin 
regulators K562 Ram et al., 2011 See ref 3.76 
Act. Activated; Stim. Stimulated; Max. maximum. GEO: Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/) 
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4.3 Discussion 
The mechanisms dictating HTLV-1 proviral targeting and long term survival of infected cell 
clones are not fully understood. We have developed a method which is able to identify and 
quantify an unprecedented number of proviral integration sites, giving us for the first time a 
deep insight into potential correlates of proviral integration, which will lead to further 
mechanistic testing of proviral integration. In order to elucidate the effect of the genomic 
environment on initial proviral integration of HTLV-1, we utilized the previously used in 
vitro infection model for initial infection. Infected cells were kept in culture for no more than 
two weeks (required for the elimination of any residual cells from MT2, the infecting cell 
line). In this setting, selection is minimal and should represent the physiological state of 
infection prior to induction of the adaptive immune response and the long term effects of 
clonal expansion during chronic infection. We mapped the integration sites from two 
independent such experiments.   
 
4.3.1 Integration bias within and in proximity to transcription units 
The results confirmed the previously observed small bias towards integration within or in 
proximity to host transcription units (Meekings et al., 2008; Gillet et al., 2011). This bias 
towards integration within genes is considerably lower than that observed in HIV infection 
(~70%, Ciuffi et al., 2005), suggesting a fundamental difference in the mechanism 
determining integration targeting between the two viruses. In HIV-1 infection, LEDGF/p75 is 
known to have an important role in targeting HIV integrase to the host DNA (Maertens et al., 
2003), and in its absence, the preference towards integration within genes is diminished 
(Ciuffi et al., 2005). There was no bias in the relative transcriptional orientation of the host 
gene and the provirus in in vitro infection, suggesting that the bias towards same-sense 
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integration observed in integration sites mapped from infected individuals is the result of 
long-term selection acting in vivo.  
The bias towards integration in proximity to CpG islands, a marker of a transcriptionally 
active genomic region, was also higher with increasing clonal abundance, in particular when 
the CpG island lay downstream of the integration site. This is consistent with another recent 
observation (Gillet et al., 2011) that integration near a high density of activating histone 
marks was correlated with clonal abundance, suggesting that an overall active genomic 
environment is conducive to clonal expansion.  
 
4.3.2 Integration bias in proximity to TFBS. 
We observed a weak bias towards integration in proximity to any TFBS, however when 
examining each TFBS in turn, the bias observed was remarkably strong in certain cases (e.g. 
STAT1, NRSF) in single factor analysis. The bias identified was consistent across several in 
vitro and in vivo datasets, and was stronger for in vitro integration than was for in vivo sites. 
In addition, the bias towards integration in proximity to these TFBS was higher for clones of 
lower absolute abundance, suggesting that these TFBS do not confer an advantage on the 
infected clones during chronic infection but rather may be more important during initial 
integration.  Since different TFBS can cluster in particular areas of the genome (Dunham et 
al., 2012), we also carried out a multivariate (logistic regression) analysis, considering all of 
the TFBS examined, in order to identify TFBS which were independently associated with 
proviral integration targeting. The results (Figure ‎4.9) confirm HDAC6, STAT1 and p53 as 
significant independent correlates of integration, and also included INI1, NFkB and cMyc.  
STAT1 and p53 are known to play a significant role in HTLV-1 infection. HTLV-1 infection 
dysregulates p53 related pathway gene expression (Tattermusch et al., 2012). Interferon-
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stimulated genes, including STAT1, are known to be upregulated by HTLV-1 in vivo, in 
particular in HTLV-1 associated disease (Tattermusch et al., 2012). It is not yet known 
whether insertional mutagenesis may play a role in these processes.  
STAT1 has been reported to be highly associated with proviral integration of MLVs (Santoni 
et al., 2010). The authors attributed this effect to the presence of certain epigenetic histone 
marks (H3K4me3, H3K4me1 and H3K9ac) in proximity to the integration site.   
The association of HTLV-1 integration to TFBS was typically symmetrical and short range 
(within 100b of integration site), falling to random expectation beyond 1kb from the 
integration site (consistent with the idea that this is an integration related mechanism which is 
thought to be symmetrical with respect to the recognized host sequence (Grandgenett, 2005) 
due to intasome symmetry (Hare et al., 2010).  In some instances the integration bias dropped 
at distances below 100bp. This may be due to steric hindrance between the pre-integration 
complex and the DNA bound transcription factor.  Such hindrance has already been described 
in vitro (Pryciak and Varmus, 1992).   
Only a minority of integration sites were found in proximity to any particular TFBS, 
therefore the existence of the TFBS is not by itself necessary for integration. p53 in particular 
may not play a direct role in this effect as in the cell line used for in vitro infection, Jurkat, 
has been reported to be p53 null due to several mutations (Hainaut et al., 1997). Rather, the 
TFBS or factors associated with the TFBS may increase the efficiency or frequency of 
integration but the mechanism is not clear. In the case of HIV-1, host factors which are 
associated with proviral integration are well described. LEDGF/p75 has been identified as 
integrase cofactor (Cherepanov et al., 2003) which determines integrase localization 
(Maertens et al., 2003) and integration site distribution (Ciuffi et al., 2005). In its absence, 
HIV-1 preference towards integration within genes (and in particular LEGDF regulated 
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genes) is reduced (Ciuffi et al., 2005; Shun et al., 2007).  A study of host factors associated 
with HTLV-1 integrase is currently underway. 
An important limitation of this particular analysis approach is the fact that some of the 
available ChIP-seq data were not isolated in CD4
+
 T-cells, but rather in other cell types. 
While the most appropriate dataset available was used, it is possible that the distribution of 
these in CD4
+
 T-cells would be different. In addition, it is not known whether HTLV-1 
infection of CD4
+
 T-cells itself alters the genome-wide distribution of these binding sites.  
Another open question which remains, concerns the role of higher-order chromatin structure 
in targeting the integration. It is known that the conformation of the DNA determines the 
efficiency of retroviral integration (Pruss et al., 1994). It is not known what role this may play 
in HTLV-1 infection, but it is possible that the TFBS which were found associated to proviral 
targeting do not themselves improve the efficiency of HTLV-1 integration, but rather that 
they represent a nuclear localization or higher-order structure that is more accessible to the 
HTLV-1 pre-integration complex.  
 
4.3.3 Effect of genomic environment on clonal expansion in vivo 
The abundance of an HTLV-1-infected clone in vivo will be determined by the net effect of 
two opposing forces: the clone’s ability to proliferate and the clone’s susceptibility to be 
killed: the strong in vitro activity of CTL suggests that killing by the CTL response is a 
significant selection force.  If these selection forces acted equally upon all clones then we 
would expect to see all in vivo clones having similar clonal abundance. However, the high-
throughput quantification of HTLV-1 proviral integration sites (Gillet et al., 2011, and this 
work) shows that in fact there is a wide variation in clonal abundance both between infected 
128 
 
individuals and within each infected individual. We hypothesize that the genomic 
environment of the integrated provirus is a determinant of this variation, by determining the 
frequency and intensity of proviral gene expression (in particular tax and HBZ). This gene 
expression would promote cell proliferation and confer a selective advantage on particular 
clones.  The results shown here demonstrate that integration at the same orientation into or 
near a host gene favours clonal expansion, as does integration in proximity to CpG islands. 
However, opposite-sense orientation was disfavoured in vivo compared to random 
integration, which suggests that such integrated proviruses are selected out during chronic 
infection. 
General transcriptional activity appears to favour clonal expansion, especially when the 
provirus and the flanking host gene lie in the same transcriptional orientation. What is 
therefore the role of proviral expression in determining clonal expansion? In the next chapter, 
we discuss the role of the genomic environment in determining level of Tax expression.   
 
 
Publication arising from this chapter  
Melamed, A., Laydon, D. J., Gillet, N. A., Tanaka, Y., Taylor, G. P. & Bangham, C. R. 2013. 
Genome-wide Determinants of Proviral Targeting, Clonal Abundance and Expression in 
Natural HTLV-1 Infection. PLoS Pathog, 9, e1003271. 
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Chapter 5 -  Association between genomic 
features, proviral expression and clonal 
expansion 
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5.1 Introduction 
5.1.1 Retroviral Latency and the genomic integration site 
It is poorly understood how the genomic environment flanking the integrated provirus affects 
the level or the frequency of retroviral expression. It has been shown with both HIV-1- and 
HTLV-1-based vectors that expression of proviral genes can differ between otherwise 
identical clones, where the only difference is the integration site (Jordan et al., 2001; Landry 
et al., 2009).  
Lee et al. (2008) have shown that the expression of murine endogenous retroviruses can vary 
according to the tissue, suggesting an association with the expression level of the flanking 
genomic environment. Focusing on the integration sites from HIV-infected individuals under 
highly-active anti-retroviral therapy, Ikeda et al. (2007) found that almost all integrated HIV 
proviruses lay within genes. Using green fluorescent protein (GFP)-expressing Rous Sarcoma 
Virus-based vectors, Plachy et al. (2010) found that stably expressing integrants were found 
to lie within or near to broadly transcribed genes (i.e., genes which are not tissue-specific), 
whereas experiments using a similar vector based on HIV revealed that proviruses with 
inducible expression were more frequently integrated in longer intergenic regions or in highly 
expressing genes (Lewinski et al., 2005). In HTLV-1 infection, integration sites from 
provirus-expressing cell lines have been found in sites with a higher GC content (Zoubak et 
al., 1994) and proviruses expressing Tax were more likely to be found within RefSeq genes, 
or in active regions of the genome (Meekings et al., 2008). 
These results appear at first somewhat contradictory: proviral expression appears to be 
associated both with transcriptionally active regions of the host genome (i.e. not in gene 
deserts), but not with highly-expressing genes. This suggests that a more refined view is 
required to understand the mechanisms that regulate proviral transcription. The role of the 
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relative orientation with respect to the host gene has been investigated in artificial systems 
(Han et al., 2008; Lenasi et al., 2008) but conflicting results were obtained, and it remained 
unclear whether transcriptional interference plays a role in regulating proviral latency.  
 
5.1.2 Does HTLV-1 cause a latent infection? 
The role of the proviral expression in the field of HTLV-1 research is highly debated. By 
several lines of evidence, HTLV-1 appears to cause a latent infection: first, HTLV-1 virion 
particles are not found in the plasma, and cell free blood products are non-infectious (Okochi 
and Sato, 1984). Second, HTLV-1 is thought to proliferate predominantly by mitotic 
replication of the host cell, due to the low sequence diversity (Ina and Gojobori, 1990) and 
long-lived infected clones (Cavrois et al., 1996; Gillet et al., 2011). Lastly, HTLV-1 mRNA 
is often not found by real-time PCR immediately ex-vivo (Yamano et al., 2002).  
In contrast to the latent infection view, the presence of constitutively activated Tax-specific 
CTL in the circulation (Daenke et al., 1996) suggests that in fact a certain level of Tax 
expression does take place in vivo. Similarly, a chronic IgM antibody response in a certain 
proportion of infected individuals (Kira et al., 1992) suggests a persistent viral protein 
expression (Asquith and Bangham, 2008) in vivo.  
Freshly isolated HTLV-1-infected PBMCs generally do not express Tax mRNA or protein 
immediately ex vivo (Figure ‎5.1A); however, depletion of CD8
+
 cells or culture in the 
presence of concanamycin A which inhibits perforin-mediated killing by CTLs, (Figure ‎5.1B) 
allows a measurable level of Tax protein expression in a subset of infected cells after a few 
hours in culture, suggesting that Tax expression is suppressed or controlled at least in part by 
the CTL response (Hanon et al., 2000a).  
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Seemingly conflicting observations emerge: Tax is found to be the immunodominant protein 
in HTLV-1 infection (Goon et al., 2004a), and the majority of HTLV-1 infected individuals 
have both circulating active Tax-specific CD4
+
 and CD8
+
 cells, which would suggest a strong 
selection for CTL escape mutations in the tax gene. Though these can be found (Niewiesk et 
al., 1995; Furukawa et al., 2001), HTLV-1 still is relatively conserved in sequence and 
constitutively active CTLs can be found in patients throughout the duration of the infection 
(Daenke et al., 1996), able to kill Tax-expressing cells in vitro (Asquith et al., 2005a), 
suggesting that CTL escape is not a significant mechanism of persistence (Gould and 
Bangham, 1998) in HTLV-1.  
This would suggest that perhaps rather than modifying the sequence of Tax, HTLV-1 
regulates the expression of the protein to its advantage.  
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Figure ‎5.1: Expression of Tax ex vivo is controlled by CD8
+
 cell activity.  
(A) Expression of Tax ex vivo at different time points following isolation. The freshly isolated CD4
+
 
cells do not readily express Tax protein, however following short incubation in the absence of CD8
+
 
cells, a significant percentage of CD4
+
 cells express Tax protein. Samples from a HAM/TSP patient 
(TBA) and an asymptomatic carrier (HAP) are shown. (B) Incubation of PBMCs from an 
asymptomatic carrier (HT, left panel) or a HAM/TSP patient (TAZ, right panel) in the presence of 
concanamycin A (inhibits perforin mediated killing by CTLs) or in the absence of CD8
+
 cells allows 
increased Tax expression. Figure adapted from Hanon et al., 2000a  
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5.1.3 Expression kinetics in HTLV-1 infection 
Proviral gene transcription from the 5’LTR (which includes the expression of Tax itself) is 
regulated by three imperfect repeat sequences at the LTR termed the Tax responsive elements 
(TRE) (Brady et al., 1987). These sequences do not allow direct binding of Tax to the LTR 
DNA, but form a complex with cAMP-responsive element (CRE) binding/activating 
transcription factors (CREB/ATF; Giebler et al., 1997). Tax has been shown in vitro to 
interact with multiple components of this group, such as CREB and XBP1 (reviewed in 
Matsuoka and Jeang, 2007; Boxus et al., 2008) in order to transactivate many viral and host 
genes. Host genes dysregulated by HTLV-1 Tax include genes involved in cell cycle and 
apoptosis, cytokines and DNA repair (Ng et al., 2001; Chevalier et al., 2012), as well as 
genes involved with interferon pathway signalling (Suzuki et al., 2010). This transactivation 
appears to be made possible by further interactions with histone-modifying enzymes 
(HDACs, p300/CBP, PCAF and the SWI/SNF complex).  
Tax activity itself is regulated by other viral factors. The antisense viral gene HBZ has been 
shown to dysregulate Tax transactivating activity by recruitment of CREB (Figure ‎5.2, 
Gaudray et al., 2002). The viral protein p30 exerts post-transcriptional control on Tax by 
inhibiting Tax/Rex transcript export from the nucleus (Nicot et al., 2004).  
Kinetic studies using real-time PCR have shown that the first transcripts to be expressed in 
the infected cell are Tax/Rex. The level of Tax rises sharply over the first 4-8 hours, and all 
other transcripts increase at a slower rate, reaching peak expression only after about 24 hours, 
suggesting a bi-phasic kinetics of gene transcription (Rende et al., 2011). This is consistent 
with the known role of Tax in transactivating other proviral genes.  
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Figure ‎5.2: Current model of interaction between HBZ and Tax in HTLV-1 infection.  
Tax mediated transcription requires recruitment of host cell factors such as CREB2, which is inhibited 
by HBZ. Figure from Matsuoka and Jeang, 2007 
 
 
5.1.4 The selection forces acting upon the Tax expressing cell 
Two particular viral genes are implicated in driving cell proliferation, thus promoting clonal 
expansion, which is thought to ultimately lead to malignant transformation. The Tax protein 
has been shown to promote proliferation both in vitro (Grassmann et al., 1989) and in vivo 
(Hasegawa et al., 2006) through multiple pathways: Tax cooperates with various cell factors 
(notably CREB and p300/CBP) to activate various host factors which push the infected cell 
through cell cycle check points into S phase (reviewed in Marriott and Semmes, 2005). These 
include binding to cyclins and activating transcription of cdk2 and cdk4, driving Rb 
degradation and inactivating p53. In addition, Tax upregulates the expression of various 
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cytokines and their receptors such as IL-15 and IL-2, which can promote proliferation 
(Matsuoka and Jeang, 2007).   
The more recently identified HTLV-1 gene, HBZ (Gaudray et al., 2002) has also been shown 
to support proliferation of infected cells in vitro (Satou et al., 2006), possibly mediated by the 
host protein Activating transcription factor 3 (ATF3) which can upregulate CDC2 and cyclin 
E2. (Hagiya et al., 2011). In a HBZ-transgenic mouse model (Satou et al., 2011), CD4
+
 T cell 
proliferation was also observed, as well as development of inflammatory lesions in the skin 
and lungs. Conversely, infection of rabbits with HBZ-null HTLV-1 mutants revealed that 
HBZ was not essential for HTLV-1-mediated lymphocyte proliferation (Arnold et al., 2006). 
HBZ mRNA expression correlates with indicators of HAM/TSP disease severity (Saito et al., 
2009). 
It has yet to be fully clarified whether Tax or HBZ play a more significant role in chronic 
infection and in disease: While Tax was found to be necessary for maintenance of 
transformed phenotype in particular cell lines (Yamaoka et al., 1992), its expression is 
abrogated in ~60% of ATLL cases either through proviral deletions at the 5’LTR (Tamiya et 
al., 1996), mutations in tax gene (Furukawa et al., 2001) or methylation of the 
enhancer/promoter region of the HTLV LTR (Taniguchi et al., 2005). HBZ mRNA, however, 
is consistently found in all cases of ATLL, and HBZ appears to be protected from mutations 
(Fan et al., 2010).  
Alongside its crucial activities for transactivating proviral and host genes, Tax also represents 
the immunodominant antigen recognized by CTL, and anti-Tax CTL can be found circulating 
in the blood of the majority of HTLV-1-infected individuals (Jacobson et al., 1990; Goon et 
al., 2004a; Parker et al., 1992) with or without associated disease. IFN-γ and IL-2 CD8+ T 
cell responses to Tax are found (using ELIspot) in most infected individuals (Hilburn et al., 
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2011), whereas CD8
+
 T cell responses to HBZ are only found in the minority of infected 
individuals. The rate of Tax
+
 cell killing per day per autologous CD8
+
 cell is inversely 
correlated with HTLV-1 proviral load (Asquith et al., 2005a) and cells expressing a higher 
amount of Tax protein are killed more efficiently (Kattan et al., 2009).  
Lastly, Tax protein (Cartier and Ramirez, 2005) and Tax-specific CTL (Jacobson et al., 1992) 
are found in the CNS in HAM/TSP, consistent with the notion that Tax may play a role in 
pathogenesis of HTLV-1. However there are conflicting hypotheses on the role of HTLV-1-
specific CD8
+
 cells which may either play a protective role against HTLV-1 disease or an 
active role in the pathogenesis (Bangham, 2009; Jacobson, 2002) or, perhaps most likely, 
both (Bangham, 2009). 
It appears, therefore, that two opposing forces act on the Tax-expressing clone, determining 
the survival and expansion potential of the clone. On the one hand, Tax is able to drive clonal 
expansion. On the other, Tax expression exposes the infected cell to a CTL response.  
 
5.1.5 Aim 
We aim to test the hypothesis that the genomic environment flanking the integrated provirus 
affects the transcriptional state of the provirus, and to test whether the level of proviral 
expression is correlated with clone abundance.  
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5.2 Results 
In order to investigate the level of expression in different HTLV-1-infected clones, we 
cultured CD8
+
 T-cell-depleted PBMCs from 10 HAM/TSP patients overnight to allow 
spontaneous proviral expression (Hanon et al., 2000a).  We then used high-speed cell sorting 
to separate Tax-expressing and non-expressing CD4
+
 cells (figure 2.1, 2.2). Sorted cells were 
combined into Tax positive and Tax negative cell pools to allow efficient DNA extraction, 
then analysed for integration site content using our high-throughput method. In addition, 
integration sites from unsorted PBMCs from all 10 patients were analysed separately in order 
to attribute integration sites from the pooled samples back to the patients. It was possible to 
attribute 46% of clones in this manner.  
 
Table ‎5.1: flow cytometry sorting for Tax
+
, Tax
–
 cells 
Patient # 
CD4
+
Tax
+
 
cells 
CD4
+
Tax
+
 
/ CD4
+
 
CD4
+
Tax
+
 
/total 
CD4
+
Tax
–
 
cells 
CD4
+
Tax
–
/ 
CD4
+
 
CD4
+
Tax
–
 
/total 
1 497,369 38.1% 7.0% 781,154 60.0% 11.1% 
2 644,048 41.6% 10.8% 893,925 56.1% 14.5% 
3 136,793 29.2% 9.8% 326,983 69.8% 23.4% 
4 461,568 21.5% 9.0% 1,866,092 77.9% 32.6% 
5 242,228 10.8% 3.8% 2,368,791 88.4% 31.1% 
6 242,984 11.9% 6.3% 1,957,727 87.3% 46.2% 
7 106,896 16.4% 3.9% 583,892 81.8% 19.3% 
8 222,177 19.4% 3.1% 943,268 79.1% 12.5% 
9 165,110 23.6% 5.6% 587,502 73.1% 17.2% 
10 925,785 53.8% 23.2% 578,717 32.8% 14.2% 
Total cells 3,644,958   10,888,051   
Total DNA 
(μg) 
4.067   8.19   
Total 
proviral 
copies 
found 
20813   10326   
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5.2.1 Majority of clones are either 100% or 0% positive 
The integration sites identified in the Tax positive cells and in the Tax negative cells were 
added and compared in order to identify the proportion of Tax positive cells in each clone. 
The majority of clones (68%), as expected, were singletons (clones found only in one cell). 
However, even among clones in the highest abundance bin (over 10 cells), the majority of 
clones contained either > 90% or < 10% Tax positive cells, suggesting that the Tax positivity 
(or lack of) is an inherent property of certain clones (Figure ‎5.3).  
 
 
Figure ‎5.3: The majority of clones are either 100% or 0% Tax positive.  
Frequency distribution of clones according to the proportion of Tax
+
 cells in each clone, binned 
according to the number of sisters in each clone. Bin1 – 1 cell detected; bin 2 – 2-3 cells detected; 
bin3 – 4-10 cells detected; bin 4 – more than 10 cells detected. 
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5.2.2 Association between spontaneous Tax expression and 
integration within a gene.  
When the provirus was integrated within a gene, we observed a slight but significant excess 
of frequency of Tax
+
 cells Tax
–
 cells (46% vs 43% respectively, p < 10
-3, χ2 test). Consistent 
with previous observations, the integrated provirus was found more frequently in the same 
transcriptional orientation as the host gene (Figure ‎5.4). However, while the proviruses in the 
Tax
+
 cells were found with similar frequency in the same or the opposite transcriptional 
orientation to the host gene in which they were integrated, the Tax
–
 cells were significantly 
more frequently present in the same orientation as the host gene (52% of Tax
+
 vs 59% of 
Tax
–
 cells, p < 10
-15, χ2 test). Thus, T cell clones that were 100% Tax– were significantly 
more likely to carry a provirus in the same orientation as the host gene. 
 
 
Figure ‎5.4: Same-sense integration within a host TSS is associated with Tax silencing. 
Odds ratio of integration of Tax
+
 or Tax
–
 clones within a gene compared to random expectation. Tax 
expressing clones were more frequently integrated within a gene but integration in the same sense 
orientation was strongly associated with Tax silencing. Relative orientation is with respect to the 
sense strand of HTLV-1. 
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5.2.3 Integration in proximity to a TSS or CpG island 
The pattern of bias towards integration in vivo in proximity to a TSS or CpG island is 
consistent with previous findings (Figure ‎5.5A, Figure ‎5.6), with a peak bias at 1kb from the 
integration site. The bias towards integration within 1kb of a TSS was higher for Tax
+
 cells; 
however, for proviruses with an upstream nearby TSS, there was an excess frequency of 
integration in the same orientation as the host gene for Tax negative cells.  
The mean proportion of Tax
+
 cells per clone (across all clones, including singletons) was 0.6. 
We wished to test whether integration in proximity to TSS would alter this proportion. We 
found that a nearby TSS upstream of the integration site was associated with a high 
proportion of Tax positive cells if the provirus was in the opposite orientation as the upstream 
TSS, but with a lower proportion of Tax positivity if the provirus was in the same orientation. 
The closer the TSS to the provirus, the stronger these effects became (Figure ‎5.5B). This 
asymmetry was not observed for TSS downstream of the integration site (Figure ‎5.5B), where 
proximity to a TSS was associated with increased proportion of Tax positivity.   
Similarly, we observed an excess frequency of Tax + cells where the nearest CpG island lay 
downstream of the integration site, and an excess frequency of Tax
–
 where the nearest CpG 
island lay upstream of the integration site. (Figure ‎5.6) 
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Figure ‎5.5: Tax expression is favoured in proximity to TSS, but disfavoured in proximity to 
upstream TSS of the same orientation.  
‘Upstream’, ‘Downstream’ and relative orientation are with respect to the sense strand of HTLV-1. 
(A) Mountain plot showing the odds ratio of integration of Tax
+
 or Tax
–
 clones in proximity to TSS 
compared to random expectation. (B) Clones with upstream TSS had a higher mean positivity if the 
nearest upstream TSS was in the opposite orientation, and a lower mean positivity if the nearest 
upstream TSS was in the same orientation. The presence of a downstream TSS was associated with 
increased Tax positivity, regardless of orientation.  
A 
B 
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Figure ‎5.6: Odds ratio of integration in proximity to CpG island.  
Bias towards integration in proximity to CpG island was similar between Tax-expressing and non-
expressing clones, but was higher in Tax-expressing clones if a CpG island lay downstream of the 
integration site. ‘Upstream’, ‘Downstream’ are with respect to the sense strand of HTLV-1. 
 
 
5.2.4 Integration in proximity to TFBS 
Consistent with previous in vivo results, there was a small preference towards integration in 
proximity to a TFBS (within those TFBS tested using available ChIP-seq data) for both Tax
+
 
and Tax
–
 cells. In very close proximity upstream of the integration site (within 10 bases) there 
was a slightly greater bias for the Tax
+
 cells than for Tax
–
 cells. (Figure ‎5.7). 
 We wished to test whether integration in proximity to the different TFBS would alter the 
mean frequency of Tax
+
 positivity of the infected clone. We observed that for certain TFBS 
(including STAT1, cJun, NRSF; Figure ‎5.8) the presence of a TFBS in close proximity 
upstream of the integration site was associated with increased mean Tax positivity. In stark 
contrast, a BRG-1 upstream to the integration site was associated with Tax negativity. An 
infected cell with a BRG-1 downstream to the integration site, however, was more likely to 
be Tax positive.  
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In order to identify TFBS which were independently associated with Tax positivity or 
negativity, a multivariate logistic regression analysis was carried out as previously described, 
using the outcome measure of Tax
+
 cell and integration within all tested TFBS within 100 or 
1000 bases as explanatory variables. The results (Figure ‎5.9) confirmed the asymmetric 
effects of the BRG-1 binding site, and in addition revealed significant asymmetric 
associations between Tax expression and several other TFBS, notably STAT1, NRSF, and 
HDAC1. Thus, an NRSF binding site (Figure ‎5.8C) 100bp downstream was a significant 
predictor of Tax negativity, but the closest upstream NRSF binding site was not 
independently associated with Tax expression.. Conversely, a STAT1 binding site (Figure 
‎5.8D) at 100bp or HDAC1 binding site at 1kb upstream of the provirus strongly favoured Tax 
expression, but the presence of a downstream STAT1/HDAC1 binding site was not an 
independent predictor of Tax expression after multivariate analysis.  
 
 
Figure ‎5.7: Integration in proximity to any TFBS of those tested.  
Small preference towards integration in proximity to any TFBS with a small excess preference for 
Tax expressing clones to have TFBS in close proximity upstream to the integration site. ‘Upstream’, 
‘Downstream’ are with respect to the sense strand of HTLV-1. 
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Figure ‎5.8: Tax expression is altered by integration in proximity to particular TFBS.  
The mean proportion of clones within 10b-1000kb of a nearby TFBS was calculated to determine the 
effect of nearby TFBS on Tax positivity. The effect of nearby TFBS on Tax expression was notably 
asymmetrical.  ‘Upstream’, ‘Downstream’ are with respect to the sense strand of HTLV-1. 
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Figure ‎5.9: Integration in proximity to TFBS: multivariate analysis.  
TFBS that were independently associated with Tax expression were identified by multivariate 
analysis. Outcome measure was Tax expression of a given cell. TFBS shown above the line were 
associated with Tax expression (OR>1); TFBS below the line were associated with Tax silencing (OR 
<1). Model 1 and Model 2 (carried out independently) test for TFBS within 1kb and 100bp of 
integration site, respectively.   
 
5.2.5 Association between Tax expression and clone abundance.  
Lastly, we wished to test the distribution of Tax positive cells and Tax negative cells between 
the different clone abundance bins. We assigned all clones to abundance bins based on the 
number of sisters in each clone. While small (low abundance) clones were the most frequent 
both among Tax
+
 cells and Tax
–
 cells (as small clones are remarkably more numerous than 
larger ones), the slope was significantly (p = 0.006, ANCOVA test) higher in Tax
+
 cells, 
because there were more Tax
+
 cells in the singletons than in the largest clones (Figure ‎5.10). 
Across all clones, the fraction of Tax
+
 cells in each clone abundance bin was significantly 
negatively associated (p<10
-16, χ2 test for trend) with clonal abundance. Among the clones 
which we were able to attribute to each patient, the negative correlation was observed for 
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most patients; however in a few patients (in particular, those with a high oligoclonality index; 
Figure  5.11) the largest clone abundance bin included a high number of Tax
+
 cells. Therefore, 
at least for HAM/TSP patients, the majority of the high frequency of Tax-expressing cells 
observed is due to a large number of small clones, rather than a small number of expanded 
Tax-expressing clones.  
 
 
 
Figure ‎5.10: Frequency distribution of Tax
+
, Tax
–
 cells between different clone abundance.   
In both Tax
+
 (left) and Tax
–
 (right) cell populations, the proviral load was dominated by smaller 
clones. However the proportion of Tax
+
 cells declined significantly with increasing clone abundance 
(ANCOVA test for difference in slope, p = 0.006).  
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Figure ‎5.11: Tax+ cells were more frequent in smaller clones. 
(A) Mean fraction of Tax
+
 cells in bins of increasing clonal abundance (total number of cells in each 
respective clone). The fraction of Tax
+
 cells was negatively correlated with clonal abundance  
(p < 10
-16, χ2 test for trend). (B) In the majority of patients there was an inverse correlation between 
clone abundance bin and fraction of Tax
+
 cells. While this correlation was highly significant in all 
patients combined (see A), in certain patients (particularly those with a high oligoclonality index) the 
most abundant clones contained a high proportion of Tax
+
 cells. Clones were binned according to the 
number of sisters observed, as above.  
 
A 
B 
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5.3 Discussion 
The mechanism of proviral latency is of great importance in retroviral infection. HIV-1-
infected individuals receiving highly-active anti-retroviral therapy (HAART) maintain a 
population of transcriptionally latent proviruses which persist in resting CD4
+
 cells (Finzi et 
al., 1997; see also Durand et al., 2012) as a reservoir which can reactivate upon interruption 
of therapy. During HTLV-1 infection it was long debated whether there is proviral expression 
during in vivo infection. HTLV-1 gene expression is difficult to detect in fresh PBMC; 
however, the strong, constitutively active anti-HTLV-1 CTL found in infected individuals 
suggests frequent reactivation of the proviral genes in vivo, though this may be intermittent, 
regulated by the viral genes and host immune system (Bangham et al., 2009).  While it is 
difficult to detect Tax protein in fresh PBMCs, a short-term culture of CD8
+
 cell-depleted 
PBMCs reveals a population of infected cells expressing Tax protein (Hanon et al., 2000a). 
Here, I used this phenomenon in order to investigate the effect of the genomic environment 
on the likelihood of Tax expression by an infected cell.  It is difficult to say with certainty 
what is the magnitude or frequency of Tax expression in vivo, and it is impossible to say that 
the same HTLV-infected cells which spontaneously express Tax in culture would also 
express Tax in vivo. However, the fact that cells which express Tax ex vivo turn over more 
rapidly in vivo (Asquith et al., 2007) and the association between the proportion of such ex 
vivo expressing CD4
+
 and clinical outcome (Asquith et al., 2005b) suggest there is a clear 
clinical relevance to cells that spontaneously express Tax
+
 ex vivo.  
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5.3.1 Transcriptional interference is a possible mechanism of 
proviral latency. 
In this work I observed an association between spontaneous expression of Tax and 
integration within genes or in proximity to transcription start sites. Tax expression was also 
weakly associated with the presence of a CpG island in proximity (in particular downstream) 
and with certain TFBS. This confirms previous work (Zoubak et al., 1994; Meekings et al., 
2008) and is consistent with the idea that on a large scale, integration in a genomically active 
region (rather than heterochromatin) is conducive to Tax expression from the integrated 
provirus. However, refining the analysis to consider the relative position and orientation of 
the provirus and the host genome has uncovered a more localised effect: where the provirus 
was integrated just downstream of a transcription start site, the integrated provirus was 
significantly more likely to be transcriptionally silent, but only if the upstream TSS was in the 
same orientation as Tax.  This observation is consistent with the idea of transcriptional 
interference, where RNA polymerase II transcribing from the upstream promoter blocks 
initiation of transcription from 5’LTR promoter (Lenasi et al., 2008).  This mechanism has 
been tested before in single gene in vitro models with conflicting results (Han et al., 2008; 
Lenasi et al., 2008). More recently, using an HIV model of latency, infecting Bcl-2-
transduced primary cells using GFP-expressing HIV-based vector, Shan et al have shown that 
proviruses with inducible GFP expression were more likely to lie in the same orientation as 
the host gene, and were more like to be in highly active genes; persistence of GFP expression 
was associated with opposite sense integration(Shan et al., 2011). The evidence presented 
here demonstrates that in naturally HTLV-1-infected cells, same-sense orientation of the 
upstream promoter is associated with silencing of proviral gene expression, consistent with a 
mechanism of transcriptional interference.   In order to validate this mechanism, it would be 
useful to test for the expression of the upstream genes, for example in HTLV-1 –infected T 
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cell clones (Cook et al., 2012) and compare that with the level of Tax expression in each 
clone.  
We conclude that regulation of transcription of HTLV-1 Tax takes place at two levels. First at 
a regional level, the transcriptional activity of the genome favours proviral expression and 
clonal expansion (Meekings et al., 2008; Gillet et al., 2011). Second, a local effect of 
upstream promoter up to 1kb from the integration site can silence expression from 5’LTR, 
overriding the regional effects.  
 
5.3.2 Role of Transcription factors and chromatin remodellers in Tax 
expression 
While at the targeting level the associations observed between integration and nearby 
transcription factor binding sites were largely symmetrical, the effect of proximity to TFBS 
on Tax expression was often asymmetrical.   The asymmetry of these associations suggests a 
mechanistic interaction between the proviral expression and transcription of the nearby host 
genome.  A notable example of this asymmetry was BRG1, one of the two ATPase 
components of the SWI/SNF complex. This is a multi-subunit chromatin remodelling 
complex (Euskirchen et al., 2012) which controls gene expression by repositioning of 
nucleosomes in a DNA topology-dependent manner (Gavin et al., 2001). The SWI/SNF 
complex is heterogeneous, and it is thought that the particular combination of its subunits 
determines its effect on transcription (Euskirchen et al., 2011). BRG1 directly interacts with 
Tax, and suppression of BRG1 using siRNA inhibits Tax transactivation (Wu et al., 2004, 
Easley et al., 2010). Here we found that clones which had a BRG1 binding site downstream 
of the integration site were more likely to express Tax, while clones which had such a 
binding site just upstream of the integration site were more likely to be Tax silent.  
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Several other SWI/SNF subunits are known to have a role in retroviral infection.  INI1 
colocalizes and interacts with HIV-1 integrase (Kalpana et al., 1994; Turelli et al., 2001), 
however its role in HIV-1 expression is not clear. Here we found that integration with a 
downstream INI1 site within 1kb was independently associated with Tax expression, similar 
to the downstream BRG1 site.  
The DNA binding sites of other components of the SWI/SNF complex also seem to have a 
role in Tax expression. An upstream BAF170 binding site, known to be highly expressed in 
HTLV-1 infected cells (Van Duyne et al., 2011) was here found to be associated with 
spontaneous Tax expression, while a proximal binding site of BAF155, which has been 
reported to be downregulated in HTLV-1 infected cells (Van Duyne et al., 2011) was here 
found to be associated with Tax silencing (Figure ‎5.9).   
Some of the other transcription factors whose binding site was found to be associated with 
Tax expression are also known to have a role in transactivation of proviral genes. cJun and 
cofactors are recruited by Tax for transactivation from the 5’LTR , leading to histone 
acetylation (Lemasson et al., 2002); the treatment of HTLV-1 infected cells with sodium 
valproate, an HDAC inhibitor, increases the amount of Tax expression (Mosley et al., 2006).  
It is not clear what role the proximity to the binding site itself may play in upregulating 
transcription of Tax, though it may increase the efficiency of recruitment of such factors to 
the 5’LTR promoter.   
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5.3.3 Effect of proviral expression on clonal abundance  
Tax has been implicated in driving clonal proliferation. As discussed in section 5.1, it is 
known to push the infected cell through cell cycle progression, and to transform cells both in 
vitro and in animal models. In addition, cells which express Tax ex vivo have a higher 
turnover rate in vivo (Asquith et al., 2007). Therefore, we expected that clones which express 
Tax would be expanded in vivo.  However, this work has revealed the opposite, i.e. a highly 
significant negative correlation (Figure  5.11A): Tax expressing cells were significantly more 
likely to belong to small clones and there was a significantly higher number of low 
abundance clones expressing Tax (Figure ‎5.10).  This observation is likely to be due to the 
immune response.  Tax is the immunodominant protein in the CTL response against HTLV-1 
(Goon et al., 2004a; Kannagi et al., 1991) and activated autologous Tax-specific cells control 
the expression of Tax ex vivo (Hanon et al., 2000a).  In addition, cells which express a higher 
level of Tax ex vivo are killed more efficiently by autologous CTLs (Kattan et al., 2009). Our 
results agree with this – if the initial integration favours Tax expression, these cells will be 
more readily identifiable to the immune response and will consequently be cleared. We 
conclude that the small HTLV-1-infected clones express Tax in vivo, and turn over faster. 
Clones which do not express Tax readily will be able to escape CTL for longer and 
proliferate, perhaps driven by HBZ.  It would be interesting and important to compare these 
results with a similar test of HBZ expression however since there is currently no available 
method to sort HBZ-expressing cells; this cannot be tested directly. There is currently a 
project underway which aims to identify HBZ expressing clones by their ability to be cleared 
by HBZ-specific CTLs.  It is possible that the critical role of Tax in maintaining proviral load 
is not in driving clonal expansion, but in facilitating cell-to-cell transmission:  expression of 
proviral genes, promoting new virion production and mediating the cell polarization required 
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for cell-cell virus transmission through the virological synapse (Nejmeddine et al., 2005; 
Mazurov et al., 2010) 
We observed a significant negative correlation between clone abundance and the percentage 
of Tax
+
 cells. While this was highly significant in all patients combined, in a small number of 
patients (in particular those with a high oligoclonality index, Figure  5.11B) the most 
abundant clones (bin 4, clones with greater than 10 cells) contained a high proportion of Tax
+
 
cells.  What has enabled these clones to survive the CTL control? 
It is possible that antigen-expressing clones may have escaped control by the immune 
response, for example by CTL escape mutations in the tax gene (Niewiesk et al., 1995). 
Clone-specific sequencing of exon 3 of the tax gene of 38 highly abundant clones from 8 
patients did not reveal significant differences in the occurrence of Tax mutations between 
clones with a high or low frequency of Tax
+
 cells; and only in one patient was a difference in 
amino acid sequence found between one clone and the others (data not shown). 
It should be noted that since Tax transactivates all other proviral genes, the immune response 
to Tax-expressing cells could be targeted against viral proteins other than Tax itself, such as 
Gag, which is a strong target for both the CTL and antibody responses. Therefore we cannot 
rule out the possibility of CTL escape mutations in another proviral gene.   
A number of open questions remain:  
1) What drives selective clonal expansion? 
2) What is the role of Tax in HTLV-1-related disease? 
The results of this study are consistent with the idea that it is not Tax, but HBZ that is 
responsible for clonal expansion in vivo. Other evidence for this idea comes from ATLL, 
where the expression of Tax (and consequently other plus-strand proviral genes) is in fact 
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often abrogated by deletions, mutations and methylations. The finding of the duplicated host 
sequence still flanking the deleted provirus suggests that at least in some cases the deletions 
took place prior to proviral integration, and the infected clone expanded in vivo in the 
absence of Tax expression (Tamiya et al., 1996; Miyazaki et al., 2007). HBZ, which is 
expressed from the minus strand, appears protected from mutations (Fan et al., 2010), and 
HBZ mRNA expression is detected in all ATLL cases (Saito et al., 2009).  
At a given proviral load, HAM/TSP patients have a higher proportion of CD4
+
 cells 
expressing Tax than ACs (Asquith et al., 2005b). This is consistent with our previous finding 
(Gillet et al., 2011) that the increased proviral load in HAM/TSP is due to a larger number of 
different clones (rather than expansion of a few clones) and our present finding that the Tax 
expressing cells are associated with a large number of low-abundance clones rather than a 
small number of expanded Tax-expressing clones. However, the role of Tax in pathogenesis 
is not clear. Tax is more readily detectable in cells isolated from the CSF of both patients 
with HAM/TSP and ACs than in the blood (Moritoyo et al., 1999). This could imply that the 
Tax-expressing cells in the CSF are less well controlled (and may selectively proliferate) than 
those in the blood, or that Tax-expressing cells are more likely to infiltrate the CSF. In 
addition, expression of cytokines in the CSF by other infiltrating cells may promote 
expression by altering the transcriptional activity of the infected cell.  
This work opens the way to more questions. The effects of transcription factors and 
chromatin remodellers on Tax expression should be investigated in an in vitro model, and the 
implications of such effects for persistence, latency and pathogenesis should be analysed.  
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Chapter 6 -  The contribution of infected
CD8+ cells to the proviral load  
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6.1 Introduction 
6.1.1 HTLV-1 host cell tropism 
HTLV-1 is known to preferentially infect CD4
+
 cells (Richardson et al., 1990), however 
CD8
+
 cells have also been described as a reservoir for infected cells (Richardson et al., 1990; 
Nagai et al., 2001a; Cho et al., 1995; Hanon et al., 2000b). The HTLV-1-associated 
malignancy, ATLL, is a predominantly CD4
+
CD8
–
 malignancy (Uchiyama et al., 1977) , 
although relatively rare CD4
+
CD8
+
 double positive, CD4
–
CD8
–
 double negative and CD4
–
CD8
+
 phenotypes have also been described (Raza et al., 2010; Kim et al., 2006, Ciminale et 
al., 2000; Kamihira et al., 1992). The related virus HTLV-2 appears to have a complementary 
tropism, with most of its load found in CD8
+
 cells (Ijichi et al., 1992), however HTLV-2-
infected CD4
+
 cells can also be found (Lal et al., 1995).  
It is debated which is the determining factor in the host cell tropism of HTLV-1 and HTLV-2. 
Early evidence showed that the cellular receptors for HTLV-1 are found on many cell types 
(Yamamoto et al., 1984; Krichbaum-Stenger et al., 1987). Experimental in vitro infections by 
HTLV-1 were successfully done in multiple cell types, including human B cells, fibroblasts, 
endothelial and Glial cells (Yamamoto et al., 1982a; Yoshikura et al., 1984; Hoxie et al., 
1984; Saida et al., 1988), however in vivo the load appears to be present almost entirely in the 
CD4
+
 and CD8
+
 cells (Richardson et al., 1990).  
Despite apparent higher Tax expression in CD4
+
 cells than in CD8
+
 cells (Newbound et al., 
1996), experiments in which Tax/Rex sequences were swapped between recombinant HTLV-
1 and HTLV-2 did not alter the host cell tropism of either virus (Ye et al., 2003b).  
With the increased understanding of the host molecules involved in cellular entry of HTLV-1 
and HTLV-2, Jones et al. (2006) have shown that CD4
+
 cells express high levels of HSPGs 
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while CD8
+
 cells express much higher levels of GLUT-1. By modifying the expression of 
these molecules, this group was able to increase infection of CD8
+
 cells by HTLV-1, 
suggesting that that the host cell tropism is at least in part determined by the concentration or 
distribution of receptor molecules on the target cell surface. In vivo and in vitro experiments 
carried out in the rabbit model by Kannian et al. (2012) gave contrasting results. When 
animals were infected with either HTLV-1 or HTLV-2, both CD4
+
 cells and CD8
+
 cells were 
initially infected by HTLV-1, but the proviral load differed over time in the different cell 
populations. In addition, when infecting PBMCs in vitro, HTLV-1 preferentially 
immortalized CD4
+
 cells and HTLV-2 preferentially immortalized CD8
+
 cells, suggesting 
that it is the long-term selection dictating the observed difference in tropism. It should be 
noted that it is difficult to assess the relevance of these assays as the proviral load measured 
was remarkably high (up to 80% of cells), which is unlikely to be the case in the early stages 
of infection in healthy human carriers of HTLV-1.  
 
6.1.2 Clonality of HTLV-1 infected CD8+ cells.  
The issue of the clonality of infected CD8
+ 
cells has been overlooked in the HTLV-1 field. As 
HTLV-1 preferentially infects CD4
+
 T-cells and ATLL is largely a CD4
+
 T cell malignancy, 
the standard model of HTLV-1-driven transformation (Figure ‎6.1) focuses on HTLV-1-
infected CD4
+
 cells which clonally expand (presumably driven by viral genes and controlled 
by the immune response); some of the expanded clones are driven to transformation by 
somatic mutations.  
Therefore, previous clonality studies by us (Gillet et al., 2011) and others (e.g. Cavrois et al., 
1998) have analysed DNA extracted from total PBMCs, with the underlying assumption that 
the clonality in PBMCs is equivalent to the clonality in each infected subset of the PBMCs.  
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Several groups (Eiraku et al., 1998; Ureta-Vidal et al., 2001) have previously reported 
oligoclonality of both CD4
+
 and CD8
+
 in HTLV-1 infected individuals (in all clinical 
manifestations), however, these studies were done by different methods measuring or even 
quantifying clonality of CD3 variable β chain, without distinguishing between infected and 
uninfected clones.  
In recent years, a group led by Eric Wattel has carried out a series of experiments to 
investigate the difference between infected CD4
+
 and CD8
+
 cells by generating infected and 
uninfected CD4
+
 and CD8
+
 T cell clones by limiting dilution from a cohort of HAM/TSP 
patients. These experiments showed a higher rate of proliferation in infected clones than 
uninfected clones in both CD4
+
 and CD8
+
 populations; however the authors concluded that 
the mechanisms differed between the two cell types: while infected CD4
+
 clones showed an 
increase in transition through the cell cycle (thus, increased replication), infected CD8
+
 
clones showed a significant decrease in the proportion of cells undergoing apoptosis (Sibon et 
al., 2006), a cIAP-2 dependent mechanism (Zane et al., 2010). In addition, by using 
restriction enzyme IPCR to detect proviral integration sites, they were able to show that 
expanded clones were present in both the CD4
+
 and CD8
+
 cell populations.  
Using tetramers containing the immunogenic epitope Tax11-19 in the context of HLA-
A*0201, and comparing to a non-HTLV-1 epitope, Hanon et al. (2000b) have previously 
shown that Tax-specific CTLs were more likely than EBV-specific CTLs to express Tax 
themselves. This observation suggests that HTLV-1-infected CD8
+
 cells may often be the 
same cells that control the viral infection, and that clonal expansion of these cells may have 
an important role either in the dynamics or pathogenesis of HTLV-1.  
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6.1.3 Aim 
This work aims to test the hypothesis that the shape of the clonal distribution of infected 
CD8
+
 cells differs from that of CD4
+
 cells, and to investigate the role of infected CD8
+
 cells 
in determining the clonal distribution of the load. 
 
 
 
 
 
Figure ‎6.1: Standard model of HTLV-1 latency.  
Infection of CD4
+
 lymphocytes results in long term clonal expansion regulated by viral genes and 
external cofactors (e.g. co-infections such as Strongyloides stercoralis) and controlled by CTL 
response. Additional somatic mutations are then thought to allow certain clones further expansion and 
malignant transformation. Figure adapted from Mahieux and Gessain, 2007.  
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6.2 Results 
6.2.1 Magnetic associated cell sorting for CD4+ and CD8+ cell 
populations 
PBMCs from 12 HTLV-1-infected individuals were sorted by using magnetic associated cell 
separation for CD4
+
 and CD8
+
 cell populations. Details on the patients studied here are 
shown in Table ‎6.1. I selected patients with a relatively high proviral load (lowest proviral 
load in PBMC - 3.6 copies per 100 PBMC; Table ‎6.2) to ensure sufficient proviruses for 
analysis. The 12 patients included 6 HAM/TSP patients and 6 healthy carriers. One of the 
asymptomatic carriers (HGL) was diagnosed with HAM/TSP symptoms approximately 1 
year after the sample was taken.  
Purity of samples was assessed using flow cytometry, and proviral load of unsorted cells, 
CD4
+
 and CD8
+
 populations was quantified using QPCR. The HTLV-1 proviral integration 
sites were identified and quantified using the high-throughput method described in chapter 3.  
The purity of cell populations isolated from each subject is shown in Table ‎6.1.The median 
frequency of contaminating CD8
+
 cells in the CD4
+
 fraction was 0.94% (range 0.43-5.44%) 
and the median frequency of contaminating CD4
+
 cells in the CD8
+
 cell fraction was 0.47% 
(0.07-2.07%). Based on the assumption that HTLV-1 infects differentiated, mature CD4
+
 or 
CD8
+
 single-positive cells, we regarded any integration site found in both CD4
+
 and CD8
+
 
cells as a contaminating site and allocated it to the sample (either CD4
+
 or CD8
+
 cells) in 
which it was identified with a higher frequency (greater number of sisters). The number of 
contaminating sisters was inversely correlated with the purity of the cell populations, and 
there was a highly significant correlation between the proportion of CD8
+
 cells in the PBMC 
and the proportion of the load carried in CD8
+
 cells (Figure ‎6.2).  
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The proviral load was measured using quantitative PCR. The median proviral load in CD4
+
 
cells and CD8
+
 cells was 12.3 copies (6.0-30.2) and 2.0 (1.1-6.2) copies per 100 cells, 
respectively. 
The proportion of the load carried by the CD8
+
 cells was calculated based on the proviral 
load measured and the proportion of PBMCs in each cell population (see methods). The 
median percentage of the proviral load represented by CD8
+
 cells was 5.02% (2.29%-
35.32%). See Table ‎6.2 for full details.  
The proportion of the load carried by the CD8
+
 cells was then further verified by the 
proportion of sisters (in the unsorted sample) attributed to the CD8
+
 cells (across all CD8
+
 
clones found in the unsorted sample). There was a highly significant correlation between the 
results of the two methods of calculation of the CD8
+
 cell contribution to the load (Figure 
‎6.4; Pearson linear regression, p <10
-6
, r = 0.969). 
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Table ‎6.1: Patients samples used in chapter 6 
Patient  
Absolute 
counts  
Populations 
within T cells 
Populations in 
PBMC 
Purity test 
code 
Clinical 
diagnosis 
Known 
comorbidities
a
 
CD4
+
 CD8 
CD4
+
 / 
CD3
+ 
CD8
+
 / 
CD3
+
 
CD4
+
 
in total 
CD8
+
 
in total 
CD8
+
 
in 
CD4
+
 
CD4
+
 
in 
CD8
+
 
HBX AC None NA NA 63.9 33.7 45.2 13.8 1.15 2.07 
HBZ AC None 948 284 51.8 41.8 58.3 11.2 0.915 0.985 
HCP AC None 732 335 53.5 33.5 32.7 10.5 1.1 1.46 
HEZ AC Hepatitis  631 214 53.8 34.3 41.9 13.9 0.801 0.069 
HGL AC  None 835 378 63.7 33.4 47.7 14.1 0.684 0.364 
HHD AC None 1316 419 67.4 30 44.8 13.7 0.469 0.693 
TAN HAM/TSP None 588 260 42.9 48.5 47 12.4 1.95 0.11 
TAZ HAM/TSP None 1560 1058 44.1 44.6 47.8 27.1 0.858 0.573 
TBW HAM/TSP None 300 1254 12.4 85.6 26.3 58.1 5.44 0.077 
TDB HAM/TSP None 838 406 43.5 44 53 12.5 1.53 0.29 
TDL HAM/TSP Shingles 1526  707
d
 57.9 38.4 45.5 18.5 0.43 0.337 
TDT HAM/TSP None 752 392 50.6 41.5 44.4 15.3 0.959 0.573 
NA – not available.  
 
 
 
 
                                                 
a
 Absolute cell counts and data on comorbidities were supplied by Dr. Maria Antonietta of Dr. Graham Taylor’s 
group.  
b
 HEZ – Hepatitis of unknown origin (negative for HCV, HBV) 
c
 HGL – considered to be asymptomatic carrier at time of blood sample, but was diagnosed with HAM/TSP 
about. a year later. 
d
 TDL – absolute cell counts from an earlier timepoint (1 month prior) 
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Figure ‎6.2: Analysis of contaminating integration sites.  
Each integration site was attributed to either to CD4
+
 or CD8
+
 cells based on frequency in each 
sample. The number of clones in the CD4
+
 samples that were attributed to CD8
+
 cells is plotted here 
against potential causes of contamination. The strongest correlate was the proportion of CD8
+
 cells in 
the PBMCs. 
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Table ‎6.2: The viral burden in each T cell subset. 
Patient 
Proviral Load (copies per 100 cells) 
Proportion of load present in each 
population (%) 
PVL[CD4
+
] PVL[CD8
+
] PVL[PBMC] CD4
+
 CD8
+
 
HBX 6.0 1.8 3.7 91.8 8.2 
HBZ 6.5 1.7 3.8 95.2 4.8 
HCP 10.1 1.6 4.6 95.3 4.7 
HEZ 11.8 1.8 5.3 95.2 4.8 
HGL 12.8 1.9 4.3 95.8 4.2 
HHD 17.4 2.0 4.7 96.6 3.4 
TAN 10.2 2.3 6.4 94.4 5.6 
TAZ 30.2 6.2 11.3 89.7 10.4 
TBW 17.8 4.4 9.4 64.7 35.3 
TDB 10.6 1.1 3.6 97.7 2.3 
TDL 22.9 3.1 8.0 94.8 5.2 
TDT 17.3 3.6 8.0 93.4 6.6 
Median 12.3 2.0 5.0 95.0 5.0 
 
 
 
Figure ‎6.3: The contribution of CD8
+
 cells to the proviral load. 
Pink – the proviral load measured (QPCR) in CD8+ cells (copies per 100 cells). Blue – the percentage 
of the proviral load carried in the CD8
+
 cells, estimated based on PVL measured in CD4
+
 and CD8
+
 
cell population and flow cytometry data.  
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Figure ‎6.4: Two methods of estimations of the proportion of the load contributed by CD8
+
 cells.  
The proportion of the load estimated from the proportion of sisters belonging to CD8
+
 clones (from 
the high-throughput sequencing analysis) was very similar to the estimate from PVL measured in each 
population and the flow-cytometry data.  
 
6.2.2 The role of infected CD8+ cells in shaping the proviral load 
We wished to test the role of the infected CD8
+
 cells in shaping the proviral load in each 
sample. The proviral load in PBMC was strongly correlated (p<10
-6
, Pearson’s R = 0.963) 
with the proviral load in CD8
+
 cells, and also correlated (p<10
-3, Pearson’s R = 0.864) with 
the proviral load in CD4
+
 cells (Figure ‎6.5).  
We then examined the proviral load distribution in each fraction. Samples from CD8
+
 cells 
had fewer sisters (Figure ‎6.6; Right panel), which could be predicted from the lower load in 
these samples; however, the number of distinct clones in the CD8
+
 samples was even more 
remarkably lower than in CD4
+
 samples (Figure ‎6.6; left panel).  
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The oligoclonality index was significantly higher in CD8
+
 samples (median = 0.60) than in 
CD4
+
 samples (median = 0.53). That is, there was a higher diversity of distribution within 
CD4
+
 clones (Figure ‎6.7). There was no significant difference in OCI between asymptomatic 
carriers and HAM/TSP patients, in agreement with a previous report (Gillet et al., 2011). 
However, the difference in OCI between the CD8
+
 and CD4
+
 samples was only statistically 
significant for HAM/TSP patients (Figure ‎6.8). See Figure ‎6.9 for a characteristic distribution 
found in CD4
+
 and CD8
+
 samples from patient HCP. Whereas the oligoclonality index of 
HTLV-1 in CD4
+
 cells was often determined by one or few expanded clones, then a sharp 
decline and a long tail of singletons (clones which we only observe once), the CD8
+
 
distribution was often characterized by a significantly smaller number of distinct clones and a 
larger number of expanded clones, and a much smaller proportion of the load was made up 
by singletons.  
Finally, we aimed to quantify the relative role of CD4
+
 cells and CD8
+
 cells in determining 
the clone frequency distribution in unsorted PBMCs. In order to do that, we compared the 
clones identified as CD4
+
 or CD8
+
 to the clones found in the unsorted sample. See Figure 
‎6.10 for detailed (colour coded) distribution of the top 50 clones in each patient; only one out 
of the 600 clones was not initially found in either CD4
+
 or CD8
+
, however, after a close 
inspection of the sequence, we believe that clone to be a CD8
+
 clone which was mapped 
differently owing to a sequencing error. Unexpectedly, in 5 out of the 12 infected individuals 
(4/6 HAM/TSP patients) the largest clone was a CD8
+
 clone. In 8/12 individuals (including 
all HAM/TSP patients) a CD8
+
 clone was present among the 3 largest clones. An extreme 
case was patient TBW (who is known to have a distorted CD4/CD8 ratio, see Table ‎6.1), in 
whom the proviral load was dominated by a large number of CD8
+
 clones, including the 
largest clone which represents over 15% of the load.  
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In order to answer the question whether CD8
+
 clones are more likely to be major clones than 
expected by chance, we compared the proportion of clones with an absolute abundance of 
more than 1 copy per 10000 PBMCs between CD4
+
 and CD8
+
 clones ( Figure ‎6.11A). This 
proportion was significantly greater in CD8
+
 clones (~10%) than in the CD4
+
 clones (~5%; p 
= 5.36 x 10
-10, Fisher’s exact test). Ranking all clones in descending order of abundance 
(Figure ‎6.11B), CD8
+
 clones were over-represented among the 10 most abundant clones 
(clone 1-10) compared to the next 10 (clones 11-20; p = 0.01, Fisher’s exact test). 
The contribution of CD8
+
 cells to the load was correlated with the proviral load in unsorted 
cells (Figure ‎6.12A) and with the proviral load in CD8
+
 cells (Figure ‎6.12B). This association 
approached significance when all patients were included (p = 0.06 for both tests, Pearson 
linear regression), and was highly significant when excluding patient TBW, who had an 
altered CD4/CD8 ratio, and was consequently a significant outlier (p =0.02 for association 
with proviral load, p = 0.004 for association with PVL in CD8
+
 cells). No significant 
association was found between proviral load in CD4
+
 cells and the contribution of CD8
+
 cells 
to the load.  
Lastly, we wished to compare the proviral load to the oligoclonality index, as a measure of 
non-uniformity in the clone frequency distribution. We found that, as observed before (Gillet 
et al 2011), there was no correlation between oligoclonality index and proviral load in the 
unsorted PBMCs (Figure ‎6.13; top panel), or in the CD4
+
 cells (Figure ‎6.13; bottom left 
panel). In the CD8
+
 cells, however, we observed a positive correlation approaching 
significance (p = 0.06) between the oligoclonality and proviral load in CD8
+
 cells (Figure 
‎6.13; bottom right panel).  
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Figure ‎6.5: Proviral load (PVL) in CD8
+
 cells (left) and in CD4
+
 cells(right) positively correlates 
with the PVL in unsorted PBMCs.  
 
 
 
Figure ‎6.6: The CD8
+
 infected cells were characterised by a small number of clones. 
The CD8
+
 samples tested were characterized by a lower amount of sisters (proviruses; right), owing to 
a lower load and a lower amount of available DNA, however the difference in clone numbers was 
even more remarkable. (Median total sisters per CD4
+
 sample~7750, per CD8
+
 sample~960. Median 
total clones per CD4
+
 sample ~2900, per CD8
+
 sample-220).  
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Figure ‎6.7: Oligoclonality index was significantly higher in infected CD8
+
 cells than in CD4
+
 
cells. 
 
 
 
 
 
Figure ‎6.8: Greater difference between OCI[CD8
+
] and OCI[CD4
+
] in HAM/TSP patients than 
ACs.  
No significant difference was found (Wilcoxon test, see individual p.values above each comparison) 
in the unsorted sample between HAM/TSP patients and asymptomatic carriers (AC); however the 
difference in OCI between CD4
+
 and CD8
+
 samples was only statistically significant for the 
HAM/TSP patients. 
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Figure ‎6.9: Example of clonal distribution in CD4
+
 and CD8
+
 infected cell populations.  
The top 20 clones from each sample are highlighted in colour, the rest are shown in dark blue. CD4
+
 
(left) cell populations are frequently characterized by a large number of clones, and the OCI is 
increased by one or few expanded clones. In contrast, CD8
+
 (right) cell populations are frequently 
characterized by a small number of relatively large clones, increasing the OCI. Patient shown here is 
HEZ.  
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Figure ‎6.10: The CD8
+
 clones are over-represented in the top 50 clones from each patient.  
The 50 most abundant clones are shown for each patient, using representative colours for each patient 
based on which cell it is attributed to. The CD8
+
 clones (peach) represented the largest clone in 5/12 
patients, and represented at least one clone within the top three of 8/12 patients (including all 
HAM/TSP patients).  
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Figure ‎6.11: CD8
+
 clones were significantly over-represented in high-abundance clones.  
(A) The majority of clones (both CD4
+
 and CD8
+
 clones were low abundance (fewer than 1 copy per 
10000 PBMCs); however, the CD8
+
 clones were over-represented (10% of all CD8
+
 clones vs 5% of 
all CD4
+
 clones) in the clones of high abundance (greater than 1 copy per 10000 PBMC;  
p = 5.36x10
-10, Fisher’s exact test). (B) Ranking all clones for each patient by decreasing order of size, 
the CD8
+
 clones were significantly more likely to be found in the top 10 clones than in the following 
10 clones (p = 0.01, Fisher’s exact test). 
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Figure ‎6.12: The proviral load is associated with the contribution of CD8
+
 cells to the load. 
Contribution of CD8
+
 cells to the load (in percentage) to the (A) proviral load in unsorted PBMC, (B) 
proviral load in CD8
+
 cells and (C) proviral load in CD4
+
 cells. One outlier (patient TBW) was 
omitted to enable a clear assessment of the other 11 individuals.For comparison, the outlier has been 
included in the inset shown in panel (A) Statistical tests are shown including (left) or excluding (right) 
the outlier. (A) The contribution of CD8
+
 cells to the load correlated with proviral load in unsorted 
cells. (B) The contribution of CD8
+
 cells to the load strongly correlated with proviral load in CD8
+
 
cells. (C) The contribution of CD8
+
 cells to the load did not correlate with proviral load in CD4
+
 cells. 
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Figure ‎6.13: Proviral load in CD8
+
 cells correlated with the oligoclonality index (OCI).  
The proviral load (PVL) in unsorted cells (top), CD4
+
 cells (bottom left) and CD8
+
 cells (bottom 
right) was compared to the (OCI) in each cell population. PVL was quantified by PCR as copies per 
100 cells. There was no correlation in unsorted cells or in CD4
+
 cells, but there was a correlation 
approaching statistical significance in CD8
+
 cells. Values for Pearson linear regression are shown for 
each panel. Using a ranked correlation (Spearman), there was no correlation found between PVL and 
OCI in either unsorted (PBMC) or CD4
+
 cell samples. There was a significant (p = 0.02) correlation 
between proviral load and OCI in CD8
+
 cell samples.  
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6.2.3 The role of infected CD8+ cells in shaping cell populations.  
The proportion of load carried by the CD8
+
 cells is influenced by the load in the CD8
+
 cells 
but also by the cell populations in vivo. We wished to test whether there is any association 
between the CD4
+
 or CD8
+
 populations in the peripheral blood and the proviral load in those 
populations. We found that the proviral load in CD8
+
 cells, and to a lesser extent the proviral 
load in CD4
+
 cells, was positively correlated (p<10
-4
 and p<10
-3
, respectively when excluding 
TBW, p = 0.02 and p = 0.156, respectively when including TBW) with the percentage of 
CD8
+
 cells in PBMCs (Figure ‎6.14A,B). No such correlation was observed with the 
percentage of CD8
+
 cells within total CD3
+
 cells (Figure ‎6.14C,D) or with the percentage of 
CD4
+
 cells within PBMC (Figure ‎6.14E,F), suggesting that this is a virus-driven clonal 
expansion of CD8
+
 cells rather than an alteration of the CD4/CD8 T cell ratio.  
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Figure ‎6.14: The proviral load in CD8
+
 cells was strongly associated with the proportion of 
CD8
+
 cells in PBMCs.  
Comparisons of the proviral load in CD8
+
 cells (A,C,E) and CD4
+
 cells (B,D,F) with the proportion of 
CD8
+
 cells in PBMC (A, B), CD8
+
 cells in CD3+ (C, D), CD4
+
 cells in PBMC (E, F). Two p values 
and Pearson’s r are shown for each correlation test, respectively including or excluding the outlier 
(TBW, highlighted in each plot) – a CD4+ lymphopenic patient. See text and Table ‎6.1 for details.  
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6.3 Discussion 
HTLV-1 is mostly found in CD4
+
 cells in vivo, and ATLL is typically a malignancy of CD4
+
 
cells. Therefore, the role of infected CD8
+
 cells is often not directly investigated, and even 
overlooked in HTLV-1 research. In this work the aim was to investigate the role that infected 
CD8
+
 cells play in shaping the proviral load.  
We have observed that the proviral load within CD8
+
 cells (i.e proportion of provirus-positive 
CD8
+
 cells) correlates with a patient’s total proviral load (proportion of provirus-positive 
PBMCs). This could be simply explained by the infected CD8
+
 cells being a sub-population 
of all infected cells, carrying the virus to a somewhat lesser extent than in CD4
+
 cells as 
previously thought. In order to investigate these infected cells, I carried out a high-throughput 
analysis of the proviral integration sites in CD4
+
, CD8
+
 or unsorted total PBMCs.  
We have observed that while the infected CD8
+
 cells represent the minority of infected cells 
(median of just over 5% of all infected cells), their clone frequency distribution is 
significantly different from that of infected CD4
+
 cells. We quantified this difference in 
distribution in a number of ways.  
First, our measure of distribution, the oligoclonality index, was significantly higher in CD8
+
 
cell samples than in CD4
+
 cell samples, indicating that the CD8
+
 have a more unequal 
frequency distribution of infected clones. The oligoclonality index was significantly higher in 
CD8
+
 cells than in CD4
+
 cells in nearly all patients, but in particular was higher among 
HAM/TSP patients compared to asymptomatic carriers. It is difficult to say, however, 
whether the difference in statistical significance is in itself of importance to clinical outcome, 
or whether it reflects the somewhat lower proviral load in asymptomatic carriers, which also 
affects the oligoclonality index.  
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Investigating this difference in distribution, I found that in non-malignant cases, CD4
+
 cells 
may have a small number of large clones, and that the proviral load in CD4
+
 cells is 
dominated by a long tail of very small clones (most of which were observed only once). In 
contrast, the infected CD8
+
 clone distribution is often characterized by a larger proportion of 
relatively large clones among a lower total number of clones. This observation suggests that 
infected CD8
+
 cells are subject to selection forces different from those acting on infected 
CD4
+
 cells. The oligoclonality index in CD8
+
 cells positively correlated with the proviral 
load in CD8
+
 cells, while no such correlation was observed in the CD4
+
 cells. This is 
consistent with the idea that while the load is increased in CD4
+
 cells primarily by adding 
new clones, it is increased in CD8
+
 by clonal expansion. In order to answer this question it 
will be required to improve our understanding of the ratio between mitotic and infectious 
spread at equilibrium of HTLV-1 infection. There is currently a mathematical project 
underway in our group modelling the infectious to mitotic ratio in order to answer such 
questions.  
Assigning clones identified in the unsorted sample to the CD4
+
 and CD8
+
 populations, 
revealed that the role of the infected CD8
+
 cells is more important than previously estimated - 
CD8
+
 clones are often the largest (in 5/12 patients) or among the largest clones in each 
patient. In fact, CD8
+
 clones were twice as likely as CD4
+
 clones to have an absolute 
abundance of at least 1 copy per 10000 PBMC. It is clear that clonality analysis previously 
carried out (by us and others) included many large CD8
+
 clones in the analysis; selection 
forces favouring CD8
+
 clonal expansion in particular may not be apparent when examining 
clonality of unsorted PBMCs (CD8
+
 clones represent approximately 10% of all clones over 
this size limit).  
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I observed that the total viral burden, as well as the proviral load within CD8
+
 cells (the 
proportion of CD8
+
 cells which are infected) correlated with the contribution of CD8
+
 cells to 
the load (i.e. the proportion of infected cells which are CD8
+
 cells), and that the proviral load 
within CD8
+
 cells correlates with the percentage of CD8
+
 cells in the PBMC (CD8
+
/PBMC).  
 
This study leads to several important questions:  
1) Why are the CD8
+
 clones more oligoclonal than the infected CD4
+
 clones?  
2) What mechanisms and selection forces shape the distribution of CD8
+
 infected cells?  
3) What is the role of infected CD8
+
 cells in shaping the proviral load? 
4) What are the implications for the immune response against HTLV-1? 
5) What is the role of infected CD8
+
 cells in HTLV-1-associated pathogenesis? 
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6.3.1 Selection forces and potential mechanisms determining clonal 
distribution of CD8+ cells 
The observed selective expansion of a small number of infected clones suggests one of two 
(not mutually exclusive) main mechanisms driving the clonal expansion: 
1) T-cell receptor (TCR) driven: the exposure to a specific antigen may be driving activation 
and selective expansion of infected clones. The most likely source of antigen is HTLV-1 
itself, with Tax recognized to have the highest immunogenicity. However, other antigens may 
contribute to TCR-driven clonal expansion, such as cytomegalovirus.  
2) Provirus driven: the genomic environment of the provirus (chapter 4) and the tendency of a 
clone to express proviral genes (chapter 5) appear to be associated with selective clonal 
expansion. Expression of proviral genes could have an indirect effect on clonal selection (e.g. 
by exposing the infected cell to the immune response). Expression may also have a more 
direct effect as Tax is known to drive proliferation (although these experiments are often 
done on CD4
+
 cells) and to upregulate various cytokines and cytokine receptors which are 
known to be involved with regulating cell cycle and cell survival. 
Are the large CD8
+
 clones HTLV-1-specific? Hanon et al. (2000b) have previously 
demonstrated that Tax11-19-specific CTLs were themselves more likely to be expressing 
Tax. This is consistent with the idea that that infected CD8
+
 are also specific to proviral 
antigens, perhaps being infected as a result of an increased chance of virus transmission 
during the cell-cell contact required for formation of the immunological synapse (Grakoui et 
al., 1999). We aim to test in the future whether the HTLV-1-specific cells are more likely to 
be infected and whether these belong to large CD8
+
 clones (rather than small ones). Because 
a limited number of antigen specificities can be tested at one time, this may not be sufficient 
to conclude whether all large clones can be explained by a TCR-driven mechanism.  
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Oligoclonality of CD8
+
 cells in health and disease has been described in the past (Monteiro et 
al., 1995; Batliwalla et al., 1996) and clonal expansion of HTLV-1 specific CTLs has been 
extensively described in the literature. As early as 1995, Elovaara et al reported a limited 
Tax-specific TCR repertoire, based on PCR analysis of TCR Vβ usage (Elovaara et al., 
1995). The same group reported in 1996 oligoclonal expansion of Tax11-19-specific CTL in 
the blood of 3 HAM/TSP patients (Utz et al., 1996) by analysing Vβ and Vα genes and using 
a similar approach, it was then reported that HAM/TSP patients have a greater number of 
CTL clones (in blood and CSF) than asymptomatic carriers (Hoger et al., 1997). Advances in 
methods to quantify TCR clonal diversity allowed Ureta-Vidal and collegues to use an 
immunoscope method to characterize Vb distribution in CD3 cells from patiens with 
HAM/TSP and ACs, as well as uninfected controls. They reported that the degree of 
oligoclonality was higher in CD8
+
 cells than in CD4
+
 cells (both in infected and uninfected 
individuals), but higher (either CD4
+
 cells or CD8
+
 cells) in infected than uninfected. For 
HAM/TSP patients, oligoclonality in CD8
+
 was significantly higher in HAM/TSP than AC 
(Ureta-Vidal et al., 2001).  
Considering the possible association between infection and specificity, the clonal expansion 
described by these studies is consistent with that observed in this work; however, as none of 
these studies considered the proviral status of the Tax-specific cells, it is difficult to compare 
them to this work with certainty.  
Sibon et al. (2006) used a limiting dilution cloning method to compare T cell clones derived 
from infected and uninfected CD4
+
 and CD8
+
 clones. They concluded that while infected 
CD4
+
 T cells show an increased progression through the cell cycle (compared to uninfected 
clones), there was no significant difference infected CD8
+
 clones and uninfected ones. In 
contrast, infected CD8
+
 clones had significantly fewer cells undergoing apoptosis than 
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uninfected CD8
+
 clones. They concluded that infected CD8
+
 clones proliferate not through 
increased replication but through resistance to cell death. This may be related to a previous 
observation by another group, focusing on HTLV-1-specific CTLs (which may or may not be 
infected), demonstrating that Tax-specific CTLs from 4 of 5 patients tested were prevented 
from undergoing cell death by an IL-15 (and not IL-2) dependent mechanism (Azimi et al., 
2001). The same study showed that this selective blockade of cell death by IL-15 was 
observed in particular in patients where the expression of IL-15R was confined to the Tax-
specific CTLs. As Tax is known to upregulate IL-15R (Mariner et al., 2001), it is very likely 
that the effect observed by Azimi et al was in fact IL-15-mediated survival of HTLV-1-
infected CD8
+
 cells. The source of the IL-15 in vivo may be the same or other HTLV-1-
infected cells: HTLV-1 Tax is also known to upregulate IL-15 (Azimi et al., 1998; Azimi et 
al., 2000). It will be necessary in future studies to assess the expression of IL-15R and other 
cytokines/receptors (e.g. IL-2, CD25 and others) which may also be implicated in clonal 
expansion of infected CD8
+
 cells (Ku et al., 2000).  
What is the role of Tax expression of infected CD8
+
 cells in driving clonal expansion? It is 
known that in vitro they can express Tax protein (Hanon et al., 2000b); however it is not clear 
if the amount or frequency of Tax expression differs between infected CD4
+
 and infected 
CD8
+
 cells: Newbound et al. (1996) have shown that in vitro infected CD4
+
 cells express a 
greater amount of viral RNA from the 5’LTR than CD8+ cells, despite a similar load in both 
cell populations;  it was later shown by Nagai et al. (2001a) that in cells taken from patients 
with HAM/TSP, Tax expression per infected cell was variable between patients but similar 
between CD4
+
 and CD8
+
 cell population within patients. My work comparing Tax expressing 
and non-expressing CD4
+
 cells from 10 HAM/TSP patients (Chapter 5) revealed that in the 
CD4
+
 cell population Tax-expressing cells were significantly associated with smaller clones. 
This observation is consistent with the idea that expression of Tax protein in CD4
+
 cells 
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exposes the infected cell to cell killing by Tax-specific CTLs in vivo. But would infected 
CD8
+
 cells show the same trend? While we know that Tax expressing CD8
+
 cells can be 
killed by Tax-specific CTLs (Hanon et al., 2000b) it is not clear whether CD8
+
 cells are as 
susceptible or whether this killing is as efficient in CD8
+
 cells. It may be that the balance of 
effects of Tax (promoting proliferation as well as antigen presentation) is different in the case 
of infected CD8
+
, which helps them to maintain a viral reservoir in relatively large expanded 
clones.  
It remains to be tested what role the genomic environment plays in determining clonal 
expansion of CD8
+
 clones.  
 
6.3.2 Implications for disease pathogenesis 
HAM/TSP 
One of the main points of controversy in HAM/TSP research is the role of Tax-specific CTLs 
in inflammatory disease: are they protective or detrimental?  
It has also been shown that the proviral load of HAM/TSP patients is correlated with the 
frequency of HTLV-1-specific CTLs (Kubota et al., 2000; Nagai et al., 2001b). A high 
frequency of Tax-specific CTLs are found in the T cell infiltrates in CSF of HAM/TSP 
patients (Jacobson et al., 1992; Hoger et al., 1997), as well as in the lung infiltrates of patients 
with pulmonary involvement (Kawabata et al., 2012). That, together with the observation that 
a high HTLV-1 proviral load is often found in T cell infiltrates in the CNS in HAM/TSP 
patients (Lezin et al., 2005; Demontis et al., 2013), led to the notion that specific infiltration 
of infected cells across the blood brain barrier attracts HTLV-1-specific CTL which cause the 
tissue damage by a bystander effect by secretion of cytokines such as IFNγ and TNFα (Ijichi 
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et al., 1993; Daenke and Bangham, 1994). In contrast, HTLV-1-specific CTLs are also 
thought to play a protective role, controlling the proviral load throughout the infection, as the 
efficiency of Tax specific CTLs negatively correlates with proviral load (Asquith et al., 
2005a), and genetic determinants of MHC presentation to CTLs (particular HLA-I alleles) 
have been shown to be associated both with remaining a healthy carrier, and with lower 
proviral load in healthy carriers (Jeffery et al., 1999; Jeffery et al., 2000). 
By shifting the focus onto the expanded infected CD8
+
 clones, a third possibility emerges, 
which may help to reconcile seemingly conflicting findings: the high CD8
+
 T cell frequency 
is often attributed to the higher proviral load in HAM/TSP, which leads to a higher antigen 
concentration.  If indeed the expanded CD8
+
 clones observed in this work are identified as 
being HTLV-1-specific this would lead to a much more refined understanding of the role of 
infected cells in driving pathogenesis, and raises the important question whether the CD8
+
 
infected cells preferentially infiltrate the CSF, are they cleared by the immune response as 
efficiently as infected CD4
+
 T cells and are they as efficient in killing other infected cells? 
The answer to the last question is not clear, as conflicting data on a small number of infected 
clones shows that the infection either impairs or does not impair CTL function (Popovic et 
al., 1984; Mitsuya et al., 1986; Faller et al., 1988). 
Our evidence demonstrates that the proviral load (and in particular the proviral load in CD8
+
 
cells) was positively correlated with the proportion of CD8
+
 cells in the PBMC (Figure 
‎6.14A,B). This correlation results from a selective expansion of particular populations. Since 
the infected cells represent the minority of CD8
+
 cells (median of 1.95 copies per 100 CD8
+
 
cells) clonal expansion of the infected cells is not sufficient to explain this positive 
correlation; it is, however, consistent with the idea of a paracrine effect, for example 
expansion driven by cytokines secreted by infected cells. If so, this may have a role in 
187 
 
pathogenesis and may shed some light on the link between proviral load and risk of 
inflammatory disease. 
 
ATLL 
CD8
+
CD4
–
 ATLL is very rarely reported in the literature, and the best estimates put the 
CD8
+
CD4
–
 ATLL at 3.7% of cases (Kamihira et al., 1992). In addition, the phenotype of the 
infected cells may be altered during malignant transformation, because aberrant expression of 
certain cytokines (i.e. IL-4) could modify the expression of these factors (Paliard et al., 
1988).  
 Within the standard model of ATLL development (Figure ‎6.1) the malignant transformation 
follows years of clonal expansion. Consistent with this, in the BLV-infected sheep model of 
ATLL development Moules et al. (2005) have shown that the premalignant clone is expanded 
and distinct in early in infection, and a sharp increase in genetic instability coincided with the 
onset of malignancy. 
Should we have expected CD8
+
 ATLL to be more frequent? It is still not known what the 
important features of a pre-malignant clone are. Without a better understanding of these 
features, it is difficult to assess the transformation potential of infected CD8
+
 cells. Based on 
the standard model, we should expect to see more frequent CD8
+
 malignancy as the CD8
+
 
infected clones are overrepresented within the most expanded clones (both when considered 
by rank order and by absolute abundance). This reasoning would suggest that if a necessary 
or sufficient precondition for malignant transformation is clonal expansion, there would be a 
far greater frequency of CD8
+
 phenotype ATLL. The low frequency of CD8
+
 ATLL is also 
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surprising considering the observed correlation between clonal expansion and increased 
proviral load, known to be a risk factor for ATLL (Iwanaga et al., 2010; Hodson et al., 2013). 
What role does normal CD8
+
 biology play in determining the incidence of CD8
+
 ATLL? in 
other cutaneous lymphomas such as mycosis fungoides, the overwhelming majority of cases 
have a CD4
+
 phenotype (Willemze et al., 2005), however CD4
–
CD8
+
 cells are not protected 
from malignancy and CD8
+
 leukaemias are known , such as T cell Large granular 
lymphocytic leukaemia, which is most often a malignancy of CD8
+
 cells (Chan et al., 1986; 
Dhodapkar et al., 1994).  
The results presented here, demonstrating an over-representation of CD8
+
 cell clones among 
the 50 most abundant clones, suggest that long-term clonal expansion is not a necessary or 
sufficient process for eventual transformation. There are previous reports on malignant 
transformation occurring on the background of entirely polyclonal population (Iwatsuki et al., 
1990); this is also consistent with a recent observation based on high-throughput sequencing 
of longitudinal samples taken from ATLL patients, where the putative malignant clone was 
not always among the most expanded clones pre-malignancy (Cook et al, Unpublished).  
A potential mechanism for the apparent lack of CD8
+
 malignancies was proposed by Sibon et 
al. (2006), who observed an increase in aberrant cell morphologies in infected CD4
+
 clones 
compared with CD8
+
 clones, suggesting that the increased cell division they observed in 
CD4
+
 clones (compared with reduced cell death observed in CD8
+
 clones) results in an 
increased mutation rate in the CD4
+
 cells. It is difficult, however, to interpret this confidently 
as the clones studied by Sibon et al were themselves selected and cultured ex vivo, and it is 
not clear whether in vivo there is a greater rate of mutations in infected CD4
+
 cells.  
Another potential explanation is that while CD8
+
 clones can expand, there may be clonal 
succession over time (Snyder et al., 2008), and the infected subclones themselves do not 
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persist as long as their CD4
+
 counterparts. This is, however, unlikely: in Gillet et al, large 
clones were reported to expand with time, rather than to disappear. As it now seems likely 
that about 10% of those clones were CD8
+
, this is likely to have been observed in the PBMC 
data. In addition, Ureta-Vidal et al have reported observing long-lived CD8
+
 clones in 
HTLV-1 infection (not shown), however they did not distinguish infected from non-infected 
clones(Ureta-Vidal et al., 2001).  
A more targeted analysis of CD8
+
 samples taken at different timepoints will need to be done 
in order to answer this question rigorously.  
Another potential avenue for research is the related virus HTLV-2. HTLV-2 preferentially 
infects CD8
+
 cells (Ijichi et al., 1992) and has not been clearly associated with any disease, 
although it has been linked to a higher mortality than uninfected individuals from all causes 
(Biswas et al., 2010). A separate study looking into the HTLV-2 proviral integration site 
distribution in HTLV-2 carriers is currently being carried out.  
While the proviral load carried by infected CD8
+
 cells has not been the subject of a great deal 
of research over the years, these cells may have great relevance to the field of HTLV-1 
research. This present study is limited by the use of a relatively small group (12 patients), and 
by the intentional selection of patients with a high proviral load, who may not represent the 
majority of asymptomatic carriers. However, it is not likely that the basic molecular 
mechanisms of persistence will differ between high and low proviral load carriers. The 
present study highlights the difference in clonal distribution between infected CD4
+
 and 
CD8
+
 cells, which may reflect differences in the relative importance of the selection forces 
acting upon the infected cell clones. These may also lead the way to a better understanding of 
HTLV-1 related pathogenesis, and the selection mechanisms directing infected and non-
infected cell expansion in HTLV-1 infected individuals.  
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The set point of proviral load of HTLV-1 does not vary within an infected subject over the 
course of the infection, despite a strong, active immune response. Two proposed mechanisms 
for HTLV-1 escape from immune control are not sufficient to explain this. First, while Tax 
escape mutants have been found, they are not very frequent (in non-malignant infection) in 
keeping with an overall stable proviral sequence (Niewiesk et al., 1995). Second, the 
infection is not latent, and Tax expression does take place in vivo.  Evidence from the 
investigation of the immune response (in particular the CTL response) to Tax and HBZ 
demonstrates that the CTLs can control Tax expressing cells in vitro and in vivo (Hanon et 
al., 2000a; Asquith and Bangham, 2008).  
The proviral load remains the best prognostic marker of HTLV-1-related disease (Nagai et 
al., 1998; Matsuzaki et al., 2001; Iwanaga et al., 2010). The approach taken here is to 
investigate the mechanisms that take place during chronic infection and the selection forces 
acting on the load, by exploring the infected clones that make up the proviral load.  
We have developed a new method, based on the new technology of high-throughput 
sequencing to analyse and quantify HTLV-1 integration site. This method enabled us two 
avenues of research. First, the mapping to the human genome, coupled with the growing 
number of annotations to the human genome (such as the ENCODE project, see Dunham et 
al., 2012) will allow us an unprecedented view of the characteristics of the genomic 
environment at the integration site, to better understand the mechanisms that HTLV-1 utilizes 
for integration; this may even lead to insights into therapeutic or prophylaxis approaches 
targeting this process. Second, the integration site can be used as an identifying marker, 
distinguishing an infected T cell clone, allowing us to test for the dynamic changes over the 
course of the infection not just as changes to the proviral load but as changes on thousands of 
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clones simultaneously. This can be used to monitor the response to therapy against ATLL or 
HAM/TSP, to examine the characteristics of cell infiltrates in inflammatory disease, or to 
track a potentially malignant clone before initiation of disease.  
In this work I present the following main findings:  
1) The initial targeting of HTLV-1 integration was equally favoured in genes in 
either relative orientation. There was a strong bias towards integration in 
proximity to specific TFBS, notably STAT-1, HDAC6 and p53.   
2) The effect of the genomic environment on proviral expression and clonal 
expansion was largely asymmetric. An upstream host gene promoter was 
associated with silencing of Tax expression. The effect of integration in proximity 
to ChIP-seq sites of transcription factors and chromatin remodellers was often 
asymmetric, with the notable example of the SWI/SNF proteins, in particular 
BRG1.  
3) Tax expression was associated with less expanded clones, suggesting that the cells 
more readily expressing Tax are efficiently controlled by the immune response in 
vivo. 
4) While infected CD8+ cells represent the minority of the proviral load, they are no 
less important – as shown by a high degree of oligoclonality (which positively 
correlated with the proviral load in those cells), CD8
+
 clones were over-
represented among the most expanded clones. 
The work carried out in this thesis adds significantly to previous work (Gillet et al., 2011; 
Meekings et al., 2008) to build a growing picture of the factors associated with integration 
targeting, proviral expression and clonal expansion (Figure ‎7.1). Initial integration was 
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favoured in genomically active regions, in particular within genes or in proximity to gene 
start sites or CpG islands, or in gene-dense regions (Meekings et al., 2008). There was no 
initial bias for a particular relative orientation of the host genes, suggesting that the bias 
observed in vivo (favouring same-sense orientation) is entirely driven by long-term selection, 
rather than integration bias.  
These results, in the context of previous findings, suggest two levels of control of the proviral 
expression. First, a regional effect - integration in genomically active regions favours proviral 
expression (Meekings et al., 2008, and this work). Second, a more local effect, within 10 kb 
of the integration site, where the existence of an upstream promoter of the same orientation as 
Tax, may silence the expression from the 5’LTR. One possible mechanism described which 
could account for this effect is the transcriptional interference (Shearwin et al., 2005). The 
observed preferential expansion of clones with same-sense proviral orientation is consistent 
with the observation that clones which do not express Tax (for example by mutation of Tax) 
gain a selective advantage and outgrow their counterparts.  
Unlike the largely symmetrical effect of the host genome on initial integration, both the 
relative position of the nearest host gene (upstream or downstream of the provirus) and its 
relative orientation showed significant associations with clonal abundance and expression. It 
will be important to take this asymmetry into account in future analysis of the host 
environment flanking the retroviral genome.   
Observations reported here demonstrate that it is not simply access to chromatin which 
determines proviral integration and expression. First, while integration in proximity to some 
TFBS showed a remarkable bias, this was not the case for others. Second, the role of relative 
position and orientation of host genes or TFBS found in regards to proviral expression and 
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clonal expansion indicate a mechanistic interaction between transcription of the HTLV-1 
proviral genes and transcription of the flanking host genes.  
What, therefore, determines clone abundance in vivo? While general transcriptional activity 
appears associated with Tax expression, it is also associated with proviral expansion (Gillet et 
al., 2011). A potential explanation is that the regional effect also determine the magnitude or 
rate of HBZ expression. HBZ has been suggested to play a role in cell proliferation, and is an 
inhibitor of Tax by sequestering host factors (Gaudray et al., 2002; Basbous et al., 2003).  A 
potential role for HBZ in driving clonal expansion is also in line with analysis of host 
genetics which showed that possessing an HLA genotype predicted to bind strongly to HBZ 
peptides is protective in HTLV-1 (Macnamara et al., 2010). It appears that most infected 
individuals have a good immune response against Tax. This response shapes the clonal 
distribution and causes the Tax-expressing clones to remain small. This controls the virus 
over the long-term, allowing a subclinical persistent infection, which aids the spread of the 
virus in the population over several decades.  The role of Tax may be in driving cell-to-cell 
transmission, adding new clones. Over time, large clones become more abundant (Gillet et 
al., 2011) and the chronic immune response leads to inflammatory disease.  It is possible that 
individuals who also have an MHC genotype which allows them to identify HBZ expressing 
cells, are able to clear the Tax
–
 clones more efficiently, leading to a lower proviral load and a 
reduced risk of HTLV-1-related disease.  
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Figure ‎7.1: Summary: the emerging picture of factors associated with spontaneous Tax 
expression integration targeting and clonal expansion.  
(A) Factors associated with presence or absence of spontaneous Tax expression of a given cell after 
overnight incubation. (B) Genomic environment features associated either with targeting of the initial 
integration (left panel) or clonal expansion in vivo (right panel). Findings were made in this work 
unless otherwise stated. 1 – Meekings et al., 2008, 2 –Gillet et al., 2011.  
 
  
196 
 
HTLV-1 is mostly found in CD4
+
 cells in vivo, however a median of 5% of infected cells are 
CD8
+
 cells. The infected CD8
+
 cells examined here had a distinct clonal frequency 
distribution from that of infected CD4
+
 cells, characterized by fewer, relatively expanded 
clones. The correlation between the degree of oligoclonality and proviral load in CD8
+
 cells, 
not observed for CD4
+
 cells, suggests that clonal expansion (rather than de novo infection) 
has a more significant role in proliferation of these cells. This will need to be tested further, 
potentially with the use of mathematical models currently being developed to model the 
infectious to mitotic spread ratio in HTLV-1 chronic infection. As CD8
+
 cells (in particular, 
HTLV-1 specific CTLs) are potentially implicated in HTLV-1-mediated pathogenesis, more 
consideration should be taken to whether these are infected or not, and the mechanisms that 
promote their proliferation. The results of this study support a protective role for HTLV-1 
specific CTLs regulating expression of proviral proteins and proliferation of infected cells.  
This work carries implications both for the field of HTLV-1 research as well as other 
retroviruses, since mechanisms employed by HTLV-1 to regulate its expression would also 
be used by other retroviruses, such as latent HIV. The population level findings of this work 
will lead to further mechanistic testing of mechanisms of HTLV-1 persistence.  
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Appendix I: Oligonucleotides used in this work 
PCR and sequencing primers:  
Name Sequence 
Actin fw TCACCCACACTGTGCCCATCTATGA 
Actin rev CATCGGAACCGCTCATTGCCGATAG 
SK43 CGGATACCCAGTCTACGTGT 
SK44 GAGCCGATAACGCGTCCATCG 
5LTRFW CTCGCATCTCTCCTTCACG 
5LTRRV CTGGTGGAAATCGTAACTGGA 
LTRseq GGTTGAGTCGCGTTCT 
Bio3 CCTTTCATTCACGACTGACTGCCG 
Bio3aa CCTTTCGTTCACGTCTGACTGCCG 
Bio3b CTTTTCATTCACGACTGACTGCCG 
Bio3c CCTTTCATTCACGACTAACTGCCG 
Bio3d CCTTTCATTCACGACTGACTGCCA 
Bio3e CCTTTCATTCACAACTGACTGCCG 
Bio4 TCATGATCAATGGGACGATCA 
P5Bio5 
AATGATACGGCGACCACCGAGATCTACACTGGCTCGGAGCCAGCG
ACAGCCCAT 
P5Bio5a 
AATGATACGGCGACCACCGAGATCTACACTGGCTCGGAGCCAGCG
ACAGCCCAC 
P7 CAAGCAGAAGACGGCATACGA 
P5 AATGATACGGCGACCACCGA 
VUshort GATCGGAAGAGCGAAAAAAAAAAAAA 
VUlong 
TCATGATCAATGGGACGATCACAAGCAGAAGACGGCATACGAGAT
NNNNNNCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
HTLVseq CAGCCCATCCTATAGCACTCTCCAGGAGAGAAATTTAGT 
SBS8 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
SBS8rev AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACCG 
  
                                                 
a
 Bio3a-Bio3e, P5Bio5a are patient specific primer variations of Bio3, P5Bio5.  
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Mutiplexing Barcodes  
See VUlong – the long arm of the VU linker. Underlined sequence is a 6 letter barcode 
distinguishing between each sample. 
 
Barcode 
number 
Barcode sequence  
(5’‎to‎3’) 
VU1 ATCACG 
VU2 CAGGAC 
VU3 TGCACT 
VU4 GCTCTA 
VU5 CTAGAG 
VU6 ATCCGT 
VU7 GGTACG 
VU8 AATTCC 
VU9 CGTATA 
VU10 AATCCC 
VU11 TGTGTG 
VU12 CACACA 
VU13 TACTAC 
VU14 AGACCT 
VU15 GCCTGT 
VU16 GACTAG 
VU17 GATCTG 
VU18 TAGCAG 
VU19 CTGAAC 
VU20 GAACTC 
VU21 CTATGC 
VU22 GTCTGA 
VU23 CCAAGA 
VU24 GGACCA 
VU25 CATCAT 
VU26 GCACGA 
VU27 TTGAGT 
VU28 ATCACG 
Barcode 
number 
Barcode sequence  
(5’‎to‎3’) 
VU29 TTCCCA 
VU30 TATCCT 
VU31 TGACAG 
VU32 TACGCC 
VU33 TGCCTC 
VU34 GCCACC 
VU35 TTTGGC 
VU36 TCACAT 
VU37 TGTAAG 
VU38 TTGACG 
VU39 TTACAC 
VU40 TCCACG 
VU41 TTTTAA 
VU42 TATGGG 
VU43 GAGCGT 
VU44 TCAAAG 
VU45 TTATTC 
VU46 TAGGAA 
VU47 TACGTA 
VU48 TTTATA 
VU49 TATCAG 
VU50 TTGCGC 
VU51 ATAGCG 
VU52 TCTACA 
VU53 TATCTA 
VU54 TCGTAA 
VU55 TGGGCG 
VU56 TCGCCA 
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Appendix II – abstract of publication associated with this thesis  
Melamed, A., Laydon, D. J., Gillet, N. A., Tanaka, Y., Taylor, G. P. & Bangham, C. R. M. 
(2013) Genome-wide Determinants of Proviral Targeting, Clonal Abundance and Expression 
in Natural HTLV-1 Infection. PLoS Pathog 9(3): e1003271.  
The regulation of proviral latency is a central problem in retrovirology. We postulate that the 
genomic integration site of human T lymphotropic virus type 1 (HTLV-1) determines the 
pattern of expression of the provirus, which in turn determines the abundance and pathogenic 
potential of infected T cell clones in vivo.  
We recently developed a high-throughput method for the genome-wide amplification, 
identification and quantification of proviral integration sites. Here, we used this protocol to 
test two hypotheses.  First, that binding sites for transcription factors and chromatin 
remodelling factors in the genome flanking the proviral integration site of HTLV-1 are 
associated with integration targeting, spontaneous proviral expression, and in vivo clonal 
abundance.   Second, that the transcriptional orientation of the HTLV-1 provirus relative to 
that of the nearest host gene determines spontaneous proviral expression and in vivo clonal 
abundance. 
Integration targeting was strongly associated with the presence of a binding site for specific 
host transcription factors, especially STAT1 and p53. The presence of the chromatin 
remodelling factors BRG1 and INI1 and certain host transcription factors either upstream or 
downstream of the provirus was associated respectively with silencing or spontaneous 
expression of the provirus. Cells expressing HTLV-1 Tax protein were significantly more 
frequent in clones of low abundance in vivo. We conclude that transcriptional interference 
and chromatin remodelling are critical determinants of proviral latency in natural HTLV-1 
infection.  
